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Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by progressive 
joint destruction often resulting in functional disability and increased mortality. With 
appropriate therapies, it is possible to delay or even prevent evolution of patients into RA 
and/or induce remission. Thus the identification of individuals not only early in the disease 
course but at risk of developing RA is important. Following on this concept, we investigated 
the presence of systemic autoimmunity among individuals at risk of RA based on  
environmental exposures, and conducted a meta-analyses showing an early therapeutic 
window of opportunity associated with sustained benefit on disease progression and structural 
damage. Since time matters, we examined both the recent criteria performance and the role of 
musculoskeletal ultrasound as tools to identify RA early in the disease course.  
One of the therapeutic goals in RA is the prevention of radiologically evident joint 
destruction, thus we evaluated a novel scoring method to assess radiological disease 
progression. We also examined the impact of inflammation on RA-associated collateral 
damage, including cardiovascular disease and bone loss. We observed within the 
epidemiology of musculoskeletal involvement that chronic inflammation in any one tissue 
clearly impacts the overall health status and disease susceptibility of the whole body.  
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A. Purpose and outline  
Inflammation is the main pathologic process involved in many chronic disorders that 
affect several organs and systems, such as the autoimmune inflammatory rheumatic diseases, 
in particular rheumatoid arthritis (RA), which often results in functional disability and 
impaired quality of life. RA is characterized by increased mortality and significant morbidity 
including several coexisting conditions such as periodontal disease, accelerated 
atherosclerosis and bone loss. Substantial data demonstrates that essentially all chronic 
diseases are related through common inflammatory mechanisms and processes and that 
chronic inflammation in any one tissue impacts the overall health status and disease 
susceptibility of the whole body. However, when and where RA starts remains unknown.  
The purpose of this thesis is to provide an overview of RA within the epidemiology of 
musculoskeletal involvement, with a focus on the phases of RA and the relevance of time 
in the management of RA, the associations and potential risk factors for RA, the tools 
used to assess disease prediction and progression, and the role of chronic inflammation 
as the common theme linking the spectrum of RA-coexisting conditions. 
The relevance of time for the burden of RA is reviewed in paper 11. Within the 
pathogenesis of RA, we investigated associations and potential risk factors for RA (papers 2-
5). We first present a systematic review on the association between the rheumatic diseases and 
periodontal disease (paper 2)2, and we examined the link between rheumatoid arthritis in 
particular, and periodontal disease in a population-based study (paper 3)3. We then 
investigated the presence of systemic autoimmunity among individuals at risk of RA, based 
on their environmental exposures, such as periodontal disease (paper 4)4, and established lung 
disease (paper 5)5, either due to a genetic deficiency (i.e. α-1 antitrypsin deficiency) or to 
smoking, which is an established risk factor for RA.  
4 
 
Early treatment improves outcomes. We show in a meta-analysis of observational studies 
and randomized controlled trials that there is a critical period during which antirheumatic 
therapy should be initiated, a therapeutic window of opportunity early in the course of RA, 
associated with sustained benefit on di sease progression and structural damage (paper 6)6. 
However, the timely initiation of anti-rheumatic therapy demands an early classification or 
diagnosis of RA, or of early arthritis at risk of developing into persistent and erosive disease. 
To help identify individuals early in the course of RA, we investigated the role of 
musculoskeletal ultrasound as a predictor of outcome in people with arthritis at the very early 
stages of the disease course (paper 7)7, and examined the performance of the recent 2010 
ACR/EULAR criteria for classification of RA in a cohort of patients with very early synovitis 
(paper 8)8.  
The goal of therapy is to improve the symptoms and signs of RA and prevent 
radiologically evident joint destruction or functional loss. In the next few papers, we 
examined the impact of inflammation at the level of the joint and investigated the 
performance and both, patient repositioning and examiner reproducibility, of an automated 
computer-based scoring method to assess radiological structural damage and disease 
progression in RA (papers 9-11)9-11. 
The following papers addressed some of the systemic consequences of chronic 
inflammation. We first focused on the role on inflammation in the established increased risk 
of cardiovascular disease in RA (papers 12-14)12-15. We investigated antioxidants and other 
novel and traditional risk factors for cardiovascular disease in RA, and assessed the 
relationship between serum uric acid, long implicated in cardiovascular morbidity, and 
inflammation in people with and without RA. Finally, we examined whether systemic 
inflammation has an impact on bone in a large epidemiologic study (paper 15)15.   
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C. Introduction 
 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is the most common immune mediated rheumatic chronic 
inflammatory disease affecting about 1% of the population16. Women are affected two to 
three times more often than men. RA can occur at any age. The peak onset is between 50 and 
75 years of age, and the prevalence is 5% among women over age 65. The lifetime risk of RA 
in adults is about 4 % in women and 2% in men17. RA is characterized by synovial 
inflammation and progressive cartilage and bone destruction that often results in substantial 
pain, disability, loss of function and other comorbidities. RA clinical features include pain, 
swelling, stiffness and a limited range of motion in the joints involved. Despite recent 
advances in treatment modalities used to modify the course of the disease, RA is associated 
with long-term comorbidity18-20 and accelerated mortality. Uncontrolled disease may confer a 
large socioeconomic and psychosocial burden as a consequence of joint destruction and 
deformity at the individual level, with loss of work productivity21,22. Given the systemic 
nature of the disease, RA clinical manifestations are not limited to the joints and range from 
constitutional symptoms to organ involvement including a wide variety of extra-articular 
manifestations such as subcutaneous nodules, pulmonary nodules, interstitial-lung disease, 
vasculitis, intestinal fibrosis, lung involvement, pericarditis, and eye involvement (e.g. 
episcleritis, uveitis). Furthermore, chronic inflammation has detrimental effects not only as a 
result of direct damage but also due to collateral damage in other systems and tissues resulting 
in comorbid diseases18-20. RA is associated with significant comorbidity including systemic 
features with accelerated atherosclerosis, pulmonary, skeletal, and psychological involvement, 
and other diseases such as periodontitis. Structural damage occurs very early in the course of 
the disease and is closely related to unsuppressed disease activity.  
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The clinical presentation of RA is very heterogeneous. Among patients presenting with 
symptoms of early inflammatory arthritis, 60% have a s elf-limiting disease while 40% 
develop a chronic persistent arthritis. The diagnosis/classification of RA relies upon the use of 
clinical criteria23,24, as no di agnostic serological test is available. RA features include 
autoantibody production such as rheumatoid factor (RF) and the highly RA-specific anticyclic 
citrullinated antibodies (ACPA), which define disease subgroups with distinct prognosis25. 
Ultrasound or magnetic resonance imaging may detect joint inflammation and structural 
changes early in the disease course, while radiographs of the hands and feet may be normal in 
up to 80% of patients with early RA. The last two decades have seen important advances in 
understanding the incidence, treatment and outcome of patients with early rheumatoid 
arthritis. With appropriate therapies, it is possible to delay or possibly even prevent evolution 
of patients with undifferentiated arthritis into rheumatoid arthritis (RA) and/or induce 
remission in a substantial proportion of patients with RA. Furthermore, preventing the burden 
of RA may be best managed by identifying patients at risk of developing RA and intervening 
very early26,27. However, when and where RA starts remains unknown, and as clinicians, we 
are still far from being able to produce an individualised treatment plan for each patient, 
partly because current prediction tools for RA are not perfect.  
The purpose of this thesis is to provide an overview of RA within the epidemiology of 
musculoskeletal involvement, with a focus on the phases of RA and the relevance of time 
in the management of RA, the associations and potential risk factors for RA, the tools 
used to assess disease prediction and progression, and the role of chronic inflammation 
as the common theme linking the spectrum of RA-coexisting conditions. 
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D. Pathogenesis of rheumatoid arthritis 
Although widely recognized as an autoimmune disease, the cause of RA remains unknown. A 
range of stimuli have been implicated as possible primary causes that activate the immune 
response. These include environmental factors, hormonal factors, connective tissue proteins, 
immunoglobulins and infectious agents, such as bacteria or viruses, which may trigger RA in 
those with a genetic susceptibility. The clinical syndrome of polyarticular synovitis is initiated 
by multiple factors or a combination thereof in genetically susceptible hosts, and once started, 
the process becomes self-perpetuating and expands to the whole body (Figure 1).   
 
Figure 1. Genes and environment in the development of rheumatoid arthritis  
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1. Genetic and environmental factors  
1.1.  Genetics 
Several genetic loci have been linked with RA susceptibility and severity. Twin studies, with 
concordance rates of 15-30% for monozygotic and 5% for dizygotic twins imply a genetic 
susceptibility28. Genetic factors contribute between 53-65% of the risk of RA28. The strongest 
link between a genetic factors and RA is the association with an epitope in the third 
hypervariable region of the human leukocyte antigen (HLA)-DRB1 molecule (amino acids 
67-74) known as the shared epitope (SE)29, particularly in seropositive or ACPA positive RA. 
The SE also confers disease severity as SE carriage (1 or 2 alleles) is associated with 
erosions30. Genes outside of the major histocompatibility complex (MHC) region are 
associated with RA. Several genes with single-nucleotide polymorphisms (SNPs) have been 
linked to ACPA positive RA, mediated by T-cell pathways including stimulation, activation, 
and functional differentiation (e.g. protein tyrosine phosphatase N22 (PTPN22) and cytotoxic 
T-lymphocyte antigen 4 gene (CTLA4)), the nuclear factor kB (NF-kB) dependent signalling 
pathway (e.g. TRAF1-C5  a nd c-REL), cytokine induced signals (STAT4), or other 
pathways31, including PADI-4 gene (peptidyl arginine deiminase type IV), Fcγ receptors (Fc 
receptors for IgG), CD40 and several cytokines, chemokines and cytokine-receptor loci. 
Disease risk may be increased by gene-gene interactions compared to the risk conferred by 
any given gene32. The majority of genetic variants confer risk to ACPA-positive RA while 
other variants may be restricted to ACPA-negative RA, allowing a subclassification of RA33. 
A gene-environment interaction between smoking and HLA-DRB1 (SE) alleles has been 
identified in ACPA-positive RA. The genetic factors involved in ACPA negative RA are less 
well known and involve different pathways, such as interferon regulatory factors, lectin-
binding proteins and different HLA alleles (e.g. HLA-DRB1*03)25.  
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1.2. Epigenetics 
Epigenetics, defined as inherited changes in gene expression that are not encoded in the DNA 
sequence itself, have been recognized as important factors in controlling the expressed 
genome via gene transcription. Epigenetic modifications can influence disease susceptibility 
and severity in RA34-38. Major epigenetics modifications include DNA methylation, histone 
modification, microRNA activity (miRNAs) and other post-translational processes, that 
directly influence genes involved in inflammation and tissue destruction. Importantly, the 
epigenome is influenced by environmental factors through life38. 
1.3. Smoking 
Smoking is a strong environmental risk factor for the development of seropositive and ACPA 
positive RA, with a clear dose-response relationship. RA risk increases after 10 pack-years of 
smoking and remains elevated up to 20 years after cessation39. Smoking not only boosts the 
risk of developing RA among susceptible individuals, it can also increase disease severity and 
reduce the clinical effectiveness of medications used to treat RA. Strong combined gene-
environment effects have been observed, with markedly increased risks of ACPA-positive RA 
among SE homozygotes who were heavy smokers (OR 53), heavy coffee drinkers (OR 53), or 
oral contraceptives users (OR 45)40. Smoking in and of itself is of interest as a risk factor for 
autoimmunity41. Citrullination is a post-translational modification of proteins within the 
context of inflammation42, recognized to occur in the lung of smokers, and thought to 
influence occurrence of antibodies directed against citrullinated proteins43. Smoking has been 
shown to contribute to citrullination of self-peptides and anti-citrulline autoimmunity44. 
Genetic susceptibility factors for RA and smoking are associated mainly with development of 
ACPA positive RA and linked to the SE, as well as smoking, PTPN22 and the gene BRD2, 
with an antibody response to the citrullinated α-enolase peptide-1 (CEP-1)45.  
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1.4. Infectious agents  
Infectious agents have been implicated with RA, including virus (Epstein Barr virus (EBV), 
cytomegalovirus), retrovirus, Escherichia coli, proteus species, and their products such as 
superantigens and heat-shock proteins (HSP), which share antigenic determinants with host 
proteins, resulting in the development of cross-reactive antibodies that may induce an 
autoimmune molecular mimicry response, e.g. two proteins that possess the shared epitope are 
EBV gp110 and Escherichia coli dnaJ, which is an antigenic heat-shock protein46. Infectious 
agents of the oral cavity have been suggested to contribute to RA aetiology, including 
periodontal bacteria47-49. Studies have demonstrated an antibody response against oral 
anaerobic bacteria in serum49,50 and synovial tissue47, as well as presence of oral bacterial DNA 
in the serum and synovial fluid of patients with RA 48. Porphyromonas gingivalis is a common 
pathogen in periodontal disease that has a microbial peptidyl arginine deiminase (PPAD) 
enzyme51,52, which has been shown to citrullinate proteins53. Thus, it is conceivable that 
periodontal disease is associated with RA and may have a causal role in the etiology of RA. 
1.5. Periodontal disease  
Periodontal disease (PD:periodontitis) is a chronic inflammatory disease characterized by loss 
of the periodontal ligament and alveolar bone, and is a major cause of tooth loss. Chronic 
periodontitis is arguably the most prevalent chronic inflammatory disease of humans. A 
growing number of clinical studies have suggested associations between chronic periodontitis 
and various rheumatic diseases, in particular RA. Such an association may be very important 
from a clinical and public health perspective for several reasons. Firstly, there are several 
processes through which chronic periodontitis may be part of a causal pathway in the 
pathogenesis and/or activity status of rheumatoid arthritis. If proven, given the high 
prevalence of chronic periodontitis, a large proportion of RA incidence and/or morbidity 
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could be attributable to chronic periodontitis. Importantly, chronic periodontitis would 
represent a m odifiable risk factor as very effective treatments for chronic periodontitis are 
available. Secondly, chronic periodontitis would contribute to morbidity in patients with RA. 
Periodontitis is a leading cause of tooth loss in adults, which has important clinical 
consequences, including nutritional status and quality of life. Furthermore, chronic 
periodontitis is associated with an increased incidence of coronary heart disease and stroke, 
and this association may at least in part be causal.  
1.5.1. Association between periodontitis and the rheumatic diseases 
We conducted a s ystematic review of the literature on the association between 
rheumatic diseases and chronic periodontitis (paper 2)2. Studies identified by searching 
PubMed database and published until November 2008 were considered. We also performed a 
hand search on reference lists of original articles as well as conference proceedings. We 
identified that published studies vary widely with respect to design, setting, and methods used 
to ascertain associations between rheumatic diseases and periodontitis. The majority of 
studies are relatively small prevalence case-control studies. Frequently, control subjects were 
volunteers recruited from the staff working at the study centres (e.g. university/hospital staff) 
or patients attending dental clinics raising concerns regarding study validity. The majority of 
oral care is administered in the primary care sector, and patients attending dental clinics or 
hospitals are unlikely to be representative of the general population. This may have resulted in 
over- or underestimation of the association between rheumatic disease and periodontitis/tooth 
loss. Another difficulty when evaluating the evidence for an association between rheumatic 
disease and periodontitis relates to lack of consistent criteria used to define a “ case” of 
periodontitis. Periodontitis can be assessed clinically by measuring periodontal probing depth 
and attachment levels at various sites of the dentition or by measuring alveolar bone loss from 
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radiographs. Definitions of periodontitis in clinical research are based on either measure or on 
combinations thereof and vary widely between studies. Attempts to define case definitions of 
periodontitis for clinical studies (similar to the ACR criteria for RA) have only recently been 
made and have not yet been universally adopted. In addition, some studies have looked at 
serological markers of periodontitis (e.g. antibodies to periodontal pathogens), which may not 
correlate well with the clinical phenotype. Furthermore, some studies have used self-reported 
markers of periodontitis, which frequently lack validity. The majority of studies employed 
ACR criteria for defining RA; however, some studies used self-reported RA, which is 
notoriously inaccurate (specificity of 6%).  
1.5.2. Link between rheumatoid arthritis and periodontal disease 
We conducted a population based study based on the US National Health and 
Nutrition Examination Survey (NHANES III)(paper 3)3. RA was based on the ACR1987 
criteria. Periodontitis was defined based on a standardized clinical examination by calibrated 
dental examiners. Participants with 4 out of 6 ACR criteria evaluated had a 4-fold increase in 
the odds of periodontitis (OR 4.1; 95% CI 1.3-13.1), after adjusting for age, gender, 
race/ethnicity, and smoking. RA was also associated with a 3-fold increase in the odds of 
edentulism (complete tooth loss) controlling for age, gender, race/ethnicity, and smoking. 
This association was particularly strong for those with seropositive RA (OR 4.5, 95% CI 1.2, 
17), and was largely preserved with further adjustment for a number of potential confounders 
including education, income, diabetes, bone mineral density, BMI, and physical activity.  
Several biologically plausible causal and non-causal mechanisms may account for this 
association (reviewed in paper 2)2 as illustrated in Figure 2. Recent evidence suggests that 
periodontitis may indeed be a causal factor in the initiation and maintenance of the 
autoimmune inflammatory response in RA. If so, chronic periodontitis may represent an 
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important modifiable risk factor for RA. In addition, patients with RA may be at increased 
risk for periodontitis and tooth loss through various mechanisms. Additional non-causal 
pathways include genetic, environmental and behavioural exposures common to both 
conditions. Susceptibility to chronic inflammatory diseases, including periodontitis and RA, is 
determined by the interplay between genetic factors and environmental exposures, which 
could represent common risk factors for both disease, and thus confound the association 
between RA and periodontitis (non-causal pathways). Periodontitis could be a causal factor in 
the pathogenesis of RA through various pathways, including periodontal pathogens and 
Porphyromonas gingivalis in particular53. Conversely, PD may predispose to RA (Figure 2).  
 
Figure 2. Possible pathways in the association between RA and periodontal disease 
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A common periodontal pathogen, Porphyromonas gingivalis, expresses a peptidyl arginine 
deiminase (PAD) enzyme51,52 that citrullinates mammalian proteins53. Thus, individuals with 
periodontitis are exposed to citrullinated antigens that may become systemic immunogens 54. 
Subjects with periodontitis may have positive ACPA in the absence of rheumatoid arthritis55. 
Antibody titres to P. gingivalis have been correlated with anti-citrullinated protein antibodies 
(ACPA) in subjects with RA50. An immunodominant epitope in citrullinated α-enolase 
(antibodies to citrullinated α-enolase are specific for RA) has been identified. The sequence 
similarity and cross-reactivity with bacterial enolase from P. gingivalis may indicate a role for 
this periodontal pathogen in priming inflammation in RA56. 
 
1.6. Autoantibodies   
Rheumatoid factor (RF), an auto-antibody reacting with the Fc portion of immunoglobulin G 
(IgG), is present among 70-80% of patients with RA and about 10-20% of the general 
population. RF is associated with disease severity and extra-articular manifestations, but it is 
not specific to RA as it can be found in other chronic inflammatory conditions. More specific 
tests for RA have been developed over recent years, encompassing a range of antibodies 
against cyclic citrullinated peptides and proteins (CCP) under the umbrella term ACPA. 
ACPA may have different reactivities, including antibodies against CCP, mutated citrullinated 
vimentin (MCV), citrullinated α-enolase peptide-1 (CEP-1), citrullinated fibrinogen, 
citrullinated fibronectin and citrullinated collagen II. The presence of both RF and ACPA 
antibodies has a high specificity for the development of RA and actually precede the 
appearance of clinically identifiable arthritis by several years57-59. This suggests that the initial 
immune dysregulation in RA occurs years prior to symptoms onset, although how this 
develops is yet unknown. 
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Citrullinated proteins have been identified in different types of inflammatory arthritis, as well 
as at other sites of inflammation. However, the development of ACPA appears to be specific 
to RA and is predictive of RA disease severity and clinical outcome60. Since ACPA appear 
very early in the course of the disease, their detection is important to identify the most 
destructive form of RA, allowing early combination therapy to prevent irreversible structural 
damage60. ACPA positive forms of RA may represent a clinically and pathologically distinct 
subpopulation. Two main ACPAs are used in clinical practice, anti-cyclic citrullinated peptide 
(anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) antibodies. Both are markers 
of RA disease severity61,62 and extra-articular disease63, particularly lung disease64. The lung 
has been suggested as a s ite of initial RA-related immune dysregulation based on t he 
occurrence of lung involvement in early RA, as well as the association with smoking, and 
occupational exposures such as silica dust, mineral oil, and air pollution65-86, which suggests 
that respiratory exposures activating the immune system may lead to the development of RA. 
Smoking has been shown to contribute to citrullination of self-peptides and ACPA 
autoimmunity43,44. The combined effect of shared epitope, PTPN22 and smoking showed a 
strong association with the anti-CEP-1 positive subset compared with the anti-CEP-1–
negative / ACPA positive subset, suggesting that CEP-1 is a specific citrullinated autoantigen 
that links smoking to genetic risk factors in the development of RA45. The stress of mucosal 
barriers may trigger post-translational modifications mediated by peptidyl arginine deiminase 
enzymes such as PAD4, that result in citrullination of proteins or peptides present in mucosal 
tissues. These modified proteins or peptides may result in ACPA response and reactivity 
triggering autoimmunity. To investigate this, we conducted two prospective studies in 
samples of non-RA patients potentially at risk of developing RA, based on their exposures 
and/or diagnoses. Based on r ecent EULAR recommendations on t he specific preclinical 
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phases up to the development of RA87, we included individuals classified as (b) (i.e. with 
environmental risk factors for RA), and tested whether these individuals had progressed from 
(b) to (c) (i.e. whether these individuals at risk for RA had developed systemic autoimmunity 
associated with RA).  
1.6.1. Role of periodontitis in the induction of RA-related autoimmunity  
This study tested the autoantibody repertoire in periodontal disease (paper 4)4, 
following on our  previous observations based on our  population-based study, in which we 
observed a significant four-fold increase in the odds of periodontitis in people with RA 
(paper 3)3 and our systematic review of the literature suggesting an association between 
periodontitis and RA (paper 2)2. Further, P gingivalis is a common periodontal pathogen with 
a PPAD enzyme, which is unrelated to PAD enzymes in vertebrates89. Nonetheless, microbial 
PAD activity deaminates arginine in fibrin found in periodontal tissue51 and citrullinates 
mammalian proteins53, thus it is conceivable that PD may have a causal role in the etiology of 
RA. We hypothesized that RA-specific autoimmunity may be generated in the gums and that 
periodontal citrullination might be a relevant process generating autoantibodies in PD. The 
purpose of this study was to determine the immune reactivity to ACPA and their 
uncitrullinated control peptides in patients with periodontitis diagnosed by periodontal and/or 
radiological examination. Serum samples were tested for the following ACPA by ELISA: 
anti-cyclic citrullinated peptide (anti-CCP), anti-mutated citrullinated vimentin (anti-MCV), 
anti-citrullinated α-enolase peptide-1 (CEP-1), vimentin (cit-vim), fibrinogen (cit-fib) and 
their uncitrullinated forms CParg (negative control peptide for CCP) REP-1, vim and fib). 
Multiple regression models were used to evaluate differences in ACPA response between 
individuals with and without periodontitis, adjusting for potential confounders. We analysed 
96 patients with and 98 without periodontitis, none of whom had RA at inclusion. The 
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prevalence of anti-CCP and anti-MCV was around 1% in both PD and non-PD subjects. 
Periodontitis, compared with non-PD, was associated with a higher frequency of positive 
antibodies to CEP-1 (12% and 3%, respectively; p=0.02) and its uncitrullinated form REP-1 
(6% and 2%, respectively; p<0.001). Positive antibodies against fib (negative control peptide 
for cit-fib) and CParg were also more common among those with PD compared to non-PD 
patients (26% and 3%; p<0.001, and 9% and 3%; p=0.06, respectively). After adjusting for 
confounders, patients with periodontitis had 43% (p=0.03), 71% (p=0.002) and 114% 
(p<0.001) higher CEP-1, REP1 and fib antibody titres, compared with patients without 
periodontitis. After stratification for smoking, non-smokers with PD, compared with non-PD, 
had significantly higher titres of antibodies against CEP-1 (103%, p<0.001), REP-1 (91%, 
p=0.001), vimentin (87%, p=0.002), and fib (124%, p<0.001), independent of confounders, 
confirming that the antibody response was not due to smoking. We have shown that PD is 
associated with an antibody response to both citrullinated and uncitrullinated peptides of the 
RA autoantigens, and primarily to the uncitrullinated variants. This loss of tolerance could 
then lead to epitope spreading to citrullinated epitopes as the autoimmune response in 
periodontitis evolves into that of pre-symptomatic RA (paper 4)4.  
1.6.2.  Lung disease in the induction of antibodies to citrullinated antigens  
Given that citrullination, and anti-citrullinated protein antibody formation occurs in 
smokers, in his study we measured the autoantibody reactivity in a cohort of patients with 
lung disease (paper 5)5. We compared the autoantibody reactivity in subjects with usual 
chronic obstructive pulmonary disease (COPD) due to smoking (n=113), subjects with lung 
involvement due to α1-antitrypsin deficiency (AATD) (non-smokers, n=257), and healthy 
non-smokers (n=22). We measured ACPA (i.e. anti-cyclic citrullinated peptide (anti-CCP) 
and anti-mutated citrullinated vimentin (anti-MCV) antibodies) and also anti-elastin, given 
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that liberation of elastin peptides from the damaged lung may be a mechanism of autoimmune 
lung disease. Anti-elastin antibodies were higher in controls relative to AATD (p=0.008) and 
COPD (p<0.001), and in AATD relative to usual COPD (p<0.001). Anti-elastin levels showed 
a threshold at 10 pack-yrs, being higher in those who had smoked less (p=0.004). Smoking 
was the main determinant of anti-elastin antibody levels, which fall after 10 pack-yrs. With 
regards to ACPA, anti-CCP antibodies were higher in COPD than AATD (p=0.002) and were 
positive 8/257 (3.1%) AATD subjects and 6/113 (5.3%) of those with usual COPD. Anti-
MCV antibodies were also higher in COPD than AATD and were positive in 34/257 (13.2%) 
of AATD subjects and 20/113 (17.7%) with usual COPD. These results suggests that the lung 
may contribute to the development of autoimmunity related to RA, by inducing antibodies to 
citrullinated autoantigens (paper 5)5.  
Taken together, the results of the two herein presented studies (papers 4 and 5 respectively), 
conducted among patients with other diseases that may predispose to the development of RA, 
i.e. periodontitis and lung disease, suggest that a breach of tolerance to citrullinated and 
uncitrullinated autoantigens may occur in association with disease at mucosal barriers, 
particularly in periodontitis. It is therefore conceivable that the pathogenesis of RA starts in 
tissues other than the joints, i.e., systemic autoimmunity is triggered by processes distant from 
the joints, a process which may or may not be followed by a ‘second hit’ leading to clinically 
apparent inflammatory arthritis in susceptible individuals. Individuals within the preclinical 
phase may be suitable targets in future strategies of primary prevention of RA. The spectrum 
of preclinical RA is wide, varying from individuals manifesting only with autoantibody 
production and no s igns or symptoms to those who become symptomatic and then have 
clinically apparent arthritis.  
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1.7. Gender and other factors 
Sex hormones or sex specific factors influence RA susceptibility. The majority (70%) of 
people with RA are women. Female hormones play a role in RA, possibly due to the 
stimulatory effects of oestrogen on the immune system90,91. Various reproductive factors may 
be involved, as pregnancy is often associated with remission in the last trimester, with common 
postpartum disease flares, and also illustrated by the increased risk of RA associated with 
nulliparity, and RA risk reduction by breastfeeding for 1 year or more92. Of note, men with RA 
have lower levels of testosterone and dehydroepiandrosterone (DHEA) and higher estradiol 
levels93,94 although whether this is a consequence of inflammation is unknown. Stressful events 
such as emotional or physical trauma and a lower socioeconomic status have been related to the 
development of RA, while alcohol intake may be protective. The role of vitamin D as modifier 
of RA risk remains equivocal95.  
2. Synovial inflammation 
RA is considered as an immune-mediated syndrome with involvement of both innate and 
adaptive immune systems. Different cells of the immune system and a broad range of 
cytokines, which trigger and amplify inflammatory pathways and promote the activation of 
other cells, such as fibroblasts, chondrocytes and osteoclasts, participate in a complex chain of 
events leading to persistence of synovial inflammation and active joint destruction31.  
Leucocytes migrate and infiltrate the synovium producing synovial inflammation. Migration of 
leucocytes is facilitated by endothelial activation in synovial microvasculature, increased 
expression of adhesion molecules and chemokines. Microscopic changes include 
neoangiogenesis induced by cytokines, insufficient lymphangiogenesis, which limits cell exit 
96,97, and fibroblast activation resulting in the generation of synovial inflammatory tissue. 
While T cells are increased in the synovial tissue, their functional role remains unclear. Broad 
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spectrum targeting T cells or T cells deletion therapies have shown no efficacy 98, which may 
suggest the need to refine the target to specific T cell subsets31. Myeloid cells and plasmacytoid 
dendritic cells, which express cytokines, HLA-II molecules and co-stimulatory molecules 
involved in T cell activation and antigen presentation99,100, are increased in the RA synovium. 
T cell co-stimulation with abatacept, a fusion protein containing CTLA4 and the Fc fragment 
of IgG1, is effective in RA. The role of 17 helper T cells (Th17), a cell subset producing IL-17, 
21, 22 and TNF-α, has been implicated in RA101. Th17 differentiation, promoted by IL-1β, 6 21 
and 23 and other mediators, does inhibit regulatory T cells, shifting the balance towards 
inflammation. IL-17 synergizes with TNF-α to activate fibroblasts and chondrocytes and 
inhibit regulatory T cells102. The involvement of CD20+ B cells is confirmed by the efficacy of 
rituximab in RA103. B cells are localized in T cell-B-cells aggregates as ectopic lymphoid 
follicles supported by APRIL, BlyS and chemokines in the synovium104. Plasma cells in the 
synovium and periarticular bone marrow are not targeted by rituximab, thus the role of B cells 
in RA may involve autoantigen presentation and cytokine production, in addition to 
autoantibody production31.  Other cells of the innate immune system migrate to the synovial 
membrane in response to colony-stimulating factors, including macrophages, natural killer 
cells and mast cells. Macrophages are key players in synovial inflammation, activated by toll-
like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLRs) that recognize molecular patterns associated with pathogens and endogenous 
ligands105, and also by cytokines, immune complexes, T cell interactions, lipoprotein particles 
and liver X-receptor agonists106. Neutrophils in the synovial fluid, produce prostaglandins, 
proteases and reactive-oxygen species107. Activated mast cells 108 and their products (e.g. 
vasoactive amines, cytokines, chemokines, and proteases)109 activate chondrocytes, synovial 
fibroblasts and macrophages that contribute to joint inflammation110.  
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2.1. Cytokines  
The inflammatory cytokine network contributes to the pathogenesis of RA111,112. TNF-α is a 
potent cytokine that activates cytokine and chemokine expression, endothelial-cell adhesion 
molecules expression, regulatory T cells suppression, and promotes angiogenesis113. IL-6 
mediates systemic effects such as anaemia, acute-phase responses, cognitive dysfunction, and 
lipid alterations. Consequently, inhibition of these cytokines has emerged as an important 
therapeutic target. IL-1 family cytokines promote cell activation of endothelial cells, 
leukocytes, chondrocytes and osteoclasts111. IL-1 blockade however has shown limited clinical 
response. Other pathways targeting cytokines are under way, including B-lymphocyte 
stimulator (BlyS), IL-17, a proliferation-inducing ligand (APRIL), granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF), and 
RANKL receptor activator of NF-kB ligand. The development of specific small-molecule 
inhibitors may evolve with the understanding of the intracellular signalling molecules such that 
regulate cytokine receptor mediated functions. Fostamatinib blockade of spleen tyrosine 
kinase, which is implicated in B-cell and Fc receptors, is effective in some patients114,115, while 
tofacitinib, a inhibitor of Janus kinase (JAK) pathways which mediate the function of 
cytokines, interferons and other mediators116,117. 
2.2. Tissue response 
RA is characterized by synovial hyperplasia with expansion of the membrane lining where 
fibroblast-like synoviocytes (FLS) display anchorage independence, loss of contact inhibition 
and expression of cytokines, chemokines, adhesion molecules, matrix metalloproteinases 
(MMPs), and tissue inhibitors of metalloproteinases (TIMPs)118. These cells contribute to 
cartilage destruction and persistence of inflammation, sustaining T-cell and B-cell survival and 
adaptive immune organization119. FLS have been shown to migrate and spread RA to 
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unaffected joints120. The molecular basis promoting synovial hyperplasia is unknown, but 
possible explanations in addition to FLS proliferation, include apoptosis resistance mediated by 
different pathways including stress proteins expression121, p53 mutations122 and synoviolin, a 
E3 ubiquitin ligase regulating the cell proliferation/apoptosis balance123. Other potential factors 
include methylation and acetylation of cell-cycle regulatory genes and altered expression of 
microRNA in fibroblast-like synoviocytes124. Cadherin-11, a surface molecule, appears to have 
a critical role in the synovial lining processes and migration of FLS leading to damage125-127. 
2.3. Cartilage destruction 
FLS adhesion and invasion is facilitated by the loss of lubricin, a secreted glycoprotein that 
protects cartilage surface inhibiting synovial cell overgrowth128. FLS produce MMPs and other 
enzymes that degrade the collagenous cartilage matrix in a process not entirely opposed by 
endogenous enzyme inhibitors such as TIMPS, resulting in biomechanical alterations. 
Chondrocytes regulating matrix formation undergo apoptosis in response to cytokines in the 
synovium, which results in cartilage destruction seen as joint space narrowing on x-rays. 
2.4. Bone destruction 
Bone erosion occurs early in the course of the disease affecting 50% of cases within the first 
year129. The periosteal surface adjacent to articular cartilage is invaded by osteoclasts in 
response to synovial cytokines, in particular NF-kB ligand (RANKL) and macrophage colony-
stimulating factor130. Osteoclast differentiation and activation is promoted by cytokines such as 
IL-1, 6, 17 a nd TNF-a131, the therapeutic blockade of which reduces erosion formation31. 
Osteoclasts enzymes destroy mineralized cartilage and subchondral bone leading to resorption 
pits that are seen as bone erosions on radiographs31. Erosions occur in sites with a mechanical 
predisposition such as the second and third metacarpal bones132. Bone marrow is accessed by 
synovial tissue through erosions resulting in bone marrow inflammation (seen as osteitis seen 
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on MRI), involving T-cell and B-cell aggregates133. However, the temporal association in the 
interaction between the inflamed synovium and bone marrow in RA remains unknown. 
Whether the lesions on each side of the cortical bone occur simultaneously, or whether bone 
involvement (osteitis) precedes the erosion is unclear, thus RA may start in the bone marrow 
and then spread to the synovial tissue31. However, bone repair of the erosions is unlikely. 
Chondroblast and osteoblast precursors differentiation from mesenchymal cells is inhibited by 
dickkopf-1 and frizzled-related protein-1 induced by cytokines134. Understanding of the 
synovium-derived mesenchymal stem cells biology may open therapeutic strategies135,136. 
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E. Development of rheumatoid arthritis 
The development of RA from preclinical to full-blown clinical disease can be understood 
using a metaphor of the growth of a plant from its seed to a mature plant as suggested by 
Hazes & Luime137. There are no signs or symptoms of the disease in the preclinical phase, yet 
the genetic risk factors for RA are present, and the exposure to environmental risk factors, 
such as smoking, lung disease or periodontal disease, among others, may or may not have 
occurred. At this point, autoimmunity may develop, as suggested by the presence of 
autoantibodies such as ACPA or RF. This pre-articular phase can develop into a phase where 
joint pain is present without clinically objective synovitis. In the initial clinical phase, 
unspecific inflammatory arthritis can be identified but it is not classifiable. The disease 
develops in the next clinical phases to become fully classifiable into RA. The development of 
RA is illustrated on Figure 1. The spectrum of preclinical RA is wide, varying from patients 
manifesting only with autoantibody production and no signs or symptoms to those who have 
become symptomatic and have clinical synovitis. Recently a European League against 
Rheumatism (EULAR) recommendation for terminology to be used to define specific 
preclinical phases up to the development of RA has been published87. Individuals would be 
described as having: (a) genetic risk factors, (b) environmental risk factors, (c) systemic 
autoimmunity associated with RA, (d) symptoms without clinical arthritis, (e) unclassified 
arthritis, and (f) RA, in the context of prospective studies. According to these 
recommendations, (a) to (e) can be used in any combination, for example, an individual may 
have (a) + (b), or (a) + (b) + (c), or (a) + (b) + (d), etc. Recognized biomarkers that are known 
to be present before the development of RA include for example presence of synovitis on 
imaging but not clinically, or presence of RF and/or ACPA, reflecting systemic autoimmunity 
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associated with RA. People in the preclinical phase should be targeted in prevention strategies 
as early immune modulation may prevent disease among those at risk of RA26,27.  
1. Does time matter?   
Early diagnosis of RA is essential to then implement an early management plan that may 
change the disease course to improve patient outcomes. Effective treatment strategies became 
available in the 1990s and it is now widely accepted that these strategies should be 
implemented early in the disease course138. Compared with delayed treatment, early initiation 
of disease-modifying drugs (DMARDs) in recent-onset RA is more effective in inducing 
disease-remission139-141, preventing progression of structural damage139,142,143, and preserving 
physical function and work ability141,144,145. Identifying people at risk for RA, within the 
spectrum of preclinical disease, is important as these should be targeted in future strategies for 
secondary prevention of RA. 
2. Is there a therapeutic window of opportunity? 
It is now clear that outcome is improved by the early introduction of disease modifying anti-
rheumatic drugs (DMARDs)6. We have shown in a meta-analysis of observational studies and 
randomized controlled trials that there is a critical period during which antirheumatic therapy 
should be initiated6, a therapeutic window of opportunity early in the course of RA, associated 
with sustained benefit on s tructural damage (paper 6)6. Early identification of patients with 
RA is essential to allow the prompt institution of therapy. However, the timely initiation of 
antirheumatic therapy requires an early classification or diagnosis of RA, or of early arthritis 
at risk of developing into persistent and erosive disease. 
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F. Prediction models for the development of rheumatoid arthritis 
Prevention of structural damage is an important goal of therapy and early combination therapy 
improves outcomes in RA; thus, it is important to improve the prediction of RA early in the 
disease course. Clinical prediction rules have been developed to improve the early 
identification of patients at risk for RA146-148 before the 2010 A CR/EULAR classification 
criteria for RA. The most widely used models were developed using data from the Leiden 
early arthritis clinic. The first model was developed to predict persistent and persistent erosive 
disease in all patients with early arthritis146. This model, also known as the Visser score, 
includes information on weighted variables, which are symptom duration, morning stiffness 
duration, arthritis in 3 or  more joints, MTP tenderness, RF positivity, ACPA positivity, and 
erosions. The AUC of the Visser score was 0.84 for discriminating between self-limiting and 
persistence, and 0.91 f or discriminating between erosive and non-erosive persistence. A 
second model was developed by the same group to predict the development of 
undifferentiated arthritis into RA as defined by the ACR 1987 criteria147. This model, also 
known as the Leiden score, included other weighted variables, such as age, gender, global 
health, morning stiffness, pattern of joint involvement distribution, tender and swollen joint 
counts, RF and ACPA positivity, and CRP levels. The AUC for the Leiden model was 0.89 
(SD±0.014). The Leiden score has been validated in the Birmingham cohort of newly 
presenting patients with very early synovitis149. However, the prediction models are not 
perfect as they do not capture patients early in the disease course or with subclinical disease. 
1. Role of ultrasound as a predictor of outcome in very early arthritis  
Given that ultrasound imaging may detect joint inflammation and structural changes early in 
the disease course, in particular in the pre-articular phase when the presence of inflammatory 
arthritis is not observed by the physician, we investigated the role musculoskeletal ultrasound 
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as a predictor of outcome in people with arthritis at the very early stages of the disease course 
(paper 7)7. In this longitudinal study of newly presenting patients with very early synovitis, 
ultrasound demonstrated subclinical joint involvement in patients developing RA. Compared 
to the Leiden score, ultrasound significantly increased the AUC for predicting RA (AUC 
0.905 vs. 0.962, respectively), indicating that ultrasound counts provide independently 
predictive data over and above the Leiden score. In particular, ultrasound scanning of the 
MCP, wrists and MTP joints provides the optimum minimal ultrasound data to improve RA 
prediction.  
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G. Classification criteria for rheumatoid arthritis 
The classification criteria for RA were originally published in 1958 a nd revised in 198723. 
Evidence indicates that early diagnosis leading to early intervention is a strategy that reduces 
and even prevents RA consequences. Thus, prompt initiation of disease-modifying 
antirheumatic drugs (DMARDs) aiming at remission is the goal of therapy. The classification 
criteria do not perform well identifying early RA among cases of recent-onset arthritis150. In 
2010, the American College of Rheumatology (ACR)/European League against Rheumatism 
(EULAR) revised the criteria for identification of patients with newly presenting 
inflammatory arthritis who are at high risk of persistence and erosive damage, and for use as a 
basis for initiating disease-modifying therapy24. Based on the data from existing early arthritis 
cohorts and previous prediction models146-148, the new criteria include disease duration, the 
presence of RF or ACPA, the extent and pattern of joint involvement, and the presence of an 
acute phase response. However, the performance of these new criteria had not been tested in 
an independent cohort of patients with very early arthritis. 
1. Performance of the 2010 RA classification criteria in very early arthritis 
We assessed the performance of these new criteria in patients with early synovitis, seen within 
3 months of the onset of inflammatory arthritis, and followed for 18 months to determine 
outcomes and the cumulative fulfillment of 2010 and 1987 criteria and management (paper 
8)8. Among 265 patients included in the study, 60 had alternative diagnoses at baseline. Of the 
remaining 205 patients, 20% met both 1987 and 2010 criteria, 3% met only 1987 criteria and 
22% met only the 2010 criteria at baseline. The 2010 c riteria, when applied at baseline, 
detected more patients who eventually required disease-modifying antirheumatic drugs 
(DMARDs), especially methotrexate, within the first 18 m onths. However, more patients 
whose disease eventually resolved without ever requiring DMARD were classified at baseline 
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as RA according to the 2010 criteria than with the 1987 criteria. We concluded that the 2010 
ACR/EULAR criteria allow more rapid identification of patients requiring methotrexate 
compared with the 1987 ACR criteria when applied at baseline. However, if these criteria are 
to be used in very early disease, over diagnosis is an important issue to consider (paper 8)8. 
Our results were in line with recent studies indicating that the 2010 ACR/EULAR criteria are 
more sensitive for the identification of patients early in the disease course151,152. Importantly, 
when we investigated the role musculoskeletal ultrasound as a predictor of outcome in people 
with arthritis at the very early stages of the disease course, we found that 83% of those who 
developed RA met the 2010 ACR/EULAR criteria at baseline. When we replaced the clinical 
joint examination variables by joint ultrasound variables using these criteria, then 93% of 
patients were classified as RA at baseline, showing that ultrasound scanning does improve the 
prediction and classification criteria for RA early in the disease course (paper 7)7.  
  
31 
 
H. Disease outcome  
The course of RA is variable. About 15-20% of patients have intermittent disease with flares 
and a relatively good prognosis. However, the majority have progressive disease with either a 
slow or a severe course. The outcome of RA depends upon the degree of structural damage, 
the physical function status, psychological health, and the presence of coexisting conditions. 
1. Physical function  
Functional capacity is a useful tool for assessing clinical effectiveness of therapeutic 
interventions. Functional disability indices are based on self-report questionnaires, which 
have been validated such as the Stanford Health Assessment Questionnaire (HAQ)153,154 and 
the Arthritis Impact Measurement Scale Health Status Questionnaire (AIMS)155. However, 
these instruments focus on the physical impact, rather than the psychological impact of RA, 
which may contribute up to 20% towards disability156,157. The SF-36, a g eneric health 
instrument consisting of 36 i tems organized in 8 domains including function and impact of 
physical disability and participation, is designed to assess overall health status158.  
2. Disease activity  
Disease activity indicators include swollen and tender joint counts, pain, patient and 
evaluator global assessments of disease activity assessed (PGA and EGA, respectively), 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), duration of morning 
stiffness, and fatigue. The disease activity scores (DAS) provides a global summative and 
continuous score for disease activity assessment159. A simplification of the DAS, the DAS28, 
reduced the joints evaluated to 28 joints, is more practical and widely used in clinical trials 
and clinical practice160. The DAS28 includes swollen and tender joint counts of 28 j oints, 
global health assessment, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). 
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Ranges of disease activity based on DAS28 scores have been proposed: remission 
(DAS28<2.6), low (DAS28 2.6-3.2), moderate (DAS28 3.2-5.1), and high (DAS28>5.1).  
The Simplified Disease Activity Index (SDAI) uses five of the core set variables (SDAI = 
TJC28 + SJC28 + PGA + EGA + CRP) and gives a linear sum of untransformed variables161. 
The SDAI has been validated and has high sensitivity and specificity for predicting change in 
DMARD therapy when compared to DAS28 at a cutpoint of 15162-164. The Clinical Disease 
Activity Index (CDAI), a further simplification of the SDAI, uses the same measures as the 
SDAI but does not require CRP measurement (CDAI = TJC28 + SJC28 + PGA + EGA). The 
CDAI correlates well with other disease activity scores and response criteria, as well as 
disease progression and functional impairment 161,165,166. 
 
Several self-reported instruments are available for the assessment of RA activity. These 
include the RA disease activity index (RADAI), the rapid assessment of disease activity in 
rheumatology (RADAR), and a modified Routine Assessment of Patient Index Data 
(RAPID3)167-170. The RADAI has five items, including patient-assessed joint counts167 and the 
RADAR has six items relates to symptoms, function, work impact, psychological and social 
health and satisfaction168. However, these instruments are rarely used in clinical trials. Patient 
centered outcomes most widely used are global assessments of disease activity with visual 
analog scales, HAQ scores and the SF-36. The RAPID3, expanded from the RAPID includes 
a HAQ, physical function, pain, patient global estimates, all normalized to 0-10, added and 
divided by 3 to give a score on a scale of 0-10169,170 and provides similar information to the 
DAS28 or the CDAI170. 
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3. Response criteria  
 
3.1. ACR response criteria  
An early attempt to define minimal response were the Paulus criteria171, which provided 
the basis for the ACR response criteria172. The ACR criteria measure the frequency of benefit 
(i.e. the proportion of patients achieving a defined response) in a categorical response. The 
ACR20 response is defined as improvement of at least 20% in the number of both swollen 
and tender joint counts, as well as 20% improvement in ≥3/5 variables (PGA, EGA, pain 
visual analog scales, HAQ, acute phase response). The ACR50 and ACR70 criteria 
correspond to 50 and 70% improvement, respectively173.  
3.2. EULAR response criteria 
The EULAR response criteria, based on the DAS28, categorize improvement into either 
good or moderate responses. A good response is defined by a decline in score >1.2 and results 
in the achievement of low disease activity (DAS28<3.2). A moderate response is defined by a 
decline in DAS28 by >1.2  or  by a decline in DAS28 of 0.6 t o 1.2 a nd reaching at least 
moderate disease activity (DAS28<5.1) 174,175. Disease activity varies in RA, partly due to 
endogenous rhythms of the disease but mainly as a result of therapeutic interventions, which 
depend on the efficacy, side effects or withdrawal of therapy. In contrast, structural damage is 
cumulative and irreversible. The degree of damage depends on di sease activity and 
inflammation as well as repair176. As structural damage progresses, disease activity 
assessment by clinical examination becomes more difficult. The symptom and signs of 
inflammation may be caused either by persistent disease or as a result of mechanical damage. 
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4. Remission criteria  
Remission criteria defined by the American College of Rheumatology (ACR) are based on 
absence of symptoms for at least 2 consecutive months or low disease activity scores. 
However, clinical remission defined by these criteria does not rule out radiographic 
progression and disability, as clinical parameters do not appear to correlate with radiographic 
progression and structural damage. Therefore, because those in remission at one time need to 
have a low risk developing radiographic progression or loss of function, the ACR/EULAR has 
recently proposed new definitions of remission of RA177, in which a number of different 
individual disease activity measures are considered at the same time. Based on these criteria, 
remission is achieved when the number of tender and swollen joints, the patient global 
assessment score (scale 0-10) and the CRP concentrations (mg/dl) are all ≤1. An alternative 
definition is a Simplified Disease Activity Index (SDAI) ≤3.3177. 
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I. Disease progression and structural damage  
Prevention of structural damage is an important goal of therapy. Radiographic imaging is 
considered the ‘gold standard’ for assessment of disease progression in RA178, and used 
extensively in clinical trials as the primary outcome measure. Furthermore, radiographic 
assessment of joint damage is recommended by the Food & Drug Administration (FDA) as an 
outcome measure that supports the prevention of structural damage claims in clinical trials of 
pharmaceutical interventions in RA179. The radiographic assessment using traditional scoring 
methods such as the Sharp or Larsen systems is subjective and based on a  qualitative 
assessment of the joints180,181. Other imaging modalities used in RA include ultrasound and 
magnetic resonance imaging (MRI), however, these are not widely adopted as they are 
operator dependant and/or expensive. A recent study observed that clinical and radiographic 
measures of RA generally correlated well with MRI. However, changes in MRI and 
clinical/radiographic measures did not correlate well, probably because MRI is more sensitive 
than radiographs and more objective than DAS28182.  
The available radiographic scoring methods do not attempt to provide a true measure of 
the size of the radiographic structures; rather, a score is given on an ordinal scale that is based 
on a comparison to representative examples. Several computerized techniques and software 
tools have been developed to measure radiographic changes on digitized radiographs 
Computer-based methods to measure radiographic joint space width (JSW) have the potential 
to improve the longitudinal assessment of RA by providing an objective and continuous 
outcome measure with enhanced reliability and sensitivity to change. 
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1. Computer-based method to assess disease progression 
We developed a semi-automated software application to measure radiographic JSW of the 
proximal interphalangeal (PIP), and metacarpophalangeal (MCP) joints on di gitized hand 
radiographs. We assessed the diagnostic performance of a s emi-automated computer-based 
method for measuring joint space width.  
1.1. Sensitivity to change 
We compared the diagnostic performance of a computer-based method for measuring 
JSW with the Sharp joint space narrowing (JSN) scoring method in a random sample of early 
RA patients with sequential hand radiographs scored with the Sharp method from the 
National Data Bank for Rheumatic Diseases. Hand joint space width was measured with our 
automated computer-based method in a blind and random order. We constructed a receiver 
operating characteristics curve and compared the diagnostic performance of the computer 
based and Sharp methods based on t he areas under the curve. We included 129 early RA 
patients with radiographic follow-up. Changes in the software and Sharp methods were highly 
correlated (R = 0.75, p<0.001). The computer-based method was significantly more 
discriminant than the Sharp JSN subscale: The area under the curve of the software method 
was 0.96 (95% CI 0.94, 0.99) compared to 0.93 (95% CI 0.89, 0.96) for the Sharp subscale (p 
= 0.024). At the most discriminant cut-off, specificity of the software method was 88.4% 
(95% CI 81.5% - 93.3%) compared to 81.4% (95% CI 73.6% - 87.7%) for the Sharp subscale 
(p = 0.04); sensitivity was 87.6% (95% CI: 80.6% - 92.7%) for the computer-based method 
compared to 82.2% (95% CI: 74.4% - 88.3%) for Sharp subscale (p = 0.13). We observed that 
the software method for measuring JSW was more discriminant than the semiquantitative 
Sharp JSN subscale (paper 9)9. Our data suggests that image analysis software can be used to 
provide quantification of structural changes on a continuous scale (paper 9)9. 
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1.2. Repositioning reproducibility  
An additional and previously unreported source of error is the change in JSW due to 
patient repositioning. In a subsequent study we measured the long-term patient repositioning 
reproducibility of software-measured radiographic JSW. We included 136 patients, selected 
from subjects in the National Data Bank for Rheumatic Diseases, with baseline and follow-up 
hand radiographs with a follow-up time of less than or equal to 3 years. To eliminate any JSW 
change due to real disease progression, evaluation was performed on unaffected joints, 
defined as having a total Sharp score of zero at both baseline and follow up. The Root Mean 
Square Standard Deviation (RMSSD) and coefficient of variation (CoV) were used as the 
reproducibility metrics. The RMSSD (CoV) was 0.14 mm (10.5 %) for all joints, 0.18 mm 
(10.9 %) for the MCP joints, and 0.08 mm (8.3 %) for the PIP joints.  The distribution of JSW 
change was asymmetric suggesting that actually joint narrowing occurred for many of the 
joints. A second analysis was performed excluding joints where the loss of JSW was greater 
than three standard deviations. For this analysis, the RMSSD (CoV) was0.10 mm (7.5 %) for 
all joints, 0.12 mm (7.2 %) for the MCP joints, and 0.07 mm (7.1 %) for the PIP joints. We 
observed that repositioning reproducibility is very good but is likely to be a dominating factor 
compared to reader and software reproducibility, and further evidence is given that a software 
method is able to detect changes in some joints for which the Sharp score is insensitive 
(paper 10)10.   
1.3. Reader reproducibility 
The objective of this study (paper 11)11 was to evaluate the reproducibility of a computer-
based method to measure the radiographic joint space width (JSW) in patients with RA. We 
used hand radiographs from a random sample of patients with RA. The semi-automated 
computer-based scoring system automatically delineated joint margins on MCP and PIP joints 
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to measure the JSW. Four readers independently evaluated digitized hand radiographs on two 
separate occasions. Inter-rater and intra-rater reproducibility was assessed with intraclass 
correlation coefficients (ICC), RMSSD and CV were used as the reproducibility metrics. The 
average reader time was 36 seconds per joint and 4.4 minutes per hand. Mean JSW was 1.65 
mm and 1.03 mm for MCP and PIP joints, respectively.  The inter-rater ICC values ranged 
between 0.96 and 0.98, and the RMSSD between 0.03 and 0.036. The CV was 2.2% and 2.9% 
for MCP and PIP joints, respectively.  R egarding intra-rater reliability, the ICC ranged 
between 0.95 and 0.97, and the RMSSD between 0.02 and 0.031 mm. The CV was 1.8% and 
2.2% for MCP and PIP joints, respectively. The proposed software-measured radiographic 
JSW is reliable, both in terms of interrater and intrarater reliability, and a short reader time. 
This semi-automated system has the potential for use in large clinical studies and should 
provide a quantitative, reproducible and more objective outcome measure of joint structural 
damage and response to therapy (paper 11)11.  
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J. Are there systemic consequences to local disease? 
Chronic inflammation in RA affects other organs such as the liver (anaemia of chronic disease 
and elevated acute phase response), lungs (inflammatory and fibrotic disease), brain (fatigue 
and cognitive function decline), muscles (sarcopenia), and bone (osteopenia, osteoporosis, 
fractures)31. Cytokines also make muscle and adipose tissues insulin-resistant, resulting in an 
inflammation-associated metabolic syndrome183,184. Inflammatory mediators, including 
cytokines, immune complexes, and altered lipid particles, circulate to promote several 
comorbidities in patients with RA31. The same inflammatory mediators involved in synovial 
pathology are also implicated in generating pathology in extra-articular tissues. Taken 
together, this suggests that chronic inflammation is the common theme linking the spectrum 
of RA-coexisting conditions (Figure 3).  
Figure 3. Systemic consequences of rheumatoid arthritis 
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1. Cardiovascular disease in rheumatoid arthritis (RA)  
Persons with RA have a reduced life expectancy and increased mortality compared with 
the general population185-189. Epidemiologic studies have clearly demonstrated that an increase 
in prevalence of cardiovascular disease underlies the increased morbidity and mortality risk 
documented in patients with RA, and is independent of traditional cardiovascular risk 
factors190,191 or medications used to control the disease. RA is an independent risk factor for 
coronary artery disease. Patients with RA and systemic involvement have an increased risk of 
coronary events192. The higher cardiovascular mortality rates in those with more severe 
disease support the notion that greater systemic inflammation confers additional risk. 
Preclinical atherosclerosis in RA is also associated with longer and more severe disease. 
Moreover, there is an increased cardiovascular disease (CVD) risk early in the course of RA, 
probably related to subclinical inflammation in the prearticular phase of RA193,194. 
Inflammatory pathways that have been implicated include cytokines (e.g. IL-6 and TNF-α), 
acute-phase reactants (CRP and ESR), immune-complexes, and altered lipid particles (e.g. 
proinflammatory HDL) that increase endothelial activation and may contribute to plaque 
instability. An inflammation-associated metabolic syndrome has been suggested 183,184, which 
was associated with higher coronary calcification scores on c omputed tomography scan in 
patients with RA195. Further, lipid biochemistry is closely linked to inflammation, thus active 
RA is associated with reduced serum levels of total, HDL, and LDL cholesterol, which may 
increase in response to therapy196,197. Thus, inflammation plays a key role in atherogenesis 
associated with RA and its complications. 
Importantly, other novel and potentially modifiable risk factors, such as antioxidant vitamins 
and serum uric acid levels, as well as other unknown CVD risk factors may account for the 
increased CVD risk in RA. Previous reports have shown inverse associations between 
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inflammation and antioxidant serum levels, in particular carotenoids198-200. Moreover, intakes 
of antioxidant vitamins and other micronutrients or their serum concentrations, including 
carotenoids 201-203, vitamin C 204-206, vitamin E 207,208, and folate and homocysteine 209-211 have 
been reported to be inversely associated with CVD incidence and mortality. An inverse 
association between vitamin D levels and CVD risk and risk factors has been suggested based 
on the biologic effects of vitamin D, which include immunomodulatory effects 212,213, 
antiproliferative effects on myocardiocytes 214,215, as well as effects on the renin-angiotensin 
system 216,217. Thus, in the context of a chronic inflammatory disease, deficiency of 
antioxidants and/or vitamins may be associated with accelerated atherosclerosis in RA.  
1.1. Antioxidants and other novel cardiovascular risk factors in RA 
We compared novel risk factors for CVD, including inflammatory biomarkers, antioxidants 
and vitamins, as well as traditional CVD risk factors in participants with RA and non-RA 
controls in a large population sample. RA was defined based on 1987 ACR criteria and non-
RA subjects were defined as those who had no ACR criteria. We performed univariate and 
multivariate analyses of the association between RA and each novel and traditional CVD risk 
factor in RA vs. non-RA subjects. The sample included 5,302 subjects, 131 (2.5%) with RA 
and 4,444 ( 84%) without RA. Plasma levels of antioxidants α-carotene, β-cryptoxanthin, 
lutein/zeaxanthin, and lycopene were significantly lower in RA compared with non-RA 
subjects in multivariate analysis adjusting for potential confounders. There was no difference 
in vitamin D levels between groups. Compared with non-RA participants, subjects with RA 
were more likely to have increased CRP levels in multivariate analysis adjusting for potential 
confounders. RA and non-RA participants had similar prevalence of traditional CVD risk 
factors and previous CVD. We concluded that the prevalence of traditional CVD risk factors 
in RA cases compared with controls was similar. Among novel CVD risk factors, C-reactive 
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protein (CRP) was significantly higher, and antioxidant levels were significantly lower in RA 
compared with non-RA (paper 12)12. CRP, a biomarker of inflammation, is an independent 
predictor of future vascular events in the general population218,219. Antioxidant depletion can 
be seen in relation to inflammation; however, the lower antioxidant status in RA was not fully 
explained by the inflammatory process, suggesting that there might be other pathways 
involved in this association, which may be involved in the increased CVD risk in RA.  
1.2. Serum uric acid and cardiovascular disease 
Serum uric acid (SUA) is a potent endogenous antioxidant220-223. Elevated serum uric acid 
(SUA) has been associated with cardiovascular disease (CVD) for decades. However, whether 
or not hyperuricemia has a direct, independent causal role in atherosclerosis has been debated. 
Some authors suggest that it is merely a marker of traditional risk factors for CVD, including 
the metabolic syndrome224 (Figure 4). However, there are other potential pathways for which 
experimental data exist that may implicate elevated SUA as a causal CVD risk factor225, such 
as circulating platelet activation226, low-density lipoprotein (LDL) oxidation227, free radical 
release228, vascular smooth muscle cell proliferation229, crystal accumulation within 
atherosclerotic plaques230, antiproliferative effects on e ndothelium and impaired endothelial 
nitric oxide production leading to endothelial dysfunction231. Another possible mechanism is 
that uric acid may cause inflammation. Indeed, several in-vitro and experimental data support 
such a direct, proinflammatory role of SUA225,232,233 (Figure 4).  
Inflammatory processes are involved in atherogenesis as well as in the rupture or erosion 
vulnerability of an atherosclerotic lesion. CRP is an independent predictor of future vascular 
events in the general population218. Guidelines suggest measuring CRP as an aid to coronary 
risk assessment in adults without CVD234-237.  
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Figure 4. Possible pathways between serum uric acid and cardiovascular disease (CVD) 
 
1.2.1. Association between SUA and inflammation  
Previous studies have suggested that SUA may have a direct role in atherogenesis; however, 
data from clinical and epidemiologic studies on such an association are scarce238-241, 
particularly on a relationship between SUA and biomarkers of inflammation. Therefore we set 
out to evaluate the association of SUA with CRP and its dose-response relationship in a large 
representative sample of the US general population (paper 13)13. The study sample included 
10,882 participants. Participants taking gout medications or with hypouricemia were 
excluded. There were 4,942 men and 5,434 women. Men had mean higher SUA and lower 
CRP concentrations compared with women (SUA 6.01±1.3 vs. 4.71±1.3 mg/dl and CRP 
0.38±0.88 vs. 0.55 ± 0.86 mg/dl, respectively). There was a positive linear dose-dependent 
association between SUA and CRP concentrations in both genders.  
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The associations were strongest in participants with BMI<25 and smallest in obese 
individuals (p for interaction: p<0.0001). There was no e ffect modification by age, 
race/ethnicity, or smoking. We have shown in this large epidemiologic study, an independent 
direct association between SUA and CRP in the general population. Even within the normal 
range and among those without comorbidities or taking prescription medications or 
NSAIDS/analgesics, serum uric acid concentrations were independently associated with 
higher CRP levels among men and women, particularly in lean and overweight individuals. 
Hyperuricemia associated with higher CRP concentrations. There was a p ositive linear 
association between SUA and CRP across the normal range of SUA concentrations. These 
associations were independent of comorbidities, medications and other potential confounders, 
and were modified by BMI. The results of our study confirm previous observations and show 
for the first time positive linear association between CRP and SUA, even across the normal 
range of SUA (Figure 4), which was independent of age, gender, race/ethnicity, income, 
smoking, alcohol intake, hypertension, GFR, BMI, physical activity, diabetes, arthritis, 
previous CVD, CHF, stroke, COPD, metabolic syndrome, insulin resistance, and prescription 
medications, with robust associations after excluding participants taking prescriptions 
medications or having comorbidities. These findings could have important clinical and public 
health implications as SUA may contribute to the atherosclerotic process by increasing 
inflammation.   
1.2.2. Association between SUA and inflammation in RA 
We have shown in a large epidemiologic study an independent association between SUA 
and CRP in the general population (paper 13)13. However, it is unclear whether this 
association holds in the context of a “high-grade” chronic inflammatory disease, such as RA. 
The purpose of this study was to evaluate the association between SUA and CRP in a cohort 
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of patients with RA (paper 14)14. We included 400 consecutive patients with RA meeting 
ACR criteria for RA classification, recruited from routine outpatient clinics at the Department 
of Rheumatology of the Dudley Group of Hospitals. A priori we excluded participants with 
concomitant gout. We used fractional polynomial regression to evaluate the association 
between SUA and CRP, adjusting for age, gender, smoking, seropositivity, hypertension, 
diabetes, creatinine levels, glomerular filtration rate (GFR<60), body mass index (BMI), and 
use of medications such as diuretics, antihypertensives, aspirin, and statins. Models with 
further adjustment for presence of the metabolic syndrome, disease activity (DAS28), and 
medications used for RA (i.e. DMARDS, biologics, steroids) were also fitted. After excluding 
participants with concomitant gout, the study sample included 381 participants with RA. Of 
those, 74% were female, 76% were seropositive, 70% were hypertensive and 10% had 
diabetes. Mean age was 61 years (SD±12) and mean disease duration was 12.5 years 
(SD±10.5). Men had higher SUA and CRP concentrations than women (6.0±1.3 vs. 4.9 ±1.5 
mg/dl and 17.3±20.8 vs. 16.8±23.5 mg/dl, respectively). There was a non-linear association 
between SUA and CRP concentrations (overall p-value 0.01) independent of confounders. We 
have shown that SUA concentrations are independently associated with inflammation among 
individuals with RA (Figure 4). The physiologic basis of this association, as well as its 
significance, both in terms of the articular and cardiovascular phenotype of RA require further 
exploration. However, the recognition RA as a risk factor for cardiovascular CVD is essential 
for clinicians, as important modifiable risk factors frequently remain untreated242. 
Cardiovascular risk should be assessed and modifiable risk factors should be treated 
effectively in patients with RA. Furthermore, since chronic inflammation may be a modifiable 
risk factor for atherosclerosis, RA disease activity should be managed aggressively.  
46 
 
2. Bone loss in rheumatoid arthritis 
The inflammatory process has adverse effects on bone remodeling, both focal and systemic243. 
The impact of RA on bone includes structural joint damage (marginal erosions, subchondral 
bone erosions) and periarticular osteoporosis as well as generalized osteoporosis, which is 
multifactorial, including osteoporosis risk factors in addition to inactivity, inflammation, and 
use of corticosteroids. Bone formation is decreased in patients with RA not treated with 
steroids244. Osteoporosis is frequent among patients with RA245-250, and an increased risk of 
osteoporotic fractures across all age groups, gender and different anatomic sites has been 
shown251. Vertebral fractures are common, with a prevalence of 15% even after early DAS-
steered treatment in RA patients252. Bone loss in RA is associated with an imbalance in bone 
remodeling; the bone resorption process is mediated by osteoclasts via the RANKL–RANK–
osteoprotegerin system253. Cytokines, such as TNF-α, IL-1 and IL-17, accelerate the process 
of osteoclast differentiation by upregulating RANKL254. Higher serum levels of CRP have 
also been associated with lower BMD in women and older adults. While chronic 
inflammatory diseases predispose to fractures and bone loss251,255, it is unclear whether 
inflammation also has such an effect among people without chronic inflammatory diseases or 
whether this association holds in a representative sample of the general population.  
2.1. Relationship between bone loss and inflammation  
The purpose of this study was to examine the relationship between bone mineral density 
(BMD) and inflammation as measured by C-reactive protein (CRP) in a large representative 
US population-based sample from the National Health and Nutrition Examination Survey 
(NHANES). We included participants aged 20+ with BMD (total and subregions) measured 
by dual-energy x-ray absorptiometry (DXA) scans. The association between CRP and BMD 
was evaluated using multivariable linear regression models, adjusting for potential 
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confounders and further adjustment for comorbid diseases, medications and serum vitamin D 
levels. The study sample included 10,475 participants, among which there were 53% 
Caucasians, 22% Mexican-American, 18% African-American, and 7% were other races. Men 
had higher BMD and lower CRP concentrations than women. BMD (total, subtotal, 
extremities, ribs, and trunk subregions) was inversely associated with CRP quintiles both in 
men and women in a dose-dependent manner (total BMD p f or trend: <0.0001 for men; 
0.0005 for women). The associations were independent of medications, comorbidities and 
other potential confounders. The results remained largely unchanged with further adjustment 
for serum vitamin D levels. We concluded that among men and women in a large 
representative population-based sample, CRP was inversely and independently associated 
with total BMD in a dose-dependent manner 15(paper 15). We then confirmed these results in 
a European population-based sample256. These data support the notion that, even among 
individuals without chronic inflammatory diseases, inflammation has a detrimental impact on 
bone.   
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K. Management of rheumatoid arthritis 
Over the last 15 years the management of RA has markedly expanded. Disease modifying 
drugs (DMARDs), of which methotrexate in particular, have replaced NSAIDS as first-line 
treatment257-259. Increasing knowledge of RA pathogenesis has resulted in the development of 
new targeted treatments (Figure 5). The recently developed targeted treatments designed 
using a biotechnological approach, known as ‘biologics’, have supplemented and in part 
replaced conventional DMARDs. The first biologics registered for RA block TNFα, a 
cytokine which is present in the RA synovial tissue260. The TNF blockers include infliximab 
(chimeric antibody), etanercept (a soluble receptor), adalimumab (a humanized antibody). 
More recently, certolizumab (a pegylated antibody fragment), and golimumab (a human 
monoclonal antibody) have been added to the anti-TNF armamentarium. Combination 
treatment of a T NF blocker and methotrexate, in patients who fail initial treatment with 
methotrexate or other DMARDs, is effective in a subset of patients. Other biologics registered 
for RA treatment are rituximab, a chimeric antibody which depletes CD20 positive cells, 
abatacept, which blocks the interaction between CD80 or CD86 on T cells and antigen 
presenting cells, and tocilizumab, which blocks the IL-6 receptor. These drugs decrease 
disease activity in a degree similar to that of TNF blockers.  
Despite the armamentarium of drugs developed over the last few years, early disease 
remission is only achieved in a proportion of patients, and often patients have to be treated 
with relatively expensive treatments. Therefore, there is a need to better understand RA 
pathogenesis to further improve response to treatment.    
Recent advances in drug development that show promise in RA management involve 
tofacitinib, a Janus-associated kinase (JAK) inhibitor. Tofacitinib binds and inhibits important 
intracellular enzymes JAK1, JAK2, and JAK3, which are involved in immune cell activation, 
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cytokine production and signalling. A phase 2B randomized controlled trial of tofacitinib 
compared with adalimumab, a TNF inhibitor, or placebo261, showed that tofacitinib therapy 
resulted in a rapid clinical response compared with the other groups. Adverse events included 
urinary tract infections, anaemia and diarrhoea. Phase III studies on t ofacitinib therapy are 
underway. Another tyrosine kinase inhibitor that targets spleen tyrosine kinase (Syk) has 
shown efficacy in RA115.  
Figure 5 summarizes the management pathway in RA. Once the patient has been classified24, 
the antibody status and in particular the ACPA status should be defined. There are currently 
several therapeutic options in RA, which can be used with a treat-to-target strategy262, with 
the ultimate goal of inducing clinical remission177. 
 
Figure 5. Rheumatoid arthritis management pathway 
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L. Summary 
This thesis set out to provide an overview of RA within the epidemiology of musculoskeletal 
involvement, with a focus on t he comorbidities and potential risk factors for RA, the 
relevance of time in the management of RA, the tools used to assess disease prediction and 
progression, and the role of chronic inflammation as the common theme linking the spectrum 
of RA-coexisting conditions and consequences.  
Paper 11 summarized the relevance of time for the burden of RA. With regards to the 
pathogenesis of RA, we investigated potential risk factors and their associations with RA 
(papers 2-5). Paper 22 presented a s ystematic review showing that tthe majority of clinical 
and epidemiologic studies suggest that patients with RA have an increased prevalence of 
periodontitis and tooth loss. However, the strength of the association remains unclear, and all 
available studies are cross-sectional, thus the temporality of the association cannot be 
ascertained. Several causal and non-causal pathways could explain the observed association. 
Emerging evidence suggests that periodontitis may have a direct causal role by initiating and 
sustaining the auto-immune inflammatory response underpinning RA. Additional non-causal 
pathways include genetic, environmental and behavioural exposures common to both 
conditions. Further causal pathways may emerge from pharmacological, physiological and 
behavioural exposures associated with RA, affecting periodontitis incidence and/or 
progression in individuals with RA. Paper 33 demonstrated that having RA was associated 
with 4-fold increase in the odds of periodontitis, and a 3-fold increase in the odds of 
edentulism (complete tooth loss) controlling for age, gender, race/ethnicity, and smoking in a 
population-based sample. Following on t hese observations, Paper 44 investigated the 
presence of systemic RA-related autoimmunity among individuals periodontal disease. We 
tested for ACPA given that these antibodies are highly specific for RA and epitope spreading 
51 
 
arises several years prior to the onset of clinical features. We found that after stratification for 
smoking, non-smokers with PD, compared with non-PD, had significantly higher titres of 
antibodies against CEP-1, REP-1, vimentin, and fibrinogen, independent of age and sex. In 
patients without RA, periodontitis was associated with higher titres of antibodies to both 
citrullinated and uncitrullinated peptides in non-smokers. This data suggests that periodontitis 
may contribute to the development of autoimmunity related to RA, by inducing antibodies to 
uncitrullinated variants of citrullinated autoantigens. 
Paper 55 investigated the presence of systemic autoimmunity among individuals potentially at 
risk of RA based on other environmental exposures. In this study, we compared the ACPA 
reactivity among patients with lung disease, either due to a g enetic deficiency (i.e., α-1 
antitrypsin deficiency, AATD) or to smoking (i.e., COPD), which is an established risk factor 
for RA, and healthy non-smokers. With regards to ACPA, anti-CCP antibodies were higher in 
COPD than AATD. Anti-MCV antibodies were also higher in COPD than AATD and were 
positive in about 13% and 18% of AATD and COPD subjects, respectively. These data 
suggest that the lung may also contribute to the development of autoimmunity related to RA, 
by inducing antibodies to citrullinated autoantigens. Recognized biomarkers that are known to 
be present before the development of RA include the presence of RF and/or ACPA, reflecting 
systemic autoimmunity associated with RA.  
Taken together, the results of the two herein presented studies (papers 4 and 5 respectively), 
conducted among patients with other diseases that may predispose to the development of RA, 
i.e. periodontitis and lung disease, suggest that a breach of tolerance to citrullinated and 
uncitrullinated autoantigens may occur in association with disease at mucosal barriers, 
particularly in periodontitis. It is therefore conceivable that the pathogenesis of RA starts in 
tissues other than the joints, i.e., systemic autoimmunity is triggered by processes distant from 
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the joints, a process which may or may not be followed by a ‘second hit’ leading to clinically 
apparent inflammatory arthritis in susceptible individuals. Individuals within the preclinical 
phase may be suitable targets in future strategies of primary prevention of RA. The spectrum 
of preclinical RA is wide, varying from individuals manifesting only with autoantibody 
production and no s igns or symptoms to those who become symptomatic and then have 
clinically apparent arthritis. This is important as Paper 66 demonstrated in a meta-analysis of 
observational studies and randomized controlled trials, that there is a therapeutic window of 
opportunity early in the course of RA, a critical period during which antirheumatic therapy 
should be initiated, associated with sustained benefit on di sease progression and structural 
damage. However, the timely initiation of anti-rheumatic therapy requires the early 
identification of patients at very high risk of RA or of early arthritis at risk of developing into 
persistent and erosive disease. To help identify individuals early in the course of RA, Paper 
77 investigated the role of musculoskeletal ultrasound as a predictor of outcome in people 
with arthritis at the very early stages of the disease course and showed that ultrasound 
identifies subclinical joint involvement in patients developing RA and significantly improves 
the prediction of RA, over and above the Leiden score. Paper 88 examined the performance 
of the recent 2010 ACR/EULAR criteria for classification of RA in newly presenting patients 
with very early synovitis and observed that, compared with the 1987 ACR criteria, the new 
criteria allow more rapid identification of patients requiring methotrexate and are more 
sensitive for the identification of patients early in the disease course.  
The goal of therapy in RA is the prevention of radiologically evident joint destruction or 
functional loss. The next few papers investigated the diagnostic performance of an automated 
computer-based scoring method to assess structural damage and disease progression in RA 
(papers 9-11)9-11. Paper 99 demonstrated that compared with the semiquantitative Sharp JSN 
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subscale, the computer-based method for measuring joint space width was more discriminant 
and responsive to change. In addition, it provides quantification of structural changes on a 
continuous scale. Paper 1010 showed that the long-term patient repositioning reproducibility 
is very good and that the software method is able to detect changes in some joints for which 
the Sharp score is insensitive. Paper 1111 demonstrated that the software method is reliable, 
both in terms of interrater and intrarater reliability, and requires a short reader time. 
Therefore, this semi-automated system has the potential for use in large clinical studies and 
should provide a quantitative, reproducible and more sensitive and objective outcome 
measure of joint structural damage and response to therapy. 
The following papers addressed some of the systemic consequences of chronic inflammation, 
including cardiovascular disease in RA. Paper 1212 demonstrated that people with RA have a 
similar prevalence of traditional CVD risk factors and previous CVD than people without RA. 
Among the novel CVD risk factors, C-reactive protein was significantly higher, and 
antioxidant levels, including plasma levels of α-carotene, β-cryptoxanthin, lutein/zeaxanthin, 
and lycopene, were significantly lower in RA compared with non-RA. There was no 
difference in vitamin D levels between groups. CRP, a biomarker of inflammation, is an 
independent predictor of future vascular events in the general population. Antioxidant 
depletion can be seen in relation to inflammation; however, the lower antioxidant status in RA 
was not fully explained by the inflammatory process, suggesting that there might be other 
pathways involved in this association, which may be involved in the increased CVD risk in 
RA. Substantial data implicates serum uric acid (SUA) in cardiovascular morbidity. However, 
whether or not hyperuricemia has a direct, independent causal role in atherosclerosis has been 
debated. SUA may be just a marker of traditional risk factors for CVD, including the 
metabolic syndrome. However, there are other potential pathways between SUA and CVD 
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including inflammation. Indeed, several in-vitro and experimental data support such a direct, 
proinflammatory role of SUA. However, whether this relationship exists in the general 
population is unclear. We demonstrated in Paper 1313 an independent direct association 
between SUA and CRP. Even within the normal range and among those without 
comorbidities or medications, SUA was independently associated with higher CRP levels 
among men and women, particularly in lean and overweight individuals. These findings could 
have important public health implications as SUA may contribute to the atherosclerotic 
process by increasing inflammation; however, whether this association holds in the context of 
a “high-grade” chronic inflammatory disease, such as RA is unclear. Paper 1414 demonstrated 
that SUA concentrations are independently associated with inflammation as measured with 
CRP among individuals with RA and may contribute to the increased CVD risk in RA. Paper 
1515 illustrated in a large population-based sample that inflammation has a detrimental effect 
on bone mineral density even in people without chronic inflammatory diseases.  
In summary, we have seen within the epidemiology of musculoskeletal involvement that 
chronic inflammation in any one tissue clearly impacts the overall health status and disease 
susceptibility of the whole body. Chronic inflammation has detrimental effects not only as a 
result of direct damage but also due to collateral damage in other systems and tissues. 
Inflammatory diseases in different compartments may interact at a systemic level to influence 
inflammatory burden, bone loss, periodontal disease and cardiovascular risk. Further 
exploration of the physiologic basis of this interaction, as well as its significance in terms of 
the phenotype of RA is warranted. In the meantime, a tight control of the inflammatory 
process aiming at remission should be the goal of therapy. Importantly, preventing the burden 
of RA may be achieved by identifying people not only very early in the disease course but 
also at risk of developing RA, to implement interventions before clinical symptoms start.   
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Does time matter in the management of
rheumatoid arthritis?
Paola de Pablo, Andrew D Filer, Karim Raza and Christopher D Buckley
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 INTRODUCTION
Imagine that you wake up one morning and feel so much pain and stiffness in your
joints that every movement is agony. You can no longer dress or wash yourself without
help, let alone drive to work. Your general practitioner (GP) refers you urgently to a
rheumatologist, who tells you that you have arthritis. Although very reassuring, your
rheumatologist tells you that even with the results of blood tests, they do not yet know
which type of arthritis you have. For the moment your doctors can offer only very
general treatment until your arthritis changes to involve more joints in a particular
pattern or until other tests such as radiographs show specific features, which may take
months. Distressingly, your rheumatologist cannot tell you whether the arthritis will
get better on its own or will remain and change your life forever.
This is the scenario that greets new patients with an inflammatory arthritis such as
rheumatoid arthritis (RA), who make up 1% of our population. The truth is that we
are still very poor at predicting both diagnosis and severity of arthritis in patients who
present to early arthritis clinics. Frustratingly, new data from studies of the treatment
of RA in the early stages suggest that very early treatment has the real potential
to completely switch off disease – that is, to induce disease remission. Studies also
show that the longer the duration of disease, the more likely it is to persist, so how
can we resolve the problem that the best predictor of persistent disease in patients
with early arthritis currently is time itself? Would we wait as long to intervene in
patients with breast lumps or prostate abnormalities as we do in our patients with
arthritis?
The last two decades have seen important advances in our understanding of the
incidence, treatment and outcome of patients with early rheumatoid arthritis (ERA).
It is now clear that patients with ERA benefit from early referral and assessment
by a rheumatologist and that outcome is improved by the early introduction of
disease-modifying antirheumatic drugs (DMARDs).1 With appropriate treatments,
it is possible to delay or even prevent evolution of undifferentiated arthritis into RA
and/or to induce remission in a substantial proportion of patients with RA. However,
we are still far from being able to produce an individualised treatment plan for each
patient, as is currently the case for patients with cancer. This is because our current
understanding of RA probably embraces a number of disease subsets, each with a
different aetiology and pathophysiology.
C© Royal College of Physicians 2009 / Horizons in Medicine 2009, No 21 3
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Periodontitis in systemic rheumatic diseases
Paola de Pablo, Iain L. C. Chapple, Christopher D. Buckley and Thomas Dietrich
Abstract | Periodontitis is a chronic inflammatory disease that is characterized by loss of the periodontal 
ligament and alveolar bone, and is a major cause of tooth loss. results from clinical and epidemiologic studies 
have suggested that periodontitis and tooth loss are more prevalent in individuals with rheumatoid arthritis 
(rA). However, the strength and temporality of the association are uncertain. several biologically plausible 
causal and noncausal mechanisms might account for this association between periodontitis and rA. There 
is evidence to suggest that periodontitis could indeed be a causal factor in the initiation and maintenance of 
the autoimmune inflammatory response that occurs in rA. if proven, chronic periodontitis might represent 
an important modifiable risk factor for rA. in addition, patients with rA might show an increased risk of 
developing periodontitis and tooth loss through various mechanisms. Moreover, exposure to common genetic, 
environmental or behavioral factors might contribute to a noncausal association between both conditions.
de Pablo, P. et al. Nat. Rev. Rheumatol. 5, 218–224 (2009); doi:10.1038/nrrheum.2009.28
Introduction
Chronic periodontitis is arguably the most prevalent 
chronic inflammatory disease in humans. The defin-
ing feature of periodontitis is chronic inflammation of 
the tooth-supporting tissues, leading to the progressive 
destruction of periodontal ligament and alveolar bone. 
Periodontitis is a very common disease, affecting over 
30% of adults aged 65 years or above in the UK.1
Results from a growing number of clinical studies 
point towards a potential association between chronic 
periodontitis and systemic rheumatic diseases—in 
particular, rheumatoid arthritis (RA). If proven, such 
an association would be very important from a clini-
cal and public health perspective for several reasons. 
First, there are several processes through which chronic 
perio dontitis might be part of a causal pathway in the 
patho genesis and/or disease activity status of RA. Given 
the high prevalence of chronic periodontitis, a large 
proportion of the incidence and/or morbidity of RA 
could be attributable to chronic periodontitis, if causal-
ity was confirmed. Importantly, chronic periodontitis 
would represent a modifiable risk factor, as very effec-
tive treatments for this disease are available.2,3 Second, 
chronic periodontitis would contribute to morbidity 
in patients with RA even if the association was non-
causal. Periodontitis is a leading cause of tooth loss in 
adults,4 which can have important clinical consequences, 
including impaired nutritional status and quality of 
life.5,6 Furthermore, chronic periodontitis is associated 
with an increased incidence of coronary heart disease 
and stroke, and emerging evidence indicates that this 
association might, in part, be causal.7,8
Chronic periodontitis
Chronic periodontitis is initiated by a pathogenic bio-
film that accumulates around the gingival (gum) mar gin.9 
Susceptible patients exhibit an abnormal immune-
 mediated inflammatory response to the constituent 
microflora, which destroys the periodontal attachment 
and supporting bone (Figure 1).10 The early inflam matory 
response to the biofilm is dominated by polymorpho-
nuclear leukocytes (PMNLs),11 and data indicate that 
stimulation of pattern recognition receptors on these 
cells by periodontal bacteria and their products (for 
example, lipopoly saccharide) has a key initiating role in 
disease athogenesis.12
The gingival epithelium is also important in orches-
trating the inflammatory response.13 Early in the disease 
process, this epithelium ulcerates to expose the under-
lying connective tissues and vasculature to the biofilm. 
The exposed surface area (approximately 8–20 cm2)14 
facilitates direct entry of biofilm organisms to the circula-
tion during eating and tooth brushing.15 Peripheral blood 
PMNLs from patients with perio dontitis seem hyper-
reactive relative to controls with respect to the release 
of reactive oxygen species16 and PMNL-specific pro-
teases.17 Levels of inflammatory markers are also 
elevated,18–20 and antioxidant defenses appear compro-
mised.21 Importantly, traditional anti-infective perio-
dontal therapies, such as scaling and root planing, with or 
without adjunctive antimicrobials, not only improve the 
symptoms of patients with periodontitis but also improve 
vascular endothelial dysfunction7 and antioxidant status21 
and reduce PMNL hyper-reactivity.22
There is also strong evidence for a genetic component 
to disease susceptibility in ~50% of patients,23 although 
this genetic basis remains poorly understood. In certain 
individuals, there is evidence of hyper-reactivity in 
PMNLs and monocytes,22,24 as well as subtle variations 
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Association of Periodontal Disease and Tooth Loss
with Rheumatoid Arthritis in the US Population
PAOLA de PABLO, THOMAS DIETRICH, and TIMOTHY E. McALINDON
ABSTRACT. Objective. To test for an association of periodontitis and tooth loss with rheumatoid arthritis (RA).
Methods. The third National Health and Nutrition Examination Survey (NHANES III) is a nationally
representative cross-sectional survey of noninstitutionalized civilians. We included participants aged ≥
60 years who had undergone both musculoskeletal and dental examinations. RA was defined based on
American College of Rheumatology criteria. Dental examinations quantified decayed and filled surfaces,
missing teeth, and periodontitis. Periodontitis was defined as at least 1 site exhibiting both attachment
loss and a probing depth of ≥ 4 mm. We classified dental health status as (1) no periodontitis, (2) peri-
odontitis, or (3) edentulous (i.e., complete tooth loss). We performed multivariate multinomial logistic
regression models with dental health status as the dependent and RA as the independent variables.
Results. The sample consisted of 4461 participants, of whom 103 were classified as having RA.
Participants with RA had more missing teeth (20 vs 16 teeth; p < 0.001), but less decay (2% vs 4%;
p < 0.001) than participants without RA. After adjusting for age, sex, race/ethnicity, and smoking, sub-
jects with RA were more likely to be edentulous [odds ratio (OR) 2.27, 95% confidence interval (CI)
1.56–3.31] and have periodontitis (OR 1.82, 95% CI 1.04–3.20) compared with non-RA subjects. In
participants with seropositive RA there was a stronger association with dental health status, in particu-
lar with edentulism (OR 4.5, 95% CI 1.2–17).
Conclusion. RA may be associated with tooth loss and periodontitis. (First Release Nov 15 2007;
J Rheumatol 2008;35:70–6)
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Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by synovial inflammation that results in destruc-
tion of joint tissues. Periodontitis is a chronic inflammatory
disease characterized by loss of the periodontal ligament and
alveolar bone, and is a major cause of tooth loss, particularly
in the elderly1. Tooth loss has important clinical consequences,
including reduced dietary quality and quality of life2,3.
Periodontitis and RA appear to share numerous character-
istics including certain pathogenetic processes4,5, cytokine
profiles6, markers of inflammation7,8, association with HLA-
DRB19,10, interleukin 1ß (IL-1ß) and tumor necrosis factor-α
(TNF-α) polymorphisms11-14, presence of citrullinated pro-
teins and peptide epitopes4, and rheumatoid factor (RF)4,15,16.
This suggests that subjects susceptible to RA may also have
higher rates of periodontal disease.
Further, there are reasons to suspect that the role of peri-
odontitis in RA might be based on more than just shared sus-
ceptibility. For example, induction of adjuvant arthritis in
Lewis male rats is associated with periodontal breakdown,
increased cytokines and matrix metalloproteinases in gingival
tissues, and alveolar bone loss17.
Studies have also demonstrated an antibody response
against oral anaerobic bacteria in synovial tissue18 and
serum19, and the presence of oral bacterial DNA in the syn-
ovial fluid and serum of patients with RA20. Also, periodontal
pathogens may express the peptidyl arginine deiminase (PAD)
enzyme responsible for citrullination of peptide antigens4.
Indeed, several clinical studies suggest a possible association
between periodontitis/tooth loss and RA21-25, although some
studies did not find a positive association26-28. However, no pop-
ulation-based data on this association have been reported.
Our objective was to compare periodontal disease and
tooth loss prevalence in subjects with and without RA in the
US population.
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ABSTRACT
Background Studies suggest that periodontitis may be
a risk factor for rheumatoid arthritis (RA). The purpose
of this study was to determine whether periodontitis is
associated with autoantibodies characteristic of RA.
Methods Serum samples were tested for anti-cyclic
citrullinated peptide (CCP), anti-mutated citrullinated
vimentin (MCV), anti-citrullinated α-enolase peptide-1
(CEP-1), anti-citrullinated vimentin (cit-vim), anti-
citrullinated ﬁbrinogen (cit-ﬁb) and their uncitrullinated
forms anti-CParg (negative control for anti-CCP), anti-
arginine-containing α-enolase peptide-1 (REP-1), anti-
vimentin and anti-ﬁbrinogen antibodies in patients with
and without periodontitis, none of whom had RA.
Results Periodontitis, compared with non-periodontitis,
was associated with a normal frequency of anti-CCP and
anti-MCV (∼1%) but a higher frequency of positive anti-
CEP-1 (12% vs 3%; p=0.02) and its uncitrullinated form
anti-REP-1 (6% vs 2%; p<0.001). Positive antibodies
against uncitrullinated ﬁbrinogen and CParg were also
more common among those with periodontitis compared
to non-periodontitis patients (26% vs 3%; p<0.001,
and 9% vs 3%; p=0.06). After adjusting for
confounders, patients with periodontitis had 43%
(p=0.03), 71% (p=0.002) and 114% (p<0.001) higher
anti-CEP-1, anti-REP-1 and anti-ﬁbrinogen titres,
compared with non-periodontitis. Non-smokers with
periodontitis, compared with non-periodontitis, had
signiﬁcantly higher titres of anti-CEP-1 (103%,
p<0.001), anti-REP-1 (91%, p=0.001), anti-vimentin
(87%, p=0.002), and anti-ﬁbrinogen (124%, p<0.001),
independent of confounders, conﬁrming that the
autoantibody response in periodontitis was not due to
smoking.
Conclusions We have shown that the antibody
response in periodontitis is predominantly directed to the
uncitrullinated peptides of the RA autoantigens
examined in this study. We propose that this loss of
tolerance could then lead to epitope spreading to
citrullinated epitopes as the autoimmune response in
periodontitis evolves into that of presymptomatic RA.
BACKGROUND
Rheumatoid arthritis (RA) is a chronic immune-
mediated inﬂammatory disease characterised by syn-
ovial inﬂammation and cartilage and bone destruction
that often results in structural damage, disability and
functional loss. Causes of RA remain unknown but a
complex interplay between genetic and environmen-
tal factors is involved in its development.1 A key
feature of RA is the presence of antibodies to citrulli-
nated peptide/protein antigens (ACPA) and these have
now been included as a criterion in the recent
American College of Rheumatology/European League
Against Rheumatism (ACR/EULAR) RA classiﬁcation
criteria.2 ACPA can be detected with generic assays
such as citrullinated peptide antibodies (anti-CCP)3 or
antibodies to distinct autoantigens such as citrulli-
nated ﬁbrinogen, vimentin, α-enolase and collagen.4
ACPA levels are predictive of disease severity and
adverse clinical outcomes,5 6 and increasing evidence
implicates ACPA in RA aetiopathogenesis.4
Studies have suggested an association between RA
and periodontitis.7 8 Periodontitis, one of the most
common chronic inﬂammatory diseases, is charac-
terised by loss of the periodontal ligament and alveo-
lar bone, and is a major cause of tooth loss.
Periodontitis is initiated by a pathogenic bioﬁlm accu-
mulating above and below the gum margin, which in
susceptible patients triggers a dysregulated inﬂamma-
tory immune response that causes collateral
host-tissue damage.9–11 Periodontal bacteria enter the
circulation and trigger an acute-phase response
involving C-reactive protein and ﬁbrinogen,12 and
may activate neutrophils.13 Porphyromonas gingiva-
lis, a common periodontal pathogen associated with
periodontitis, is the only prokaryote known to
express an endogenous peptidyl-arginine deiminase
(PPAD) enzyme14 that citrullinates human proteins,15
which are abundantly present in periodontal
tissues.16 It is therefore conceivable that increased
citrullination of human or bacterial proteins by
PPAD, or host peptidyl-arginine deiminases (PAD), in
patients with periodontitis may result in a break in
immune tolerance to citrullinated proteins and play a
causal role in the initiation of RA.
It has therefore been hypothesised that
RA-speciﬁc autoimmunity may be generated within
the periodontium and that periodontal citrullina-
tion may be important in generating autoantigens
in periodontitis.17 Once systemic tolerance is lost,
epitope spreading and cross-reactivity may result,
perpetuating the immune response leading to RA.
ACPA appear many years before disease onset,18–22
in the preclinical phases up to the development of
RA,23 suggesting that the initial immune dysregula-
tion occurs years before symptom onset, although
how this takes place initially is yet to be deter-
mined. Interestingly, in a recent study using an
animal model, immunisation with both uncitrulli-
nated and citrullinated enolase caused rapid-onset
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arthritis,24 and higher antibody titres to uncitrullinated and
citrullinated enolase were shown in mice immunised with
recombinant P gingivalis citrullinated and uncitrullinated
enolase, indicating that the initiation of the response was not
necessarily citrulline dependent.
Few studies have shown that patients with periodontitis have
a slightly increased presence and/or titres of ACPA compared to
controls,4 8 but these studies have all been small and differences
between patients and controls were not statistically signiﬁcant.
Moreover, antibodies to peptides and their uncitrullinated con-
trols from speciﬁc citrullinated antigens have not been investi-
gated. The purpose of this study was to determine the immune
reactivities to peptides from citrullinated and uncitrullinated
antigens in non-RA individuals with and without periodontitis.
METHODS
Study sample
The study sample comprised patients who had been referred to
Birmingham Dental Hospital for treatment of periodontitis or
for surgical removal of third molars who had been enrolled in
clinical trials on outcomes of periodontal treatment and lower
third molar surgery, respectively. Patients in the periodontal
study had moderate or advanced periodontitis25 and were other-
wise healthy and did not meet any of the following exclusion
criteria: pregnancy, lactation, course of anti-inﬂammatory or
antimicrobial therapy or vitamin supplementation within the
previous 3 months, regular mouthwash use, and any special
dietary requirements (eg, coeliac disease). The presence of mod-
erate to advanced periodontitis was conﬁrmed by clinical and
radiographic examination. Patients in the third molar study
required surgical removal of at least one lower third molar with
the following exclusion criteria: pregnancy, lactation, regular use
of anti-inﬂammatory medication or vitamin supplementation.
The presence or absence of periodontitis was ascertained by
determination of bone loss from radiographs of the dentition.
Smoking status was collected at the study visit and classiﬁed as
never, former and current. All subjects provided written
informed consent and studies were approved by the NHS
Research Ethics Service (REC ref 05/Q2707/252 and South
Birmingham LREC/0405).
Antibody measurements
Fasting blood samples were collected at baseline, that is, before
initiation of any dental treatment and immediately processed,
aliquotted and stored at −80°C until analysis.
Anti-CCP antibodies were quantiﬁed using second-generation
assays (Phadia UniCAP system; Phadia Ltd, Milton Keynes, UK).
Antibodies against mutated citrullinated vimentin (anti-MCV
IgG) were determined using a quantitative immunometric
enzyme immunoassay (ORGENTEC Diagnostika GmbH,
Mainz, Germany). These are clinically validated tests with a
cut-off for positivity of 10 U/ml and 20 U/ml, respectively.
Antibodies to the uncitrullinated equivalent of CCP (CParg)
were measured by ELISA. Sera diluted 1:100 were incubated on
plates pre-coated with the antigen (kindly provided by
Eurodiagnostica, Malmo Sweden) for 30 min. Plates were
washed and incubated with peroxidase-conjugated mouse anti-
human IgG (Hybridoma Reagent Laboratory, Baltimore, USA)
(diluted 1:3000 in RIA buffer) for 30 min at room temperature.
After a ﬁnal wash bound antibodies were detected with TMB
substrate (Biolegend, San Diego, USA). The reaction was
stopped by the addition of 1 M H2SO4 and absorbance mea-
sured at 450 nm. Optical density (OD) values obtained for each
sample were evaluated against a panel of normal healthy indivi-
duals to determine relative reactivity.
Antibodies to immunodominant peptides from established RA
autoantigens were also measured, including citrullinated
α-enolase (amino acids 4–21: KIHA-Cit-EIFDS-Cit-GNPTVE)
(CEP-1),26–30 citrullinated vimentin (amino acids 60–75:
VYAT-Cit-SSAV-Cit-L-Cit-SSVP)21 27 31–34 and citrullinated
ﬁbrinogen β chain (amino acids 36–52: NEEGFFSA-Cit-
GHRPLDKK).21 27 31 33 Serum samples from patients and con-
trols were analysed for antibodies to these peptides by ELISA.
Cysteine residues were added at the amino and carboxy-termini
of each peptide to facilitate cyclisation, and antibodies to the
corresponding arginine-containing control peptides (arginine-
containing α-enolase peptide-1 antibodies (REP-1); vimentin
and ﬁbrinogen β chain) were measured in parallel. Ninety-six
well plates were coated with peptide at 10 mg/ml overnight at
4 °C, washed with PBS-Tween (0.05%) and blocked with 2%
BSA for 2 h. Samples were diluted 1:100 in RIA buffer (10 mM
Tris, 1% BSA, 350 mM NaCl, 1% Triton-X, 0.5%
Na-deoxycholate, 0.1% SDS) and added in duplicate for 1.5 h.
Plates were washed with PBS-Tween (0.05%) and incubated with
peroxidase-conjugated mouse anti-human IgG (Hybridoma
Reagent Laboratory, Baltimore, USA) (diluted 1:3000 in
RIA-buffer) for 1 h at room temperature. After a ﬁnal wash to
remove unbound conjugate, bound antibodies were detected
with TMB substrate (Biolegend, San Diego, USA). The reaction
was stopped by the addition of 1 M H2SO4 and absorbance was
measured at 450 nm. OD values obtained for each sample were
evaluated against a standard curve for each of the citrullinated
peptides and uncitrullinated vimentin peptides and expressed as
μ/ml. There was no standard curve available for antibodies to
REP-1 or uncitrullinated ﬁbrinogen peptide and these were
expressed as OD units. Values greater than the 98th percentile
of the healthy controls used in this study were considered posi-
tive for all antibodies.
Statistical analysis
Summary statistics were calculated as appropriate. For univariate
comparisons between patients with and without periodontitis
we used χ2 and Mann–Whitney U tests for categorical and con-
tinuous variables, respectively. Multiple linear and logistic
regression models were used to compare titres of antibodies to
citrullinated and uncitrullinated antigens and prevalence of sero-
positivity between patients with and without periodontitis,
adjusting for age, sex and smoking. Antibody titres were log
transformed to achieve normality for linear regression models.
To facilitate interpretability of the resulting estimates, antibody
titres were standardised and expressed as percentage differences
between groups, calculated as (eβ−1)×100. STATA statistical
software was used for all analyses.
RESULTS
The total sample included 194 participants, of whom 96 had
periodontitis and 98 did not have periodontitis, with a mean
age of 46 years (SD±8.9) and 29 years (SD±7.3), respectively.
The proportion of women was similar in both groups (62% and
59%, respectively). Current smoking was prevalent in 24% of
subjects with periodontitis and 22% of the non-periodontitis
subjects. Ever smoking, deﬁned as current and previous
smoking, was present among 29% and 45% of the patients with
and without periodontitis (p=0.02), respectively. None of the
participants had a diagnosis of RA at the time of the study.
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Antibody seropositivity
There was a low prevalence of antibody seropositivity to the
generic tests for ACPA including anti-CCP and anti-MCV,
with frequencies around 1% in both periodontitis and non-
periodontitis subjects (ﬁgure 1). Among the antibodies to
peptides from speciﬁc citrullinated antigens, anti-CEP-1 seroposi-
tivity was signiﬁcantly higher in patients with periodontitis com-
pared with non-periodontitis (12% and 3%, respectively;
p=0.02). There was no signiﬁcant difference in the frequency of
anti-citrullinated vimentin (cit-vim) or anti-citrullinated ﬁbrino-
gen (cit-ﬁb) (range 2–5%) in periodontitis and non-periodontitis.
The prevalence of antibody seropositivity to the non-citrullinated
peptides REP-1 (arginine control peptide for CEP-1) and ﬁbrino-
gen was much higher in periodontitis. Anti-REP-1 seropositivity
was found in 16% with periodontitis compared with 2% in non-
periodontitis (p<0.001). Similarly, anti-ﬁbrinogen (negative
control peptide for cit-ﬁb) and CParg antibodies (negative
control peptide for CCP) were also more common among those
with periodontitis compared to non-periodontitis patients (26%
vs 3%; p<0.001, and 9% vs 3%; p=0.06, respectively).
Logistic regression models
Logistic regression analyses showed that patients with periodon-
titis were signiﬁcantly more likely to have positive anti-CEP-1
(OR 4.1, 95% CI 1.1 to 15) compared to patients without peri-
odontitis, but this difference was attenuated after adjusting
for age. After controlling for major confounders, patients with
periodontitis were signiﬁcantly more likely to be anti-REP-1 and
anti-ﬁbrinogen positive compared with patients without peri-
odontitis (OR 7.11, 95% CI 1.4 to 36 and OR 10, 95% CI 2.5
to 40, respectively) (table 1).
Antibody titres
The distribution of the antibody repertoire in periodontitis com-
pared with non-periodontitis status is shown in ﬁgure 2. Serum
antibody titres were signiﬁcantly higher in patients with periodon-
titis compared with those without periodontitis for antibodies
against CEP-1 (p<0.0001), REP-1 (p<0.0001), cit-vim
(p=0.003), vimentin (p<0.0001), and ﬁbrinogen (p<0.0001),
but not cit-ﬁb (p=0.1) (ﬁgure 2). There was no difference between
the two groups in anti-CCP, anti-CParg and anti-MCV levels.
Linear regression models
Univariate analyses conﬁrmed that antibody titres were signiﬁ-
cantly higher in patients with periodontitis compared with those
without periodontitis for antibodies against cit-vim, vimentin,
CEP-1, REP-1 and ﬁbrinogen, but not cit-ﬁb. These differences
between groups were attenuated by adjustment for age but
remained strongly statistically signiﬁcant (table 2).
Multivariate regression analyses showed that compared to
those without periodontitis, patients with periodontitis had
43% (p=0.03), 71% (p=0.002) and 114% (p<0.001) higher
anti-CEP-1, anti-REP1 and anti-ﬁbrinogen titres, after adjust-
ment for age, sex and smoking (ﬁgure 3). There was no differ-
ence between groups in anti-CCP, anti-CParg, anti-MCV,
anti-cit-vim and anti-vimentin titres in multivariate analyses.
There was a highly signiﬁcant interaction between periodon-
titis and smoking for anti-CEP-1 (p<0.001) and anti-vimentin
antibodies (p<0.001) in age and sex-adjusted models (table 3).
Among non-smokers, patients with periodontitis had signiﬁ-
cantly higher titres of anti-CEP-1 (103%, p<0.001), anti-REP-1
(91%, p=0.001), anti-vimentin (87%, p=0.002), and anti-
ﬁbrinogen (124%, p<0.001), compared with non-periodontitis
patients, independent of age and sex.
The levels of anti-cit-vim and anti-cit-ﬁb were also higher
among non-smokers with periodontitis compared to non-
smokers without periodontitis, although the differences did not
reach statistical signiﬁcance in multivariate models (p=0.30 and
p=0.15, respectively). Among smokers, periodontitis was asso-
ciated with increased anti-ﬁbrinogen antibodies (98%,
p=0.006) independent of age and sex. No difference was
observed for other antibodies (table 3).
The prevalence of seropositive antibody reactivity to citrulli-
nated and non-citrullinated peptides by periodontitis and
smoking status is shown in ﬁgure 4. Among smokers, those with
Figure 1 Frequency of seropositivity for citrullinated and uncitrullinated
antibodies among patients with periodontitis (PD) and without periodontal
disease (non-PD). Antibody positivity was deﬁned based on the 98th
percentile of the healthy controls. **p=0.02; *p≤0.001. CCP, cyclic
citrullinated peptide; CEP-1, citrullinated α-enolase peptide-1 antibodies;
cit-ﬁb, citrullinated ﬁbrinogen antibodies; cit-vim, citrullinated vimentin
antibodies; CParg, antibodies to the uncitrullinated equivalent of CCP; ﬁb,
uncitrullinated ﬁbrinogen antibodies; MCV, mutated citrullinated vimentin;
REP-1, arginine-containing α-enolase peptide-1 antibodies; vim,
uncitrullinated vimentin antibodies.
Table 1 Logistic regression models
Univariate Age-adjusted Multivariate*
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI)* p Value
Antibodies
CEP-1 4.1 (1.1 to 15) 0.03 2.14 (0.5 to 8.9) 0.2 1.65 (0.37 to 7.5) 0.5
REP-1 8.9 (2.0 to 40) 0.004 6.6 (1.3 to 34) 0.02 7.1 (1.4 to 36) 0.01
Fibrinogen 11.2 (3.2 to 38) <0.001 10.2 (2.5 to 41) 0.001 10 (2.5 to 40) 0.001
*Age, sex and smoking adjusted model.
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periodontitis had a higher frequency of positive anti-CParg
(p=0.004) and anti-ﬁbrinogen (p=0.007) compared to non-
periodontitis. Among non-smokers, patients with periodontitis
had a higher prevalence of positive anti-CEP1 (p=0.02),
anti-REP1 (p=0.005) and anti-ﬁbrinogen antibodies (p<0.001)
than patients without periodontitis.
Figure 2 Antibody repertoire in patients with and without periodontal disease. The boxes designate the 25th and 75th centiles, while the line in
the boxes indicating the median number. The error bars indicate the minimum and maximum values. The numbers on the x axis indicate the
periodontal disease (periodontitis; PD) status. CEP-1, citrullinated α-enolase peptide-1 antibodies; cﬁb, citrullinated ﬁbrinogen antibodies; cvim,
citrullinated vimentin antibodies; ﬁb, uncitrullinated ﬁbrinogen antibodies; REP-1, arginine-containing α-enolase peptide-1 antibodies; vim,
uncitrullinated vimentin antibodies.
Table 2 Linear regression analyses with antibody titres shown as percentage differences in patients with periodontal disease (periodontitis)
compared with patients without periodontitis
Periodontitis
Univariate Age-adjusted Multivariate*
% Δ 95% CI p Value % Δ 95% CI p Value % Δ 95% CI p Value
Antibody
Cit-vim 39 5 to 84 0.02 10 −23 to 56 0.61 6 −26 to 50 0.77
Vimentin 63 24 to 114 0.001 35 −5 to 91 0.09 29 −9.3 to 83 0.16
CEP-1 110 62 to 173 <0.001 48 7 to 105 0.02 43 4 to 98 0.03
REP-1 111 63 to 175 <0.001 70 22 to 138 0.002 71 22 to 134 0.002
Cit-fib 21 −9 to 60 0.19 19 −17 to 71 0.35 16 −19 to 68 0.41
Fibrinogen 128 76 to 194 <0.001 118 56 to 203 <0.001 114 53 to 199 <0.001
Antibody concentrations were log transformed for analyses.
*Adjusted for age, sex and smoking.
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DISCUSSION
To our knowledge, this is the ﬁrst study to examine the immune
reactivity proﬁle to citrullinated antigens and their uncitrulli-
nated forms among individuals with and without periodontitis.
The ﬁnding of an increased prevalence and titre of antibodies to
citrullinated peptides and/or their uncitrullinated controls in
periodontitis supports the hypothesis that periodontitis might
induce the autoimmunity that evolves into that of established
RA. One major unexpected ﬁnding was that antibodies to the
uncitrullinated controls such as CParg and the ﬁbrinogen
peptide were considerably increased in periodontitis relative to
their citrullinated variants, which in turn suggests that it may be
the uncitrullinated variants of the peptides that break tolerance
in periodontitis.
Of the ACPA measured in this study, only one, anti-CEP-1,
showed a signiﬁcantly increased frequency in periodontitis.
A similar increase was seen with antibodies to REP-1, suggesting
that the anti-CEP-1 response was not citrulline speciﬁc. The
increased prevalence of autoantibodies to both peptides was
conﬁrmed by a highly signiﬁcant increase in antibody titres in
periodontitis. This may be due to crossreaction with the bacter-
ial enolase from P gingivalis,28 a common periodontal pathogen
associated with periodontitis. Evidence that this crossreaction
may be relevant in vivo was previously demonstrated in an
animal model,24 in which immunisation of DR4 transgenic mice
with P gingivalis enolase, both citrullinated and uncitrullinated,
caused arthritis and antibodies to CEP-1 and REP-1. Therefore
the antibody response that we observed in periodontitis could
be induced by bacterial enolases from P gingivalis or other bac-
teria within the pathogenic bioﬁlm.
One of the most striking ﬁndings from this study was the sig-
niﬁcantly increased frequency and levels of antibodies to the
uncitrullinated ﬁbrinogen peptide in periodontitis. This cannot
Table 3 Multivariate linear regression shown as percentage differences in antibody titres in periodontitis subjects compared with
non-periodontitis subjects, stratified by smoking
Smokers Non-smokers
p For interaction% Δ 95% CI p Value % Δ 95% CI p Value
Antibody
Cit-vim −21 −52 to 32 0.37 24 −18 to 87 0.30 0.13
Vimentin −33 −53 to 9.3 0.11 87 26 to 176 0.002 <0.001
CEP-1 −22 −50 to 23 0.28 103 41 to 193 <0.001 <0.001
REP-1 41 −13 to 129 0.16 91 29 to 182 0.001 0.28
Cit-fib −12 −48 to 65 0.49 37 −11 to 108 0.15 0.15
Fibrinogen 98 22 to 220 0.006 124 52 to 230 <0.001 0.66
Linear regression models adjusted for age and sex.
Figure 3 Antibody titres shown as percentage differences in patients
with periodontal disease (periodontitis) compared with patients
without periodontitis. The dark blue columns represent the results of
univariate linear regression models and the light blue columns show
the results of multiple linear regression models controlling for age, sex
and smoking. p Values: *p<0.001; **p=0.02; §p=0.002; §§p=0.03.
CEP-1, citrullinated α-enolase peptide-1 antibodies; cit-ﬁb, citrullinated
ﬁbrinogen antibodies; cit-vim, citrullinated vimentin antibodies; ﬁb,
uncitrullinated ﬁbrinogen antibodies; REP-1, arginine-containing
α-enolase peptide-1 antibodies; vim, uncitrullinated vimentin
antibodies.
Figure 4 Prevalence of positive citrullinated and uncitrullinated
antibody reactivity by periodontal disease and smoking status. Among
non-smokers, patients with periodontitis (PD) had a higher prevalence
of positive anti-CEP-1 (*p=0.02), anti-REP-1 (*p=0.005), and
anti-ﬁbrinogen (*p<0.001) than patients without PD. Among smokers,
those with PD had a higher frequency of positive anti-CParg
(*p=0.004), and anti-ﬁbrinogen (*p=0.007) compared to non-PD. CCP,
citrullinated peptide antibodies; CEP-1, citrullinated α-enolase
peptide-1 antibodies; cit-ﬁb, citrullinated ﬁbrinogen antibodies; cit-vim,
citrullinated vimentin antibodies; CParg, antibodies to the
uncitrullinated equivalent of CCP; ﬁb, uncitrullinated ﬁbrinogen
antibodies; MCV, mutated citrullinated vimentin; REP-1,
arginine-containing α-enolase peptide-1 antibodies; vim, uncitrullinated
vimentin antibodies.
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be explained by molecular mimicry because, unlike enolase,
there is no homologue of ﬁbrinogen in prokaryotes. One
explanation may be found in the extraordinary efﬁciency with
which two enzymes from P gingivalis, arginine gingipains and
PPAD, can degrade human ﬁbrinogen into small C-terminally
citrullinated peptides.14 15 This reaction, which occurs in less
than 1 min in culture, produces peptides that would not occur
with human PAD because human PAD produce only internal
citrullines. Therefore, such peptides would be neoantigens
that could induce a T-cell response, but with the antibodies
reacting with internal (non-citrullinated) amino acid sequences.
Moreover, P gingivalis has been shown preferentially to bind
ﬁbrinogen and other immobilised extracellular matrix proteins
in the presence of their soluble forms,35 which may be a colon-
isation or nutritional mechanism in the oral cavity and may
explain why P gingivalis speciﬁcally targets ﬁbrinogen.
Similarly, there was an increased frequency of antibodies to
CParg. The mechanisms underlying these phenomena are uncer-
tain, particularly in the case of CParg, because the sequence of
the peptides in CCP and CParg has not been published.
However, with both antigens, the reaction in the periodontitis
sera was preferentially with uncitrullinated forms of the antigen.
There were also raised levels, but not a signiﬁcantly raised fre-
quency, of antibodies to both citrullinated and uncitrullinated
vimentin peptides in our periodontitis population, although the
statistical signiﬁcance of antibodies to citrullinated vimentin was
lost in multivariate analysis. Interestingly, there was a highly
signiﬁcant interaction between periodontitis and smoking for
anti-vimentin antibodies. Among non-smokers, patients with
periodontitis had signiﬁcantly higher titres of anti-vimentin anti-
bodies, compared with non-periodontitis patients, independent
of confounders.
Our ﬁnding that the autoantibody response to periodontitis is
restricted to non-smokers is intriguing. Smoking is a strong
dose-dependent risk factor both for chronic periodontitis36 and
tooth loss,37 as well as an established dose-dependent environ-
mental risk factor for antibody positive RA and RA disease
severity,38–44 which may be partly mediated through its effect
on citrullination of peptides45 46 in the lungs of smokers. Major
genetic susceptibility factors for RA (ie, HLA-DRB1 shared
epitope and PTPN22) and smoking have recently been shown
to be associated with anti-CEP-1 and anti-cit-vim-positive
RA.26 47 In the present study, there was effect modiﬁcation by
smoking. Among non-smokers, patients with periodontitis had
higher anti-CEP-1 titres than non-periodontitis patients, and all
anti-CEP-1-positive individuals were non-smokers, suggesting
that periodontal disease (periodontitis) per se, rather than
smoking, is involved in the generation of reactivity against
CEP-1 in patients with periodontitis. The anti-cit-vim and
anti-cit-ﬁb titres were also higher among non-smokers with peri-
odontitis, although the differences did not reach statistical sig-
niﬁcance after adjusting for confounders. Our results may
suggest that smoking-induced citrullination and the citrullina-
tion induced by PPAD (or neutrophil activity during periodon-
titis) are entirely different mechanisms. Furthermore, the
interaction may be due to differences in periodontal pathophysi-
ology between smokers and non-smokers. For example, it is
well established that smoking suppresses gingival inﬂamma-
tion,48 49 and recent studies suggest that the periodontal micro-
biome in periodontitis is different in smokers compared to
non-smokers.50 Moreover, cigarette smoke has been shown to
antagonise antibody-mediated HOCl release in neutrophils,51
which may have downstream effects on neutrophil extracellular
trap release.52 The mechanisms whereby periodontitis may
ultimately lead to an ACPA response and RA are unknown. Our
ﬁndings suggest that uncitrullinated peptides may break toler-
ance in periodontitis, independent of major confounders includ-
ing age, sex and smoking.
Disease duration could be a key factor in antibody formation
and antibody proﬁle. The natural course of periodontitis is
known to be that of a slowly progressing disease, which is typic-
ally asymptomatic. Given that the periodontitis group consisted
mainly of patients with relatively advanced periodontal break-
down, it is likely that they have had chronic periodontitis for
many years. Whether these antibodies occur early in the disease
course of periodontitis is yet to be determined.
In RA, ACPA precede the appearance of clinically identiﬁable
arthritis by several years,18–22 and epitope spreading occurs before
disease onset, but does not expand after disease onset.18–22 This
might explain the low frequency of antibody reactivity to the
arginine-containing control peptides for α-enolase, vimentin and
ﬁbrinogen in established RA, as reported in a study of samples
from nearly 2000 RA cases.47 Therefore, if our theory is correct it
would be predicted that antibodies to the non-citrullinated versions
of RA autoantigens may well occur before the evolution of ACPA.
Certainly, it would be well worth studying pre-disease serum
samples not only for ﬁne speciﬁcity antibodies to established citrul-
linated antigens but also for antibodies to their uncitrullinated
(arginine) control peptides.
In summary, distinct antibody reactivity against both citrulli-
nated and uncitrullinated peptides was observed between
individuals with and without periodontitis, independent of
major confounders, suggesting that uncitrullinated peptides
break tolerance in periodontitis, with epitope spreading to
citrullinated epitopes in the small proportion of patients that
may evolve into RA.
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Paper 5 
Smoke exposure as a determinant of
autoantibody titre in a1-antitrypsin
deficiency and COPD
A.M. Wood*, P. de Pablo*, C.D. Buckley*, A. Ahmad* and R.A. Stockley#
ABSTRACT: Liberation of elastin peptides from damaged lung may be a mechanism of autoimmune
lung disease. Citrullination, and anti-citrullinated protein antibody formation occurs in smokers, but
the role of smoking in autoantibody generation relevant to pulmonary disease is unclear.
Anti-elastin, anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin
(anti-MCV) antibodies were measured in 257 subjects with a1-antitrypsin deficiency (AATD), 113
subjects with usual chronic obstructive pulmonary disease (COPD) and 22 healthy nonsmokers.
Levels were compared between groups, against phenotypic features and against smoke exposure.
Anti-elastin antibodies were higher in controls relative to AATD (p50.008) and usual COPD
(p,0.00001), and in AATD relative to usual COPD (p,0.00001). Anti-elastin levels showed a
threshold at 10 pack-yrs, being higher in those who had smoked less (p50.004). No relationships
between antibody levels and clinical phenotype were seen after adjustment for smoke exposure.
Anti-CCP antibodies were higher in usual COPD than AATD (p50.002) but the relationship to
smoke exposure was less clear.
Smoke exposure is the main determinant of anti-elastin antibody levels, which fall after 10 pack-
yrs. Local antibody complexes may be a better measure of elastin directed autoimmunity than
circulating levels.
KEYWORDS: a1-Antitrypsin deficiency, autoimmune disease, chronic obstructive pulmonary
disease, smoking and health
T
he protease–antiprotease hypothesis of the
pathogenesis of chronic obstructive pulmon-
ary disease (COPD) concerns imbalances
between proteases that digest elastin and other
components of the extracellular matrix in the lung
parenchyma, and antiproteases that protect [1–2].
The origin of this theory comes from the observa-
tion that patients with a1-antitrypsin deficiency
(AATD) develop early onset emphysema [3]. a1-
Antitrypsin (AAT) is an antiprotease, which acts
predominantly to block the action of neutrophil
elastase, a protease released by neutrophils. Neu-
trophil elastase is a serine protease, the first of three
classes of protease important in COPD. The
remaining two classes are the cysteine proteases,
such as cathepsin-B, and the matrix metallopro-
teases (MMPs) [4]. In general, the serine and
cysteine proteases are capable of degrading elastin
and some forms of collagen [4], whilst MMPs have
more of an effect on collagen, gelatin and laminin
[2], all of which are components of the extracellular
matrix of the lung.
Breakdown of the extracellular matrix, particu-
larly elastin, in the lung is a key feature of both
COPD and AATD, as shown by the presence of
high levels of elastin breakdown products. A
desmosine cross-link is unique to elastin and may
be used as a marker of its degradation [5].
Desmosine and elastin peptides are elevated in
the plasma, urine and sputum of COPD patients
[6], whilst urinary levels positively correlate with
the annual rate of decline in forced expiratory
volume in 1 s (FEV1) in smokers [7]. In general,
elastin breakdown is greater in subjects with
AATD at a given level of smoking because of a
relative excess of neutrophil elastase activity in
the lung [8], confirmed by elevated desmosine
levels compared with usual COPD subjects [6].
Elastin breakdown has been proposed as a
mechanism for generation of autoantibodies
directed against elastin, which could in theory
perpetuate and/or aggravate lung destruction
[9]. In both AATD and COPD, the main stimulus
to elastin breakdown is cigarette smoking, but
studies of anti-elastin antibody prevalence in
these conditions to date have been too small to
assess smoke effects on antibody levels ade-
quately [9–11]. Although the original report of
circulating anti-elastin antibodies in COPD was
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Paper 6 
Long-Term Impact of Early Treatment on
Radiographic Progression in Rheumatoid
Arthritis: A Meta-Analysis
AXEL FINCKH,1 MATTHEW H. LIANG,1 CARMEN MUGICA VAN HERCKENRODE,2 AND
PAOLA DE PABLO1
Objective. Although early initiation of disease-modifying antirheumatic drugs (DMARDs) is effective in controlling
short-term joint damage in individuals with rheumatoid arthritis (RA), the long-term beneﬁt in disease progression is still
controversial. We examined the long-term beneﬁt of early DMARD initiation on radiographic progression in early RA.
Methods. We identiﬁed published and unpublished clinical trials and observational studies from 1966 to September 2004
examining the association between delay to treatment initiation and progressive radiographic joint damage. We included
studies of persons with RA disease duration <2 years and DMARD therapy of similar efﬁcacy during followup. The
differences in annual rates of radiographic progression between early and delayed therapy were pooled as standardized
mean differences (SMDs).
Results. A total of 12 studies met the inclusion criteria. The pooled estimate of effects from these studies demonstrated a
signiﬁcant reduction of radiographic progression in patients treated early (0.19 SMD, 95% conﬁdence interval [95% CI]
0.34, 0.04), which corresponded to a 33% reduction (95% CI 50, 16) in long-term progression rates compared with
patients treated later. Patients with more aggressive disease seemed to beneﬁt most from early DMARD initiation (P  0.04).
Conclusion. These results support the existence of a critical period to initiate antirheumatic therapy, a therapeutic
window of opportunity early in the course of RA associated with sustained beneﬁt in radiographic progression for up to
5 years. Prompt initiation of antirheumatic therapy in persons with RA may alter the long-term course of the disease.
KEY WORDS. Rheumatoid arthritis; Antirheumatic agents; Disease progression; Structural joint damage.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂammatory dis-
ease that causes progressive joint destruction and disabil-
ity and is currently without cure. It is the most common
systemic rheumatic disease, affecting 1% of the popula-
tion (1). Radiographic joint damage correlates strongly
with long-term functional decline in patients with RA, and
therefore preventing progressive joint damage has become
a key treatment objective (2,3). Until recently, the recom-
mended therapeutic strategy was to start with nonsteroidal
antiinﬂammatory drugs (NSAIDs) or low-dose glucocorti-
coids, and progressively introduce more potent antirheu-
matic therapies only if the NSAIDs and glucocorticoids
were insufﬁcient to control the disease (pyramid ap-
proach). In the last 15 years, treatment goals have evolved
from a concept of symptom control to a concept of disease
control (4). This has resulted in a more aggressive thera-
peutic approach with earlier introduction of disease-mod-
ifying antirheumatic drugs (DMARDs) (5), which have
been proven to reduce structural joint damage.
The rationale for a prompt initiation of DMARDs in
patients with RA is based on the idea that there is a critical
period, a therapeutic window of opportunity, during early
stages of the disease when treatment is more effective than
later in the course of the disease. This concept covers a
short-term effect with better disease activity responses and
Dr. Finckh’s work was supported by a scholarship from
the Swiss National Science Foundation, the Geneva Univer-
sity Hospital, the Kirkland Foundation, and by NIH grant
P60-AR-47782. Dr. van Herckenrode’s work was supported
by the Faculty of Medicine of the University of the Basque
Country Leioa. Dr. de Pablo’s work was supported by a
postdoctoral fellowship from the Arthritis Foundation and
the Kirkland Foundation. Dr. Liang’s work was supported
by NIH grant AR-47782, the Kirkland Scholar award, and a
grant from the Lupus Clinical Trials consortium.
1Axel Finckh, MD, MS (current address: University Hos-
pital of Geneva, Geneva, Switzerland), Matthew H. Liang,
MD, MPH, Paola de Pablo, MD, MPH: Brigham and Women’s
Hospital, Boston, Massachusetts; 2Carmen Mugica van
Herckenrode, MD: University of the Basque Country Leioa,
Vizcaya, Leioa, Spain.
Address correspondence to Axel Finckh, MD, MS, Divi-
sion of Rheumatology, University Hospital of Geneva,
Avenue Beau-Se´jour 26, CH 1211 Geneva 14, Switzerland.
E-mail: aﬁnckh@post.harvard.edu.
Submitted for publication December 21, 2005; accepted in
revised form April 4, 2006.
Arthritis & Rheumatism (Arthritis Care & Research)
Vol. 55, No. 6, December 15, 2006, pp 864–872
DOI 10.1002/art.22353
© 2006, American College of Rheumatology
ORIGINAL ARTICLE
864
  
 
 
 
 
 
 
 
Paper 7 
Extended report
Ann Rheum Dis 2011;70:500–507. doi:10.1136/ard.2010.131573500
 
Accepted 17 October 2010
Published Online First 
29 November 2010
 ABSTRACT 
 Objectives  Early therapy improves outcomes in 
rheumatoid arthritis (RA). It is therefore important to 
improve predictive algorithms for RA in early disease. This 
study evaluated musculoskeletal ultrasound, a sensitive 
tool for the detection of synovitis and erosions, as a 
predictor of outcome in very early synovitis. 
 Methods  58 patients with clinically apparent synovitis 
of at least one joint and symptom duration of ≤3 months 
underwent clinical, laboratory, radiographic and 38 joint 
ultrasound assessments and were followed prospectively 
for 18 months, determining outcome by 1987 American 
College of Rheumatology (ACR) and 2010 ACR/European 
League Against Rheumatism criteria. Sensitivity and 
specifi city for 1987 RA criteria were determined for 
ultrasound variables and logistic regression models were 
then fi tted to evaluate predictive ability over and above 
the Leiden rule. 
 Results  16 patients resolved, 13 developed non-RA 
persistent disease and 29 developed RA by 1987 
criteria. Ultrasound demonstrated subclinical wrist, 
elbow, knee, ankle and metatarsophalangeal joint 
involvement in patients developing RA. Large joint and 
proximal interphalangeal joint ultrasound variables had 
poor predictive ability, whereas ultrasound erosions 
lacked specifi city. Regression analysis demonstrated 
that greyscale wrist and metacarpophalangeal joint 
involvement, and power Doppler involvement of 
metatarsophalangeal joints provided independently 
predictive data. Global ultrasound counts were inferior 
to minimal power Doppler counts, which signifi cantly 
improved area under the curve values from 0.905 to 
0.962 combined with the Leiden rule. 
 Conclusion  In a longitudinal study, extended ultrasound 
joint evaluation signifi cantly increased detection of joint 
involvement in all regions and outcome groups. Greyscale 
and power Doppler scanning of metacarpophalangeal 
joints, wrists and metatarsophalangeal joints provides the 
optimum minimal ultrasound data to improve on clinical 
predictive models for RA. 
 Early therapy signiﬁ cantly improves outcomes in 
rheumatoid arthritis (RA).  1    2  Indeed, data suggest 
that the ﬁ rst 3 months after symptom onset may 
represent a pathologically distinct phase that trans-
lates into a therapeutic window of opportunity.  3  –  5  
The ability to predict the development of RA accu-
rately in patients with very early synovitis is thus 
important.  6  
 Classiﬁ cation systems for RA  7    8  and predic-
tive models such as the widely validated Leiden 
rule,  9    10  rely heavily on clinical assessment of the 
extent and pattern of joint involvement. How best 
to deﬁ ne early RA remains a subject of considerable 
debate  11  heightened by recent publication of the 
2010 American College of Rheumatology (ACR)/
European League Against Rheumatism (EULAR) 
criteria. Musculoskeletal ultrasound has been dem-
onstrated to be more sensitive than clinical assess-
ment in the detection of joint swelling,  12    13  and 
more sensitive than conventional radiography in 
the detection of erosions.  14  It is therefore important 
to evaluate the contribution of ultrasound variables 
as potential predictors of outcome in patients with 
very early disease. 
 Investigators have recently explored the use of 
restricted ultrasound joint counts to predict per-
sistent inﬂ ammatory arthritis in symptomatic 
patients with hand synovitis or arthralgia present-
ing in the ﬁ rst 3 months of disease.  15  However, the 
use of ultrasound to predict RA in this early phase 
has not been investigated, and although extended 
joint counts are being investigated as a tool to 
assess response to therapy,  16  they have yet to be 
applied to an unselected population of patients 
with very early synovitis. The aim of this study 
was therefore to evaluate the additional predictive 
ability of extended ultrasound joint counts for RA. 
We ﬁ rst compared clinical and ultrasound base-
line assessments in very early arthritis. Second, 
we compared ultrasound versus a conventional 
radiography baseline evaluation of bone erosion. 
Finally, we compared ultrasound and clinical vari-
ables for their ability to predict RA as a diagnostic 
outcome. 
 PATIENTS AND METHODS 
 Patients 
 Fifty-eight patients with clinically apparent syno-
vitis of at least one joint and inﬂ ammatory joint 
symptoms (inﬂ ammatory joint pain, and/or swell-
ing and/or morning stiffness) of 3 months or less 
duration underwent baseline assessment and 
18-month follow-up to determine diagnosis as 
previously described.  3    17  Ethical permission was 
obtained and all patients gave written informed 
consent. Patients were classiﬁ ed as having RA, reac-
tive arthritis, psoriatic arthritis or miscellaneous 
conditions according to established  criteria.  7    8    18  
  19  In order to compare the distribution of joint 
involvement with established RA, 22 patients with 
newly presenting, treatment-naive RA of over 3 
months’ duration fulﬁ lling 1987 ACR criteria were 
also recruited. 
▶  Additional data 
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Effusion in the absence of synovial thickening was not classi-
ﬁ ed as synovitis. Synovial hyperaemia was measured by power 
Doppler in each recess and the maximal score graded according 
to Szkudlarek  et al  23  : 0, absence; 1, isolated signals; 2, conﬂ uent 
signals in less than half of the synovial area; and 3, conﬂ uent 
signals in more than half of the synovial area. The presence of 
joint erosion was measured as a binary variable. Global ultra-
sound indices for greyscale synovitis and power Doppler were 
calculated by adding scores from all joints. Global ultrasound 
counts were calculated by adding scores after converting indi-
vidual joint grades to binary variables. 
 Statistical analysis 
 Analysis of data including logistic regression was performed 
using Stata 10. Comparison of clinical and ultrasound counts 
within and between groups was analysed using McNemar’s 
test and Fisher’s exact test, respectively. Other baseline clinical 
and ultrasound variables were compared between groups using 
Mann–Whitney U or Kruskal–Wallis tests. Intraobserver reliabil-
ity was evaluated by blindly rescoring representative images of 
20 patients for synovitis and power Doppler at least 3 months 
after initial scans, and analysed using κ statistics (see supple-
mentary table S1, available online only). 
 RESULTS 
 Patient characteristics 
 Patients developing RA by 1987 criteria (VERA) were  signiﬁ cantly 
older than those in other groups as expected ( table 2 ). Male 
patients were overrepresented in this group (55%) compared 
with the general RA population. No patients in the study had 
received disease-modifying antirheumatic drugs at baseline. 
Two patients (both of whom developed RA) had received a 
short course of prednisolone for 5 and 14 days before recruit-
ment. Both fulﬁ lled ACR criteria at the time of recruitment. 
Two patients in the group developing non-RA persistent disease 
(VENRA) were RF positive; one had  reactive arthritis, the other 
had psoriatic arthritis. Of ﬁ ve VENRA patients remaining unclas-
siﬁ ed, one was treated with  methotrexate and another with 
hydroxychloroquine within 1 month of presentation. The com-
parison group of 22 patients with established RA had a median 
symptom  duration of 28 (IQR 17–65) weeks and median age 55 
(IQR 45–63) years: 73% were women, and 64% were ACPA 
and/or RF positive. 
 Global clinical and ultrasound assessment of patients 
 A total of 4640 sites in 2204 joints was included in the analysis. 
Proportionately more joints were found to be involved by ultra-
sound greyscale assessment than clinical examination in VERA 
(see  table 2 ). Ultrasound assessment led to the reclassiﬁ cation 
of many patients between monarthritis, oligoarthritis and pol-
yarthritis groups. In particular nine (69%) VENRA patients were 
reclassiﬁ ed as polyarthritis, and eight (50%) resolving patients 
with a clinical monarthritis were reclassiﬁ ed as oligo or polyar-
thritis. The distribution of subclinical joint involvement found by 
ultrasound greyscale assessment in six patients with persistent 
disease and a clinical monarthritis at presentation (who without 
erosions could not be classiﬁ ed as having RA by the 2010 criteria) 
is shown in supplementary ﬁ gure S1 (available online only). 
 Effect of ultrasound assessment on joint involvement by region 
 Clinical involvement was deﬁ ned by at least one joint in a given 
region being clinically swollen and ultrasound involvement 
 Clinical, laboratory and radiographic assessment 
 Patients underwent baseline 66 swollen and 68 tender clini-
cal counts. Age, sex, symptom duration, early morning stiff-
ness duration, medication, erythrocyte sedimentation rate, 
C-reactive protein, rheumatoid factor (RF) and anticyclic citrul-
linated peptide antibody (ACPA) status were recorded. In all but 
six patients, none of whom fulﬁ lled the 1987 or 2010 criteria for 
RA or subsequently developed erosions, baseline conventional 
radiography of hands and feet was recorded, and the presence 
of erosions assessed in a blinded fashion by a single trained 
observer (AF). 
 Ultrasound assessment 
 Within 24 h of clinical assessment, patients underwent blinded 
ultrasound assessment in a temperature controlled radiology 
suite. Patients were asked not to discuss their symptoms. A sys-
tematic multiplanar greyscale and power Doppler ultrasound 
examination of 92 sites in 38 joints ( table 1 ) was performed 
based upon standard EULAR reference scans  20  using a Siemens 
Acuson Antares scanner (Siemens, Bracknell, UK) and multifre-
quency (5–13 MHz) linear array transducers. For power Doppler 
examinations, the pulse repetition frequency was adjusted to 
provide maximal sensitivity at the lowest possible value for each 
joint, resulting in a pulse repetition frequency of between 610 
and 780. Examinations took between 50 and 60 min depending 
on disease extent and patient mobility. 
 Ultrasound ﬁ ndings of synovitis, power Doppler positivity and 
erosion were deﬁ ned according to consensus deﬁ nitions.  12    20  –  22  
Greyscale synovitis in metacarpophalangeal, proximal inter-
phalangeal and metatarsophalangeal joints was graded from 
0 to 3 based upon the system of Szkudlarek and colleagues,  12  
  23  reclassifying the equivocal ‘minimal’ thickening grade as 
normal: grade 0, normal; grade 1, synovial thickening bulging 
over the line linking the tops of the periarticular bones; grade 
2, grade 1 plus extension to one bone diaphysis; grade 3, grade 
1 plus extension to both bone diaphyses. Synovitis in other 
joints was graded 0–3 as: 0, normal; 1, mild; 2, moderate; and 
3, severe, in which grade 1 demonstrates synovial thickening in 
excess of the mean plus 2 SD of normal range when available.  22  
 Table 1  Synovial intra-articular recesses and periarticular sites 
evaluated by ultrasound 
 Joint  Recess or site 
MCP (1–5), PIP (1–5), MTP (2–5) Dorsal recess
Lateral recess (PIP, MCP 1,2,5 MTP 5)
Volar recess (PIP)
Wrist Intercarpal recesses
Radiocarpal recesses
Ulnarcarpal recesses
Volar carpal recesses
Elbow Anterior recess
Humeroradial joint
Humeroulnar joint
Posterior recess
Shoulder Subdeltoid bursa
Posterior glenohumeral recess
Knee Suprapatellar recess
Medial parapatellar recess
Lateral parapatellar recess
Medial femorotibial joint line
Lateral femorotibial joint line
Ankle Anterior tibiotalar recess
Medial tibiotalar recess
Lateral tibiotalar recess
 MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; PIP, proximal 
interphalangeal joint. 
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and metatarsophalangeals joints (p<0.01). To investigate the 
low levels of clinically apparent metatarsophalangeal joint and 
ankle synovitis in VERA patients, we assessed a comparison 
group of patients with newly presenting RA of more than 3 
months’ duration. Clinical involvement of the proximal inter-
phalangeal, ankle and metatarsophalangeals joints was more 
overt in these patients ( ﬁ gure 1C ), with signiﬁ cantly greater 
involvement of the metatarsophalangeal joints (p<0.05). 
 Detection of erosive disease in early arthritis using ultrasound 
 Ultrasonographic erosions of the hands or feet were detected in 
26 joints of 13 very early arthritis patients ( table 2 ). Using con-
ventional radiography, only one erosion was visible in the wrist 
by the presence of greyscale synovial hypertrophy of at least 
grade 1. The impact of increased sensitivity of ultrasound was 
most marked in the large joints, wrists and metatarsophalan-
geal joints  ( ﬁ gure 1 , supplementary table S1, available online 
only). Among VERA patients, clinically silent involvement of 
the wrists, elbows, knees, ankles and metatarsophalangeals 
joints was identiﬁ ed signiﬁ cantly more often by ultrasound. 
In VENRA patients, metacarpophalangeal joint (p<0.05), 
wrist (p<0.05), elbow (p<0.05) and metatarsophalangeal joint 
(p<0.01) involvement was detected more often by ultrasound 
(supplementary table S2, available online only). Compared with 
groups with persistent outcomes, ultrasound detected less addi-
tional involvement in the resolving group at the wrist (p<0.05) 
 Table 2  Baseline patient demographics and global clinical and ultrasound data 
 Final diagnostic group by 1987 criteria  VERA  VENRA  Resolving 
n  29 13 16
Final diagnosis, n (%)
 RA  29 (100)  0  0
 PsA   0  5 (38)  1 (6.25)
 SLE   0  2 (15)  0
 Parvovirus related   0  0  1 (6.25)
 Pseudogout   0  0  1 (6.25)
 Reactive   0  1 (8)  0
 Septic   0  0  1 (6.25)
 Unclassifi ed   0  5 (38) 12 (75)
Age†**  63 (19–82) 45 (18–83) 40 (23–75)
Female, n (%)  13 (45)  9 (69) 10 (63)
Symptoms duration, weeks†   7 (2–12)  6 (3–12)  4 (1–9)
Morning stiffness, min† 120 (30–360) 60 (0–240) 52.5 (0–240)
NSAID use, n (%)  20 (69)  8 (62) 13 (81)
RF positive, n (%)  15 (52)  2 (15)  0
ACPA positive, n (%)  14 (48)  0  0
ESR (mm/h)†  25 (0–104) 24 (4–87) 21.5 (0–102)
CRP (mg/l)†  15 (0–102) 16 (0–83) 16 (0–244)
Swollen joint count of 66†***   8 (1–28)  2 (1–13)  1.5 (1–7)
Tender joint count of 68†*   9 (0–41)  3 (0–19)  2.5 (1–10)
DAS28 score†   4.49 (2.20–6.28)  3.90 (1.66–6.27)  3.57 (1.38–4.94)
Patients meeting ACR criteria at baseline
 1987 ACR criteria, n (%)  12 (41)  0  0
 USGS 1987 ACR criteria, n (%)‡  16 (55)  3 (23)  1 (6)
 2010 ACR/EULAR criteria, n (%)  24 (83)  2 (15)  0
 USGS 2010 ACR/EULAR criteria, n (%)‡  27 (93)  5 (38)  2 (13)
Clinical pattern, n (%)
 Monarthritis   1 (3)  6 (46)  8 (50)
 Oligoarthritis (2–5 joints)  10 (34)  6 (46)  7 (44)
 Polyarthritis (>5 joints)  18 (62)  1 (8)  1 (6)
USGS pattern, n (%)‡
 Monarthritis   0  1 (8)  0
 Oligoarthritis   1 (3)  2 (15) 11 (69)
 Polyarthritis  28 (97) 10 (77)  5 (31)
US variables
 GS index†***  35 (5–78) 14 (2–38)  6 (2–19)
 GS count of 38†***  15 (5–33)  9 (1–20)  3 (2–12)
 PD index†***  25 (5–60)  9 (2–26)  5.5 (0–16)
 PD count of 38†***  12 (3–29)  5 (1–13)  3 (0–10)
Presence of erosions
 Radiographic hand/foot erosion, n (%)   1 (3.5)  0  0
 US hand/foot erosion, n (%)  11 (38)  2 (15)  0
 Any US erosion, n (%)  11 (38)  2 (15)  1 (6.25)
 †Median (range). 
 ‡Clinical examination variables have been extended by adding ultrasonographic criteria of joint involvement (USGS grade ≥1) and 
erosion. 
 ACPA, anticyclic citrullinated peptide antibody; ACR, American College of Rheumatoloty; CRP, C-reactive protein; DAS28, disease 
activity score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; GS, greyscale 
ultrasound; NSAID, non-steroidal anti-infl ammatory drug; PD, power Doppler; PsA, psoriatic arthropathy; RA, rheumatoid arthritis; 
RF, rheumatoid factor; SLE, systemic lupus erythematosus; US, ultrasound. 
 *p<0.05, **p<0.01, ***p<0.001 Kruskal–Wallis test. 
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 Impact of ultrasound measured variables on 1987 and 
2010 RA criteria fulfi lment 
 At baseline, the 1987 ACR criteria identiﬁ ed 12 out of 29 RA 
patients, and no patients in VENRA and resolving groups. 
Adding ultrasound data identiﬁ ed 16 RA patients but misclassi-
ﬁ ed a further four patients ( table 2 ). The 2010 criteria identiﬁ ed 
26 patients (nine with ultrasound erosions) at baseline including 
two VENRA patients ( table 2 , supplementary table S3, available 
online only). The difference between these values is almost 
entirely accounted for by the 6-week rule, without which 1987 
of a VERA patient. All VERA patients with ultrasound erosions 
at joints besides metacarpophalangeals joints or wrists also had 
erosions at these hand joints, giving a speciﬁ city of ultrasound 
erosions for RA of 93%. Of 11 VERA patients with ultrasound 
erosions, eight were RF and ACPA positive, one was RF positive 
only and one was seronegative. One RF-negative patient with 
psoriatic arthritis and one with unclassiﬁ ed disease presented 
with ultrasound wrist erosions. A single resolving patient with 
a diagnosis of septic arthritis presented with an ultrasound ankle 
erosion. 
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 Figure 1  Clinical and ultrasound involvement by joint region. Joint region involvement, defi ned as the presence of at least one clinically swollen joint 
or one joint with ultrasound greyscale synovitis in a given region, in (A) the total cohort of very early arthritis patients, (B) patients who developed a 
diagnosis of rheumatoid arthritis (RA) and (C) an additional cohort of patients with newly presenting, untreated RA of greater than 3 months’ symptom 
duration. (A) Ultrasound demonstrates increased sensitivity compared with clinical examination in all joints overall. (B) Signifi cantly more clinically 
silent disease in patients developing RA is measured by ultrasound at the wrist, elbow, knee, ankle and metatarsophalangeal (MTP) joints. (C) Proximal 
interphalangeal joint (PIP), ankle and metatarsophalangeal joint disease is clinically more overt in patients with longer RA disease duration.
MCP, metacarpophalangeal joint. 
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and symmetry of metatarsophalangeal joints are most likely to 
suggest a diagnosis of RA if not clinically apparent, and may be 
combined to enhance prediction ( table 3 ). Deriving a minimal 
12-joint power Doppler ultrasound score in a similar manner to 
Naredo  et al  24  increased the AUC in this analysis. By remov-
ing the (less speciﬁ c) knee joint from this score, a signiﬁ cantly 
increased AUC of 0.962 was obtained (p<0.05,  ﬁ gure 2 ).  25  
 DISCUSSION 
 We have demonstrated a diagnostic beneﬁ t of the increased sen-
sitivity of ultrasound in an early synovitis population. Ultrasound 
assessment results in a considerable shift in disease category 
from monarthritis to oligoarthritis and/or polyarthritis, that is 
greater than that reported in patients with longer disease dura-
tions.  13  This suggests that the increased sensitivity of ultrasound 
may have a greater impact in the very early window. Comparing 
very early with later onset RA supported this, as joints such as 
the metatarsophalangeals joints were more evident clinically 
later in the disease course. The 2010 criteria proved, as expected, 
to be more sensitive at baseline than the 1987 criteria. However, 
they failed to classify all patients ultimately classiﬁ ed as RA by 
the 1987 criteria. Adding ultrasound variables to the new 2010 
criteria classiﬁ ed more patients as RA, including several later 
classiﬁ ed as RA by the 1987 criteria, one with ultrasound ero-
sions. This suggests that the detection of subclinical disease by 
imaging will similarly prove useful in optimising sensitivity and 
speciﬁ city of the 2010 criteria. 
 Global ultrasound counts improve sensitivity with some loss 
of speciﬁ city. However, ultrasound of large joints and proximal 
interphalangeals joints is not helpful in predicting RA by the 
1987 criteria. Global ultrasound joint counts therefore increased 
the discriminating ability of the Leiden rule, but require signiﬁ -
cant scanning time, and performed worse than minimal counts 
by including non-discriminating joints. Harrison and Symmons  26  
showed in the NOAR cohort that persistent synovitis was pre-
dicted by the presence of RF, a tender joint count of greater than 
six and ankle synovitis. However, ultrasound detected signiﬁ -
cantly more knee and ankle disease in all disease groups in our 
cohort, with no predictive beneﬁ t. 
 Two further ﬁ ndings from our data are important: ﬁ rst, that 
scanning the metacarpophalangeals joints, wrists and metatar-
sophalangeal joints is likely to be of useful predictive value. 
Subclinical ultrasound metatarsophalangeal joint involvement 
in very early arthritis demonstrated very good speciﬁ city for RA 
by the 1987 criteria. Long established data show that erosive 
metatarsophalangeal joint disease occurs despite the absence of 
symptoms or signs.  27  Such subclinical disease may manifest as 
a positive metatarsophalangeal joint squeeze test, a suggested 
screening tool for possible early RA.  28  Second, power Doppler 
measurements have a uniquely high speciﬁ city for RA compared 
with other groups, particularly at the metatarsophalangeals 
joints, with combined metacarpophalangeal joint, wrist and 
metatarsophalangeal joint assessments providing excellent AUC 
values. These data are compatible with those of Freeston  et al  15  
who examined associations of inﬂ ammatory arthritis in a mixed 
population of patients with arthralgia and arthritis, ﬁ nding that 
high grade power Doppler had good sensitivity and speciﬁ city 
for persistence. Therefore, in addition to correlations with ero-
sive progression, power Doppler may also have useful predic-
tive power for RA.  29    30  Of particular interest is the increased 
AUC value of power Doppler indices and counts compared 
with greyscale equivalents, suggesting that power Doppler has 
superior speciﬁ city for RA. Reducing the complexity of power 
criteria identiﬁ ed 23 VERA patients at baseline. Extending the 
2010 criteria by adding ultrasound data identiﬁ ed a further eight 
patients, including three with erosions (supplementary table S2, 
available online only). All eight were classiﬁ ed as RA regardless 
of erosions by increasing the 2010 ‘joints’ score from either two 
or three to the maximum ﬁ ve. Ultimately, at 18 months the 2010 
criteria failed to classify as RA four out of 29 VERA patients, 
including one patient with ultrasound deﬁ ned erosions. 
 Sensitivity and specifi city of clinical and ultrasound 
variables for RA by 1987 criteria 
 Clinical and ultrasound variables were assessed by calculating 
sensitivity, speciﬁ city and area under the receiver operating 
characteristic curve (AUC) for 1987 RA as an outcome ( table 3 ), 
using threshold grades of 1 or more or 2 or more for ultra-
sound variables. Shoulder, elbow, knee and ankle ultrasound 
involvement was discarded from the analysis because of lack of 
speciﬁ city for RA, despite increased sensitivity (supplementary 
table S2, available online only). Ultrasound variables generally 
improved sensitivity with some loss of speciﬁ city. Modifying 
this by imposing a higher threshold grade or requiring symme-
try resulted in improved AUC values for ultrasound variables 
in metacarpophalangeal, proximal interphalangeal and metatar-
sophalangeal joint regions compared with clinical equivalents 
( table 3 ). In this cohort, adding ultrasound to clinical variables in 
the 1987 ACR criteria increased sensitivity at a cost of speciﬁ city 
resulting in a drop in AUC. However, power Doppler variables 
performed better than greyscale variables. Furthermore, grey-
scale and power Doppler assessments of metatarsophalangeals 
joints exhibited improved sensitivity compared with clinical 
variables, whereas power Doppler variables retained high speci-
ﬁ city for RA. By combining variables with 100% speciﬁ city for 
RA (ACPA positivity, metatarsophalangeal joint power Doppler 
grade of 2 or more involvement and a metacarpophalangeal joint 
greyscale count of 8 or greater), 76% of VERA patients were 
identiﬁ ed, including eight of the 15 ACPA-negative individuals. 
 Logistic regression analyses 
 Signiﬁ cant variables on univariate analysis were entered as 
explanatory variables in logistic regression models with an out-
come of RA by 1987 criteria as the dependent variable, and the 
Leiden score  9  as the independent variable. An AUC was con-
structed to assess contribution to the prediction of RA above 
the Leiden rule for different models ( table 4 ). The AUC for the 
Leiden rule as a continuous variable was 0.905 in this sample, 
similar to the value derived by van der Helm-van Mil  et al.  9  
Global greyscale and power Doppler counts increased the AUC 
for predicting RA ( table 4 ), indicating that ultrasound counts 
provide independently predictive data over and above the 
Leiden score. 
 An important aim of this study was to identify joint regions 
with the greatest potential for use in predictive models. We 
systematically examined individual ultrasound variables in 
combination with the Leiden rule by logistic regression ( table 
4 ). This analysis precludes examination of variables with 100% 
sensitivity or speciﬁ city, which were therefore omitted. No 
proximal interphalangeal joint ultrasound variables functioned 
as independent predictors. However, highly sensitive variables 
such as greyscale and power Doppler involvement of metacar-
pophalangeal joints and wrists contributed additional predictive 
information. Moreover, highly speciﬁ c ultrasound variables such 
as high grade greyscale wrist symmetry, high ultrasound counts 
of metacarpophalangeal joints and power Doppler involvement 
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improved the AUC, and has the advantage of reducing scanning 
time. This ﬁ nding requires validation in larger studies. 
 The increased sensitivity of ultrasound for erosions was 
greater than that in the ESPOIR cohort  31  and of a similar order 
Doppler indices to 12 joints in the manner of Naredo  et al  24  had 
the effect of increasing the AUC, suggesting that joints effective 
for monitoring disease activity also have good speciﬁ city as pre-
dictors for RA. Removing the knee joint from this index further 
 Table 3  Sensitivity and specifi city of clinical and ultrasound variables for the prediction of RA 
  Sensitivity  Specifi city  Positive LR  Negative LR  PPV  NPV  AUC 
MCP joints
 MCP clinical involvement 97 69 3 0.05 76 95 0.828
 MCP clinical symmetry 65.5 97 19 0.36 95 74 0.810
 MCP GS ≥1 involvement 100 38 2 0 62 100 0.690
 MCP GS ≥1 symmetry 93 76 4 0.09 79 92 0.845
 MCP GS ≥2 involvement 90 48 2 0.21 63 82 0.690
 MCP GS ≥2 symmetry 86 79 4 0.17 81 85 0.828
 MCP GS count ≥8 45 100  0.55 100 64 0.724
 MCP PD ≥1 involvement 97 55 2 0.06 68 94 0.759
 MCP PD ≥1 symmetry 83 79 4 0.22 80 82 0.810
 MCP PD ≥2 involvement 90 66 3 0.16 72 86 0.776
 MCP PD ≥2 symmetry 83 83 5 0.21 83 83 0.828
PIP joints
 PIP clinical involvement 62 76 3 0.50 72 67 0.690
 PIP clinical symmetry 41 93 6 0.63 86 61 0.672
 PIP GS ≥1 involvement 79 62 2 0.33 68 75 0.707
 PIP GS ≥1 symmetry 48 79 2 0.65 70 61 0.638
 PIP GS ≥2 involvement 79 66 2 0.32 70 76 0.724
 PIP GS ≥2 symmetry 48 90 5 0.58 82 63 0.690
 PIP PD ≥1 involvement 76 69 2 0.35 71 74 0.724
 PIP PD ≥1 symmetry 45 90 4 0.62 81 62 0.672
 PIP PD ≥2 involvement 66 76 3 0.46 73 69 0.707
 PIP PD ≥2 symmetry 38 97 11 0.64 92 61 0.672
Wrist joints
 Wrist clinical involvement 69 86 5 0.36 83 74 0.776
 Wrist clinical symmetry 48 93 7 0.56 88 64 0.707
 Wrist GS ≥1 involvement 97 41 2 0.08 62 92 0.690
 Wrist GS ≥1 symmetry 86 62 2 0.22 69 82 0.741
 Wrist GS ≥2 involvement 79 69 3 0.30 72 77 0.741
 Wrist GS ≥2 symmetry 52 93 7 0.52 88 66 0.724
 Wrist PD ≥1 involvement 93 48 2 0.14 64 88 0.707
 Wrist PD ≥1 symmetry 83 66 2 0.26 71 79 0.741
 Wrist PD ≥2 involvement 90 48 2 0.21 63 82 0.690
 Wrist PD ≥2 symmetry 69 72 2 0.43 71 70 0.707
MTP joints
 MTP clinical involvement 17 100  0.83 100 55 0.586
 MTP clinical symmetry 10 100  0.90 100 53 0.552
 MTP GS ≥1 involvement 69 55 2 0.56 61 64 0.621
 MTP GS ≥1 symmetry 55 79 3 0.56 73 64 0.672
 MTP GS ≥2 involvement 59 72 2 0.57 68 64 0.655
 MTP GS ≥2 symmetry 41 83 2 0.71 71 56 0.621
 MTP PD ≥1 involvement 52 90 5 0.54 83 65 0.707
 MTP PD ≥1 symmetry 35 100  0.66 100 60 0.672
 MTP PD ≥2 involvement 38 100  0.62 100 62 0.690
 MTP PD ≥2 symmetry 24 100  0.76 100 57 0.621
Other variables
 Leiden score ≥8 62 93 9 0.41 90 71 0.776
 1987 ACR criteria (4/7 clinical) 79 90 8 0.23 89 81 0.845
 ACR criteria 4/7 GS 93 65.5 3 0.10 73 91 0.793
 ACR criteria 4/7 PD 86 76 4 0.18 78 85 0.810
 X-ray hand/foot erosion 3.5 100  0.97 100 45 0.517
 US hand/foot erosion 38 93 5.5 0.67 85 60 0.655
 ACPA positive 48 100  0.52 100 66 0.741
  ACPA positive or MTP PD 
≥2 Involvement or MCP GS count ≥8
76 100  0.24 100 81 0.879
 PD10 index ≥10 79 93 11.5 0.22 92 82 0.862
 ACPA, anti-cyclic citrullinated peptide antibody; ACR, American College of Rheumatology; AUC, area under the receiver operating 
characteristic curve; GS, ultrasound greyscale; LR, likelihood ratio; metacarpophalangeal joint (MCP) GS ≥1 involvement, MCP joint 
involvement with an ultrasound greyscale grade of at least 1; MCP joint GS count ≥8, at least eight MCP joints with GS involvement 
of grade ≥1; NPV, negative predictive value; PD, ultrasound power Doppler; PD10 index, summed power Doppler grades of MCP 
2–3 joints, wrists and metatarsophalangeal (MTP) 2–3 joints; PIP, proximal interphalangeal joint; PPV, positive predictive value; RA, 
rheumatoid arthritis; US, ultrasound. 
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for erosions in our very early cohort detected only one out of 
29 RA patients This test is therefore not of use in the very early 
window of disease. 
 This study has some shortcomings that we have sought to 
minimise. The low proportion of female RA patients compared 
with a normal population may be a chance ﬁ nding within a 
small group. Any subtle gender-related differences in RA 
 severity  34  are unlikely to impact on the results of this study. In 
addition, two patients with persistent unclassiﬁ ed disease that 
could potentially have developed into RA were treated with 
disease-modifying antirheumatic drugs. Our ﬁ ndings should be 
viewed with this in mind, as to omit treatment would have 
been unethical. We have harmonised any grading used with 
published schemes so as to maximise the applicability of our 
ﬁ ndings, and have taken precautions to eliminate sources of 
bias, for instance by using temperature controlled facilities to 
minimise power Doppler variability. The main limitation relates 
to the small size of this initial cohort. The sample size required 
to produce diagnostic algorithms using ultrasound measures of 
synovitis with unbiased statistical methods would be consider-
able, and data from the present study should inform the design 
of future studies. We have demonstrated that scanning not only 
the metacarpophalangeal joints, but also the wrist and metatar-
sophalangeal joints with greyscale and power Doppler, is likely 
to provide the optimum ultrasound data to improve on clinical 
predictive models for RA, and have demonstrated the unique 
predictive speciﬁ city of metatarsophalangeal joint sonography 
and power Doppler measurement for RA. These are vital ﬁ rst 
steps in the development of validated predictive algorithms 
that include ultrasound variables. 
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Consortium. 
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of magnitude to that seen by Wakeﬁ eld  et al .  14  Although not the 
strongest predictive variable in our analysis, ultrasound erosions 
had a high speciﬁ city for RA of 93%, greater than that of radio-
graphic erosions in the Leiden undifferentiated cohort (77%).  32  
Sonographers should therefore remain assured that scanning for 
ultrasound erosions is of signiﬁ cant value in conﬁ rming clinically 
suspected disease. Although a recent study presented ultrasound 
examination of the ﬁ fth metatarsophalangeal joint as a useful 
test to conﬁ rm diagnosis in RA with a mean disease duration 
of 15 months,  33  examining the ﬁ fth metatarsophalangeal joint 
 Figure 2  Area under the receiver operating characteristic (ROC) curve 
for rheumatoid arthritis (RA)  as an outcome using a 10-joint power 
Doppler index (summed power Doppler grades of metacarpophalangeal 
joints 2–3, wrists and metatarsophalangeal 2–3 joints) combined with 
the Leiden score (grey), versus the Leiden score alone (black). The 
10-joint power Doppler index was entered as an explanatory variable 
in logistic regression analysis with an outcome of rheumatoid arthritis 
RA as the dependent variable and the Leiden score as the independent 
variable. The area under the ROC curve was compared using a non-
parametric algorithm developed by DeLong  et al.  25  
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 Table 4  Impact of ultrasound on prediction of RA: multivariate 
analyses 
 Variables  p Value   AUC 
Leiden score <0.001 0.905
Global US variables
 Leiden 0.005
0.028 } 0.939 GS index
 Leiden 0.003
0.078 } 0.924  GS count
 Leiden 0.007
0.016 } 0.951  PD index
 Leiden 0.006
0.025 } 0.942  PD count
 Leiden 0.005
0.010 } 0.952  PD12 index (after Naredo  et al )24 
 Leiden 0.007
0.006 } 0.962  PD10 index
US joint counts by region
 Leiden 0.003
0.034 } 0.939  PD hand count
 Leiden 0.002
0.023 } 0.936  PD MCP count
 Leiden <0.001
0.148 } 0.926  PD PIP count
 Leiden <0.001
0.080 } 0.929  PD MTP count
 Leiden 0.005
0.030 } 0.939  GS hand count
 Leiden 0.004
0.016 } 0.943  GS MCP count
 Leiden <0.001
0.175 } 0.920  GS PIP count
 Leiden <0.001
0.547 } 0.905  GS MTP count
MCP joints
 Leiden 0.007
0.035 } 0.930  MCP GS ≥1 symmetry
 Leiden 0.002
0.049 } 0.923 MCP GS ≥2 symmetry
 Leiden 0.001
0.034 } 0.932 MCP PD ≥2 involvement
 Leiden 0.002
0.015 } 0.937 MCP PD ≥2 symmetry
Wrist joints
 Leiden 0.001
0.013 } 0.936 Wrist GS ≥2 involvement
 Leiden <0.001
0.015 } 0.939  Wrist GS ≥2 symmetry
MTP joints
 Leiden 0.001
0.026 } 0.933 MTP PD ≥1 involvement
 AUC, area under the receiver operating characteristic curve; GS, ultrasound greyscale; 
GS count, sum of greyscale data when converted to a binary variable; GS index, sum 
of greyscale grades for all scanned joints; metacarpophalangeal (MCP) joint GS ≥1 
involvement, MCP involvement with an ultrasound GS grade of at least 1; PD, ultrasound 
power Doppler; PD10 index, summed power Doppler grades of MCP joint 2–3 joints, wrists 
and metatarsophalangeal (MTP) 2–3 joints; RA, rheumatoid arthritis; US, ultrasound. 
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 ABSTRACT 
 Objective  Early identifi cation of patients with 
rheumatoid arthritis (RA) is essential to allow the prompt 
institution of therapy. The 2010 American College 
of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) classifi cation criteria, which replace 
the 1987 classifi cation criteria, have been developed 
to facilitate such identifi cation in patients with newly 
presenting infl ammatory arthritis. This study therefore 
assesses the performance of these new criteria in 
patients with early synovitis. 
 Methods  Data were analysed from patients with 
synovitis seen within 3 months of the onset of 
infl ammatory arthritis. Patients were followed for 
18 months to determine outcomes, and data on the 
cumulative fulfi lment of 2010 and 1987 criteria and 
therapy were recorded. 
 Results  265 patients were included in the study. 
60 had alternative diagnoses at baseline. Of the remaining 
205 patients, 20% fulfi lled both 1987 and 2010 criteria, 
3% fulfi lled only 1987 criteria and 22% fulfi lled only 2010 
criteria at baseline. The 2010 criteria, when applied at 
baseline, detected more patients who eventually required 
disease-modifying antirheumatic drugs (DMARD) (65 
(62%) vs 40 (38%); p<0.001), especially methotrexate 
(50 (68%) vs 31 (42%); p<0.01), within the fi rst 
18 months. However, more patients whose disease 
eventually resolved without ever requiring DMARD were 
classifi ed at baseline as RA according to the 2010 criteria 
than with the 1987 criteria (16 (8%) vs 5 (2%); p=0.01). 
 Conclusion  The 2010 ACR/EULAR criteria allow more 
rapid identifi cation of patients requiring methotrexate 
compared with the 1987 ACR criteria when applied at 
baseline. However, overdiagnosis is an important issue 
to consider if these criteria are to be used in very early 
disease. 
 Rheumatoid arthritis (RA) is a chronic destructive 
disease. However, increasing evidence suggests 
that early treatment can modulate its natural his-
tory, signiﬁ cantly slowing the rate of disease pro-
gression and increasing the likelihood of achieving 
remission.  1–5  The prompt diagnosis and treatment 
of RA is therefore crucial.  6  Traditionally, classiﬁ -
cation of RA has been based on fulﬁ lment of the 
1987 American College of Rheumatology (ACR) 
criteria.  7  These criteria were developed in patients 
with established RA of several years’ duration and 
it has been shown that they have poor sensitiv-
ity for the diagnosis of RA in patients with early 
synovitis. The 2010 ACR/European League Against 
Rheumatism (EULAR) criteria were therefore 
developed with the purpose of facilitating the early 
recognition of RA.  8  
 An important aim of the new classiﬁ cation crite-
ria was to identify individuals at high risk of per-
sistent and destructive disease, who might beneﬁ t 
from disease-modifying therapy. Consequently, 
an important phase in the development of the 
criteria was the identiﬁ cation of factors, and their 
relative weights, which were associated with a 
clinical decision to start methotrexate within the 
ﬁ rst 12 months. This was carried out through anal-
ysis of data from 3115 patients, with no evidence 
of alternative diagnoses, from nine early arthritis 
cohorts.  9  This was followed by the evaluation of 
case scenarios to determine the relative contribu-
tion of clinical and laboratory factors deemed to be 
important in inﬂ uencing the probability of devel-
oping RA.  10  Finally, the ﬁ ndings of these ﬁ rst two 
phases were integrated and the optimal cut-off for 
deﬁ nite RA was established.  8  This development 
process was therefore reliant upon the ability of 
experts to identify high-risk patients correctly and 
start treatment with methotrexate. Nevertheless 
the approach avoids the inherent circularity of 
developing new criteria from existing criteria. 
 The purpose of this study was to compare the 
performance of the 1987 and 2010 criteria in a very 
early synovitis cohort, comprising patients who 
presented within 3 months of the onset of inﬂ am-
matory arthritis symptoms and who were system-
atically followed up to determine outcomes. This is 
an ideal population to study in this context because 
it includes patients who develop persistent RA, but 
were seen within a very short time frame after dis-
ease onset—the very situation for which the new 
criteria have been constructed. Importantly, our 
cohort was not used to develop the 2010 criteria, so 
is free from the inherent bias this would generate. 
 Validating criteria for RA is problematical given 
the absence of a gold standard pathology-based 
diagnostic test against which clinical criteria can be 
compared. For this reason, we initially sought to 
compare the 2010 criteria against the 1987 criteria. 
This comparison is crucial for several reasons. First, 
there is an extensive epidemiological and clinical 
trials literature that has been developed utilising the 
1987 classiﬁ cation system. Ascertaining the degree 
of overlap between the criteria will help establish 
the extent to which previous research can be gener-
alised to patients classiﬁ ed under the new system. 
Second, for the 2010 criteria to be useful, they must 
be capable of identifying RA more rapidly than the 
1987 criteria. It is important to note that a positive 
 ▶ Supplementary fi gure 1 is 
published online only. To view 
this fi le please visit the journal 
online (http://ard.bmj.com). 
1 Department of Rheumatology, 
Sandwell and West Birmingham 
Hospitals NHS Trust, 
Birmingham, UK 
 2 Rheumatology Research 
Group, School of Immunity and 
Infection, College of Medical 
and Dental Sciences, The 
University of Birmingham, 
Birmingham, UK 
 Correspondence to 
Dr Karim Raza, Rheumatology 
Research Group, School of 
Immunity and Infection, College 
of Medical and Dental Sciences, 
The University of Birmingham, 
Birmingham B15 2TT, UK; 
 k.raza@bham.ac.uk 
 Performance of the 2010 ACR/EULAR criteria for 
rheumatoid arthritis: comparison with 1987 ACR 
criteria in a very early synovitis cohort 
 Mohammed Z  Cader, 1  Andrew  Filer, 1, 2  Jonathan  Hazlehurst, 1  Paola  de Pablo, 1, 2 
 Christopher D  Buckley, 1, 2  Karim  Raza 1, 2 
 ARD Online First, published on February 1, 2011 as 10.1136/ard.2010.143560
Copyright Article a thor (or their employer) 20 1. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
 group.bmj.com on March 25, 2011 - Published by ard.bmj.comDownloaded from 
Extended report
Cader MZ, Filer A, Hazlehurst J, et al. Ann Rheum Dis (2011). doi:10.1136/ard.2010.1435602 of 7
using a χ 2 test. The time to reach a diagnosis of RA (of patients 
diagnosed by both criteria) was compared using a Wilcoxon 
signed rank test. The latter data were presented graphically as 
a cumulative percentage of patients reaching an RA diagnosis in 
survival plot format. p Values less than 0.05 were considered sig-
niﬁ cant. Patients gave their informed consent before inclusion in 
the programme. The study received ethical approval from the 
local research ethics committee. 
 RESULTS 
 Cohort characteristics 
 Two hundred and sixty-ﬁ ve patients were included in the 
study. One hundred and thirty-seven (52%) were women and 
the median age was 49 years (IQR 35–64 years). Patients were 
seen after a median symptom duration of 42 days (IQR 25–61); 
all were seen within 3 months. Patients had a median tender 
28-joint count of 2 (IQR 1–6), tender 68-joint count of 3 (IQR 
1–7), swollen 28-joint count of 2 (IQR 1–5) and swollen 66-joint 
count of 3 (IQR 1–5). Median ESR was 27 mm/h (IQR 11–53 
mm/h) and median CRP was 21 mg/l (IQR 6–51 mg/l). 
 Classifi cation of patients using 1987 ACR and 2010 ACR/EULAR 
criteria 
 As shown in  ﬁ gure 1 , 60 patients had alternative diagnoses at 
baseline (reactive arthritis n=22, psoriatic arthritis n=12, gout 
n=10, pseudogout n=5, inﬂ ammatory bowel disease-related 
arthritis n=4, SLE n=2, sarcoidosis n=2, dermatomyositis n=1, 
Behcet’s disease n=1 and septic arthritis n=1). They were there-
fore excluded from RA classiﬁ cation criteria. Of the remaining 
205 patients, 41 (20%) fulﬁ lled both the 1987 and 2010 criteria 
at baseline assessment. There were also, however, patients only 
classiﬁ ed as RA using one or other criteria. At baseline, six of 
205 (3%) patients were identiﬁ ed as RA only by the 1987 ACR 
criteria, but a greater number of patients (46 of 205 (22%)) were 
only classiﬁ ed using the 2010 criteria. 
 Fourteen patients in the cohort developed new symptoms, 
signs or other features during follow-up that led to an alterna-
tive diagnosis and therefore became excluded from the classiﬁ -
cation criteria during follow-up, although they were included 
in all baseline analyses. Of the remaining 191 patients, at some 
point during the 18-month follow-up, 76 (40%) patients fulﬁ lled 
both the 1987 and 2010 criteria (not necessarily simultaneously). 
Sixteen (8%) patients were classiﬁ ed under only the 2010 criteria 
and 20 (11%) patients under only the 1987 criteria. As discussed 
above, when calculating the 2010 criteria score at follow-up, 
the maximum score from each of the four domains was car-
ried forward. However, it should be noted that this ‘cumulative’ 
approach only resulted in one additional RA classiﬁ cation com-
pared with a ‘non-cumulative’ analysis. 
 A comparison of group characteristics of patients classifi ed 
using 1987 ACR and 2010 ACR/EULAR criteria 
 A direct comparison was made between patients classiﬁ ed as hav-
ing RA using the 1987 and 2010 criteria ( table 1 ). Among the 205 
eligible patients in the cohort, the 2010 criteria identify far more 
patients at baseline compared with the 1987 criteria (87 (42%) 
vs 47 (23%), respectively; p<0.0001). Among patients requir-
ing DMARD (n=105), these criteria also detect more patients at 
baseline for whom DMARD were prescribed by 18 months (65 
(62%) vs 40 (38%), respectively; p<0.001), especially methotrex-
ate (50 (68%) vs 31 (42%) out of 73 patients requiring metho-
trexate; p<0.01). Data regarding the sensitivity and speciﬁ city, 
classiﬁ cation using the new criteria does not necessarily imply 
a clinical diagnosis of RA. However, in developing the 2010 cri-
teria, the identiﬁ cation of patients at risk of persistent disease 
requiring disease-modifying antirheumatic drug (DMARD) 
therapy, in particular methotrexate therapy, was a key goal. We 
thus analysed whether the 2010 classiﬁ cation criteria were bet-
ter able to identify patients who eventually required DMARD 
treatment. 
 PATIENTS AND METHODS 
 Patients were recruited from the rapid access early inﬂ ammatory 
arthritis clinic at Sandwell and West Birmingham Hospitals NHS 
Trust. Patients referred to the clinic by their general practitioners 
were seen within 2 weeks. Participants were included in the cur-
rent study if: (1) they had clinically apparent synovial swelling 
at one or more joints at their initial assessment; (2) they were 
seen within 3 months of the onset of any symptom attributed 
by the assessing rheumatologist to inﬂ ammatory joint disease 
(pain, stiffness and/or swelling); and (3) they had been followed 
up for at least 18 months. 
 Data were collected on patient demographic variables, fulﬁ l-
ment of the 1987 ACR criteria (using the list format) and symp-
tom duration. Tender (n=68) and swollen (n=66) joint counts 
were performed. C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), rheumatoid factor (RF) and anti-cyclic cit-
rullinated peptide (CCP) antibody type 2 status were measured. 
These were used to calculate scores under the new 2010 EULAR/
ACR criteria, on the basis of joint involvement, serology, acute 
phase reactants and symptom duration.  8  Radiographs were 
performed of the hands and feet. Systematic clinical follow-up, 
including metrology assessment, was carried out at 1, 2, 3, 6, 
12 and 18 months and CRP and ESR were measured at these 
time points. Data on therapy used during follow-up were also 
collected. Autoantibody status was measured at baseline only. 
Patients were classiﬁ ed as having self-limiting disease if at ﬁ nal 
follow-up (at 18 months) they had no clinical evidence of syn-
ovial swelling, were not taking DMARD and had not received 
glucocorticoid treatment in any form in the previous 3 months. 
 Several important points should be highlighted regarding our 
application of the 1987 and 2010 criteria. First, the 2010 criteria 
stipulate that patients with a likely alternative diagnosis such as 
systemic lupus erythematosus (SLE) are excluded from analy-
sis. Moreover, this process is under continuous review such that 
during follow-up an increasing number of patients are excluded. 
Indeed, a patient initially meeting the 2010 classiﬁ cation criteria 
for RA at baseline will have their RA status reversed if it later 
becomes apparent that their symptoms are due to another con-
dition. Such an exclusion process is not explicitly mentioned in 
the 1987 criteria, but is widely adopted in practice. We have 
therefore applied the same approach for both the 2010 and 1987 
criteria. The second issue relates to the cumulative fulﬁ lment 
of criteria. This issue is not explicitly addressed within either 
the 1987 or 2010 criteria, although cumulative fulﬁ lment for the 
1987 criteria is widely adopted in practice and we have allowed 
for cumulative fulﬁ lment in both criteria sets. In the context of 
the 2010 criteria, the maximum score within each of the four 
domains is carried forwards during follow-up. 
 Data analysis was performed using the statistical package for 
social sciences, version 17.0. Patient groups classiﬁ ed using each 
system were compared in terms of demographic variables, serol-
ogy, joint involvement, treatment and outcome after 18 months 
of follow-up. Differences in means were assessed using a two-
tailed, unpaired Student’s t test. Proportions were compared 
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identiﬁ cation of patients requiring DMARD and methotrexate 
based on the two sets of criteria when applied at baseline are 
also shown (see supplementary  ﬁ gure 1 , available online only). 
The percentage of patients eventually requiring DMARD among 
positive and negative predictive values and positive and nega-
tive likelihood ratios of the two sets of criteria when applied at 
baseline for subsequent DMARD use and methotrexate use are 
shown ( table 2 ). Receiver operating characteristic curves for the 
76 patients
fulfil both 1987 
& 2010 criteria
46 patients
fulfil only 2010 
criteria
20 patients
fulfil only 1987 
criteria
16 patients
fulfil only 2010 
criteria
79 patients
fulfil neither 
criteria
Baseline 
assessment
265 patients
included in 
study
41 patients
fulfil both 1987 
& 2010 criteria
6 patients
fulfil only 1987 
criteria
112 patients
fulfil neither 
criteria
60 patients
excluded due to 
alternative diagnosis 
at baseline
205 patients
14 patients
further 
excluded
Follow-up
14 28 38 1 5 79
2
9
15
271 patients
recruited
6 patients
excluded due to 
incomplete follow-up
 Figure 1  Flowchart of patients in the early arthritis cohort to compare classifi cation of rheumatoid 
arthritis (RA) using the 1987 and 2010 criteria. 
 Table 1  Comparison of patients classifi ed as having RA at baseline and after 18-month follow-up according 
to the 1987 and 2010 criteria 
 
 At baseline  After 18-month follow-up 
 1987 Criteria 
(n=47) 
 2010 Criteria 
(n=87) 
 1987 Criteria 
(n=96) 
 2010 Criteria 
(n=92) 
Age, years; median (IQR) 60 (50–69) 58 (46–68) 60 (47–70) 59 (45–68)
Female; n (%) 24 (51) 53 (61) 53 (55) 56 (61)
RF positive; n (%) 26 (55) 49 (56) 44 (46) 49 (53)
Anti-CCP positive; n (%) 28 (60) 51 (59) 48 (50) 51 (55)
Eventual outcome (after follow-up); n (%)
  Defi nitive non-RA diagnosis 3 (6) 7 (8) – –
 Self-limiting illness 5 (11) 16 (18) 12 (13) 19 (21)
DMARD use within fi rst 18 months; n (%)
 Methotrexate 31 (66) 50 (58) 60 (63) 51 (55)
 Other 9 (19) 15 (17) 18 (19) 16 (17)
 Anti-CCP, anticyclic citrullinated peptide antibody; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; 
RF, rheumatoid factor. 
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even mixture of seropositive and seronegative patients. Half 
of these patients were started on methotrexate in the ﬁ rst 
18 months. However, 12 (26%) had a self-limiting illness. By 
contrast, it is interesting to note that only four (10%) patients 
fulﬁ lling both criteria at baseline had a self-limiting illness. 
Furthermore, 27 (66%) of the patients fulﬁ lling both criteria at 
baseline required methotrexate. 
 A comparison of 1987 ACR and 2010 ACR/EULAR classifi cation 
criteria scores 
 By the end of the 18-month follow-up, there remained several 
patients who at some point fulﬁ lled only one of either the 1987 
or 2010 criteria ( table 3 ). All 20 patients classiﬁ ed as RA under 
only the 1987 criteria were RF and anti-CCP negative, but 12 
(60%) of these were started on methotrexate and the majority 
(80%) had persistent disease. The 16 patients classiﬁ ed only 
under the 2010 criteria were again predominantly seronega-
tive. However, 11 (69%) had self-limiting illness and only three 
(19%) were started on methotrexate. Most autoantibody posi-
tive patients were identiﬁ ed as RA by both criteria. The group 
of patients classiﬁ ed under both criteria again contained smaller 
proportions of self-limiting illness and higher numbers of those 
requiring methotrexate. 
 To characterise further the patients classiﬁ ed as RA at base-
line according to the 2010 criteria, a histogram of the 1987 ACR 
criteria scores was constructed for these patients ( ﬁ gure 2A ). All 
patients with a score of 4 or more would have met the 1987 cri-
teria for RA. As illustrated, many patients with low 1987 scores 
were seen before 6 weeks. Therefore, by deﬁ nition, they could 
not fulﬁ l any 1987 clinical criteria at baseline. This is an impor-
tant reason why the 1987 criteria classify so few RA patients 
at initial presentation compared with the 2010 criteria. Ignoring 
those identiﬁ ed as RA at baseline is similar for the 2010 crite-
ria and the 1987 criteria (65 (74%) vs 40 (85%), respectively; 
p=0.16). Importantly, more patients whose disease eventually 
resolved spontaneously were classiﬁ ed with RA according to the 
2010 criteria than with the 1987 criteria (16 of 205 patients (8%) 
vs ﬁ ve of 205 patients (2%); p=0.01). This includes over a quar-
ter of the patients classiﬁ ed as RA solely by the 2010 criteria at 
baseline ( table 3 ). The proportion of patients fulﬁ lling each set of 
criteria that were autoantibody positive was comparable. 
 After 18-month follow-up, the numbers of patients classiﬁ ed 
using the respective criteria were similar (96 patients with the 
1987 criteria vs 92 patients with the 2010 criteria). These patients 
were also similar in age and gender. By this stage, fewer patients 
requiring DMARD were identiﬁ ed according to the 2010 crite-
ria compared with the 1987 criteria, although the differences 
were not statistically signiﬁ cant. Data regarding the sensitiv-
ity and speciﬁ city, positive and negative predictive values and 
positive and negative likelihood ratios of the two sets of criteria, 
when applied during follow-up, for DMARD and methotrexate 
use are shown ( table 2 ). There were seven more patients clas-
siﬁ ed as RA based on the 2010 criteria who had a self-limiting 
illness (21% vs 13%). After follow-up, there were no patients 
with a deﬁ nitive diagnosis other than RA because these patients 
had been excluded. The diagnoses of those patients with RA 
according to the 1987 and 2010 criteria at baseline that were 
no longer considered to have RA at follow-up were as follows: 
2010 criteria: SLE (n=2), psoriatic arthritis (n=2), inﬂ ammatory 
bowel disease-related arthritis (n=1), Sjogren’s syndrome (n=1), 
gout (n=1); 1987 criteria: SLE (n=1), Sjogren’s syndrome (n=1), 
psoriatic arthritis (n=1). 
 Next, patients were divided into groups depending upon 
whether they fulﬁ lled both, one or neither of the classiﬁ cation 
criteria at baseline ( table 3 ). The ‘2010 only’ group contains an 
 Table 2  Sensitivity and specifi city, positive and negative predictive values and positive and negative likelihood ratios of the 1987 ACR and 2010 
ACR/EULAR classifi cation criteria when applied at baseline and during follow-up for subsequent DMARD use and methotrexate use 
 
 Analyses for criteria when applied at baseline  Analyses for criteria when applied during follow-up 
 DMARD use  Methotrexate use  DMARD use  Methotrexate use 
 2010 Criteria  1987 Criteria  2010 Criteria  1987 Criteria  2010 Criteria  1987 Criteria  2010 Criteria  1987 Criteria 
Sensitivity (%) 62 38 68 42 68 80 74 87
Specifi city (%) 78 93 72 88 73 81 66 70
Positive predictive value (%) 75 85 57 66 73 81 55 63
Negative predictive value (%) 66 59 81 73 69 79 82 91
Positive likelihood ratio 2.81 5.44 2.44 3.50 2.17 3.87 3.14 6.94
Negative likelihood ratio 0.49 0.67 0.44 0.65 0.46 0.26 0.25 0.11
 ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism. 
 Table 3  Characteristics of patient groups according to fulfi lment of RA classifi cation criteria at baseline and after follow-up 
 
 Characteristics of patient groups according to fulfi lment of 
classifi cation criteria at baseline 
 Characteristics of patient groups according to fulfi lment of 
classifi cation criteria after follow-up 
 1987 Criteria 
only; n=6 
 2010 Criteria 
only; n=46 
 Both criteria; 
n=41 
 Neither criteria; 
n=112 
 1987 Criteria 
only; n=20 
 2010 Criteria 
only; n=16 
 Both criteria; 
n=76 
 Neither 
criteria; n=79 
Age, years; median (IQR) 65 (58–70) 57 (45–67) 60 (47–70) 45 (32–63) 62 (57–71) 49 (43–55) 60 (45–70) 40 (29–55)
Female; n (%) 4 (67) 33 (72) 20 (49) 61 (54) 10 (50) 13 (81) 43 (57) 43 (54)
RF positive; n (%) 0 (0) 23 (50) 26 (63) 3 (3) 0 (0) 5 (31) 44 (58) 1 (1)
Anti-CCP positive; n (%) 0 (0) 23 (50) 28 (68) 1 (1) 0 (0) 3 (19) 48 (63) 0 (0)
Eventual outcome (after follow-up); n (%):
 Defi nitive non-RA diagnosis 0 (0) 4 (9) 3 (7) 7 (6) – – – –
 Self-limiting illness 1 (17) 12 (26) 4 (10) 61 (54) 4 (20) 11 (69) 8 (11) 53 (67)
DMARD use within fi rst 18 months; n (%)
 Methotrexate 4 (67) 23 (50) 27 (66) 19 (17) 12 (60) 3 (19) 48 (63) 6 (8)
 Other 1 (17) 7 (15) 8 (20) 16 (14) 2 (10) 0 (0) 16 (21) 11 (14)
 Anti-CCP, anticyclic citrullinated peptide antibody; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor. 
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respectively, p<0.01;  ﬁ gure 3B ). It should be noted that some 
of these patients (although not excluded at baseline) did reach 
an alternative diagnosis, such as psoriatic arthritis, during fol-
low-up. The results remain signiﬁ cant even if these patients 
are excluded. 
 Infl uence of symptom duration at presentation on 
fulfi lment of classifi cation criteria and DMARD/methotrexate 
necessity 
 Patients with a baseline classiﬁ cation of RA using the 2010 cri-
teria had signiﬁ cantly longer median symptom duration at pre-
sentation than non-RA patients (45 days (IQR 35–67) vs 42 days 
(IQR 24–62); p=0.02). This is unsurprising given that the new 
criteria themselves include a score for duration of disease. 
However, even after stratifying for patients with a duration less 
than 6 weeks (ie, duration score of 0), patients with RA still had 
a signiﬁ cantly longer median symptom duration than those with 
non-RA disease (31 days (IQR 27–35) vs 23 days (IQR 14–30); 
p<0.01). 
 Further analysis was performed selecting only patients classi-
ﬁ ed with RA using the 2010 criteria at baseline. Patients requiring 
DMARD had a signiﬁ cantly longer median symptom duration 
at presentation compared with patients not needing treatment 
(56 days (IQR 35–75) vs 42 days (IQR (34–56); p=0.03). 
the 6-week symptom duration rule would result in 22 additional 
patients meeting the 1987 criteria at baseline (giving a total of 
69 patients classiﬁ ed) and would account for 17 of the 46 (37%) 
patients only classiﬁ ed according to the 2010 criteria. 
 A histogram was also constructed to show the 2010 criteria 
scores of the patients diagnosed according to the 1987 criteria 
at baseline ( ﬁ gure 2B ). This shows that there are seven patients 
with a score less than that required for a classiﬁ cation of RA by 
the 2010 criteria and that this is only by 1–2 points. One of these 
patients had radiological evidence of erosions and thus prima 
facie evidence of RA under the 2010 criteria. 
 A comparison of time to classifi cation and DMARD/
methotrexate necessity 
 To assess whether the 2010 criteria offer a more rapid identiﬁ -
cation of RA in the early stages of disease, the time to meeting 
criteria for RA under both systems was assessed. This showed 
that patients are identiﬁ ed signiﬁ cantly earlier using the 2010 
criteria (p<0.01;  ﬁ gure 3A ). 
 Next we compared the proportions of patients requiring 
methotrexate identiﬁ ed by the different criteria at baseline. 
Of the total of 73 patients started on methotrexate, a signiﬁ -
cantly higher proportion of patients fulﬁ lled the 2010 criteria 
than the 1987 criteria at baseline (50 (69%) and 31 (43%), 
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 Figure 2  (A) Total number of 1987 criteria present at baseline in patients classifi ed as rheumatoid arthritis (RA) according to the 2010 American 
College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria. (B) Baseline 2010 criteria scores in patients classifi ed as RA 
according to the 1987 criteria. 
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duration are classiﬁ ed as RA at baseline according to the 2010 cri-
teria, compared with the 1987 criteria. Some of this is explained 
by the 6-week symptom duration rule contained within the 
1987 criteria, which prevents classiﬁ cation of patients as RA if 
seen within 6 weeks of the onset of their symptoms. However, 
29 of the 46 (63%) patients only classiﬁ ed according to the 2010 
criteria would not have been classiﬁ ed according to the 1987 
criteria at baseline, even if the 6-week rule was disregarded. Do 
these additional patients, diagnosed only according to the 2010 
criteria, really have RA? Importantly, 65% of these patients 
were positive for RF or anti-CCP antibody. Furthermore, 65% 
of these patients required DMARD therapy during follow-up. 
However, equally importantly, 12 (26%) of these patients 
had a disease that resolved without DMARD therapy over an 
18-month follow-up period. Basing treatment decisions upon 
fulﬁ lment of the 2010 criteria would thus lead to more rapid 
treatment in some patients for whom this is likely to be ben-
eﬁ cial, at the cost of the overtreatment of signiﬁ cant numbers 
of patients. During the validation of the 2010 criteria three 
cohorts were studied from Leiden, Leeds and Toronto. Among 
the cohort participants who received methotrexate within the 
ﬁ rst year from symptom onset, the proportions with a score of 
6/10 or greater ranged between 87% and 97%.  7  This contrasts 
with only 50 of 73 (69%) in our cohort who received metho-
trexate within the ﬁ rst 18 months. Therefore, almost one third 
of patients who were deemed to require methotrexate during 
follow-up (and did not have an alternative rheumatological 
diagnosis at baseline) did not fulﬁ l the 2010 criteria for RA at 
baseline. 
 The 2010 criteria were developed speciﬁ cally to identify 
patients with RA at an early stage. It is, however, interesting to 
note that during follow-up there were 20 patients who fulﬁ lled 
the 1987 criteria for RA who were not diagnosed according to 
the 2010 criteria. Despite the fact that none of these patients 
were positive for RF or anti-CCP antibody, 70% of them were 
commenced on a DMARD. 
 Our cohort is unusual in that participants have very short 
symptom durations (mean approximately 1.5 months). Given 
the well-recognised observation that symptom duration is an 
important predictor of disease persistence,  13  this may partly 
explain why the 2010 criteria performed so well in the analysis 
and validation cohorts, and why such a large proportion (38%) 
of our cohort exhibited self-limiting disease without the require-
ment for DMARD. The mean symptom duration in the analysis 
and validation datasets used in development of the 2010 crite-
ria (4.9 months) was longer than in our cohort, and only two of 
the datasets used in the development of these new criteria (from 
Austria and Norway) had mean symptom durations of under 
3 months.  8  
 Our data suggest that the 2010 criteria will allow the more 
rapid identiﬁ cation of patients requiring methotrexate com-
pared with the 1987 criteria if applied at baseline, but highlight 
that over and underdiagnosis may become important issues if 
these criteria are used to direct treatment within the phase when 
treatment makes the greatest difference—the ﬁ rst 3 months after 
symptom onset. 
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 DISCUSSION 
 Many patients who eventually fulﬁ l the classiﬁ cation criteria for 
RA according to the 1987 ACR criteria present with an undif-
ferentiated arthritis. The need to identify those whose disease 
will progress to RA has prompted the development of predic-
tive algorithms that have been validated.  11    12  A recognition of 
the potential utility of criteria to identify early arthritis patients 
who will develop a persistent destructive disease unless treated 
appropriately has led to the development of the ACR/EULAR 
2010 criteria. 
 Data from our cohort show that signiﬁ cantly more patients 
presenting with an inﬂ ammatory arthritis of less than 3 months’ 
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 Figure 3  (A) Time to classifi cation of rheumatoid arthritis (RA) using 
the 1987 and 2010 RA criteria for all patients classifi ed as RA under 
both criteria. (B) Time to classifi cation of RA using the 1987 and 2010 
RA criteria for all patients with an eventual diagnosis of persistent 
unclassifi ed infl ammatory arthritis or RA, and started on methotrexate. 
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Performance of an Automated Computer-Based
Scoring Method to Assess Joint Space Narrowing in
Rheumatoid Arthritis
A Longitudinal Study
Axel Finckh,1 Paola de Pablo,2 Jeffrey N. Katz,2 Gesa Neumann,2 Ying Lu,3
Frederick Wolfe,4 Jeffrey Duryea2
Objective. To compare the diagnostic perfor-
mance of a computer-based method for measuring joint
space width with the Sharp joint space narrowing (JSN)
scoring method in patients with rheumatoid arthritis
(RA).
Methods. A random sample of patients with early
RA, for whom sequential hand radiographs and Sharp
scores were available, was selected from the National
Data Bank for Rheumatic Diseases. Hand joint space
width was measured using an automated, computer-
based method in random order and with blinding for
clinical information. We constructed a receiver operat-
ing characteristic curve and compared the diagnostic
performance of the computer-based and Sharp methods
based on the areas under the curve.
Results. One hundred twenty-nine patients with
early RA who underwent serial radiography were in-
cluded. Changes in the computer-based and Sharp
methods were highly correlated (r  0.75, P < 0.001).
The computer-based method was significantly more
discriminant than the Sharp JSN subscale. The area
under the curve of the computer-based method was 0.96
(95% confidence interval [95% CI] 0.94, 0.99) compared
with 0.93 (95% CI 0.89, 0.96) for the Sharp subscale
(P  0.024). At the most discriminant cutoff, specificity
of the computer-based method was 88.4% compared
with 81.4% for the Sharp subscale (P 0.11); sensitivity
was 87.6% for the computer-based method compared
with 82.2% for Sharp subscale (P  0.19). The signal-
to-noise ratio for the computer-based method was 83%
compared with 70% for the Sharp subscale (P  0.013).
Conclusion. The computer-based method for mea-
suring joint space width is more discriminant than the
semiquantitative Sharp JSN subscale.
Rheumatoid arthritis (RA) is a chronic inflam-
matory autoimmune disease that leads to progressive
joint destruction, functional disability, and extraarticular
complications. Structural joint damage correlates with
long-term functional decline in RA patients (1). Thus,
controlling progressive joint damage has become a key
treatment objective (2). Conventional radiography per-
mits measurement of structural joint damage, and films
can be masked or randomized for standardized damage
scoring. Radiographic measures of structural joint dam-
age are currently considered the gold standard of treat-
ment efficacy studies in RA (3), and are used extensively
in clinical trials as the primary outcome measure. Fur-
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Paper 10 
Patient Repositioning Reproducibility of Joint
Space Width Measurements on Hand Radiographs
GESA NEUMANN,1 PAOLA DEPABLO,1 AXEL FINCKH,2 LORI B. CHIBNIK,1 FRED WOLFE,3 AND
JEFFREY DURYEA1
Objective. Computer-based methods to measure radiographic joint space width (JSW) have the potential to improve the
longitudinal assessment of rheumatoid arthritis (RA). The purpose of this report was to measure the long-term patient
repositioning reproducibility of software-measured radiographic JSW.
Methods. Patients underwent baseline and followup hand radiography examinations with a followup time of <3 years.
To eliminate any JSW change due to real disease progression, the evaluation was performed on “unaffected” joints,
deﬁned as having JSW and erosion Sharp scores of 0 at both baseline and followup. The root mean square SD (RMSSD)
and coefﬁcient of variation (CV) were used as the reproducibility metrics.
Results. The RMSSD was 0.14 mm (CV 10.5%) for all joints, 0.18 mm (CV 10.9%) for the metacarpophalangeal (MCP)
joints, and 0.08 mm (CV 8.3%) for the proximal interphalangeal (PIP) joints. The distribution of JSW change was
asymmetric, suggesting that narrowing due to RA progression occurred for several joints. A second analysis was
performed, excluding joints where the loss of JSW was greater than 3 SDs. For this analysis, the RMSSD was 0.10 mm (CV
7.5%) for all joints, 0.12 mm (CV 7.3%) for the MCP joints, and 0.07 mm (CV 7.1%) for the PIP joints.
Conclusion. Repositioning reproducibility is very good but is likely to be a dominating factor compared to reader and
software reproducibility. Additionally, further evidence is given that a software method is able to detect changes in some
joints for which the Sharp score is insensitive.
INTRODUCTION
Radiography is used routinely to monitor progression in
common and potentially disabling diseases such as rheu-
matoid arthritis (RA) and osteoarthritis (1,2). Radiographic
change is considered the “gold standard” to assess disease
progression in RA and is a common outcome measure for
clinical trials (3).
There are two main structural changes from RA visible
on conventional radiographs: 1) increase in erosion size
and number and 2) loss of joint space width (JSW). Ero-
sions, i.e., cavities created in the bone near the joint, are
seen as radiolucent or dark regions or discontinuities in
the bone margins. JSW is an indirect measure of cartilage
loss, and can be appreciated on radiographs by a decrease
in the distance between the projected margins of a joint.
Research requires reproducible and quantitative surro-
gate outcome measures; however, radiographic assessment
using traditional scoring methods such as the Sharp (4)
and Larson and Thoen (5) systems is subjective and based
on a qualitative assessment of the joints. The available
scoring methods do not attempt to provide a true measure
of the size of the radiographic structures; rather, a score is
given on an ordinal scale that is based on a comparison to
representative examples.
Image analysis software can be used to provide quanti-
ﬁcation of these structural changes on a continuous scale
and has been shown to be more responsive to change than
semiquantitative scoring (6). Computerized methods also
provide automated archiving of scores and integrate di-
rectly with digital imaging modalities. On the other hand,
software is usually not 100% reliable and a quality assur-
ance step is generally needed to ensure that the structures
of interest are accurately identiﬁed. The need for a quality
assurance step necessarily implies a degree of measure-
ment error associated with the reader and correction soft-
ware.
Several computer-based methods to measure radio-
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Abstract  
 
Objective. To evaluate the reproducibility of a computer-based method to measure the 
radiographic joint space width (JSW) in patients with rheumatoid arthritis.  
Methods. We used hand radiographs from a random sample of patients with RA from the 
National Data Bank for Rheumatic Diseases. The semi-automated computer-based scoring 
system automatically delineated joint margins on MCP and PIP joints to measure the JSW. Four 
readers independently evaluated digitized hand radiographs from patients with RA on two 
separate occasions. Reader time was recorded. Inter-rater and intra-rater reproducibility was 
assessed with intraclass correlation coefficients (ICC), root-mean square standard deviation 
(RMSSD) and coefficients of variation (CV).  
Results.  We assessed the hand radiographs from a random sample of patients with RA using the 
software method. Average reader time was 36 seconds per joint and 4.4 minutes per hand. Mean 
JSW was 1.65 mm and 1.03 mm for MCP and PIP joints, respectively.  
The inter-rater ICC values ranged between 0.96 and 0.98, and the RMSSD between 0.03 and 
0.036. The CV was 2.2% and 2.9% for MCP and PIP joints, respectively.  
Regarding intra-rater reliability, the ICC ranged between 0.95 and 0.97, and the RMSSD between 
0.02 and 0.031 mm. The CV was 1.8% and 2.2% for MCP and PIP joints, respectively.  
Conclusion.  The proposed software method for JSW measurements has good reproducibility and 
a short reader time. This system has the potential for use in large clinical studies and should 
provide a quantitative, reproducible and more objective outcome measure of structural damage 
and response to therapy.  
Key words: rheumatoid arthritis; radiograph; scoring; joint space width measurement; automated 
measurement; computer-based; reliability; reproducibility.  
  
 
 
 
 
 
 
 
Paper 12 
Antioxidants and Other Novel Cardiovascular
Risk Factors in Subjects With Rheumatoid
Arthritis in a Large Population Sample
PAOLA DE PABLO,1 THOMAS DIETRICH,2 AND ELIZABETH W. KARLSON3
Objective. To compare antioxidants and other novel and traditional cardiovascular disease (CVD) risk factors in
participants with rheumatoid arthritis (RA) and non-RA controls in a large population sample.
Methods. The Third National Health and Nutrition Examination Survey (NHANES-III) was a cross-sectional population
survey in which subjects ages>60 underwent a musculoskeletal examination. RA subjects were deﬁned as those who met
>3 of 6 available 1987 American College of Rheumatology (ACR) criteria. Non-RA subjects were deﬁned as those who met
no ACR criteria. We performed univariate and multivariate analyses of the association between RA and each novel and
traditional CVD risk factor in RA versus non-RA subjects.
Results. The sample included 5,302 subjects ages >60, with 131 (2.5%) RA and 4,444 (84%) non-RA participants. A total
of 727 subjects were excluded. Plasma levels of antioxidants -carotene, -cryptoxanthin, lutein/zeaxanthin, and lyco-
pene were signiﬁcantly lower in RA subjects compared with non-RA subjects in multivariate analysis adjusting for
potential confounders. Compared with non-RA participants, RA subjects were more likely to have increased C-reactive
protein (CRP) levels in multivariate analysis adjusting for potential confounders. RA and non-RA participants had
similar prevalence of traditional CVD risk factors and previous CVD.
Conclusion. In this large population study, RA subjects had similar prevalence of previous CVD and traditional CVD risk
factors as controls. Among novel CVD risk factors, plasma carotenoid levels were signiﬁcantly lower and CRP level was
signiﬁcantly higher in RA compared with non-RA subjects after adjustment for potential confounders. Further research
should evaluate whether these differences account for the observed increased incidence of CVD in individuals with RA.
KEY WORDS. Rheumatoid arthritis; Antioxidants; Cardiovascular risk factors.
INTRODUCTION
Rheumatoid arthritis (RA), the most common systemic,
chronic inﬂammatory, autoimmune disease, is associated
with excess cardiovascular morbidity and mortality that is
not entirely explained by traditional risk factors for car-
diovascular disease (CVD) (1–4). Novel risk factors for
CVD including inﬂammatory biomarkers, antioxidants,
and/or vitamins may contribute to excess CVD in persons
with RA.
RA and atherosclerosis share common inﬂammatory
mechanisms (5,6). There is an association between inﬂam-
matory markers and subsequent CVD in healthy subjects
(7–10). Therefore, chronic systemic inﬂammation may
contribute to the higher incidence of CVD in persons with
RA (11–14).
Moreover, there is a complex relationship between in-
ﬂammation, antioxidant vitamin status, and the risk of
CVD. Previous reports have demonstrated inverse associ-
ations between inﬂammation and antioxidant serum lev-
els, in particular carotenoids (15–17). Furthermore, in-
takes of antioxidant vitamins and other micronutrients or
their serum concentrations, including carotenoids (18–
20), vitamin C (21–23), vitamin E (24,25), and folate and
homocysteine (26–28), have been reported to be inversely
associated with CVD incidence and mortality.
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Abstract 
 
Objectives: Studies, albeit inconsistent, have suggested that serum uric acid (SUA) may have 
a direct role in atherogenesis and experimental data support a proinflammatory role of SUA. 
However, there is little data from clinical and epidemiologic studies on an association 
between SUA and inflammation. The objective was to evaluate the association between serum 
SUA and inflammation as measured with C-reactive protein (CRP). 
 
Design and setting: The National Health and Nutrition Examination Surveys (NHANES), 
conducted between 1999 and 2004 in the USA, was a cross-sectional study of a nationally 
representative sample of non-institutionalized adults aged 20+ years.  
 
Participants: The study sample included 10,376 participants with complete data. There were 
4,942 men and 5,434 women. A priori, participants taking gout medications and those with 
hypouricemia were excluded from analyses. 
 
Main outcome measure: CRP. We defined SUA into separate categories for men and women 
according to serum concentrations defined as normal low (reference), normal high, and high 
(hyperuricemia). We performed linear regression analyses of log transformed CRP on SUA, 
controlling for potential confounders, in separate models for men and women.  
 
Results: Men had mean higher SUA and lower CRP concentrations compared with women 
(SUA 6.01±1.3 vs. 4.71±1.3 mg/dl and CRP 0.38±0.88 vs. 0.55 ±0.86 mg/dl, respectively). 
There was a positive linear dose-dependent association between SUA and CRP 
concentrations. The associations were strongest in participants with BMI<25 both in men (Δ 
17%, 95% CI 11 to 25) and women (Δ 31%, 95% CI 21 to 42), and attenuated with increasing 
BMI among individuals with overweight or obesity (p for interaction: p<0.0001).  
 
Conclusions. Even within the normal range, SUA concentrations are independently 
associated with CRP among men and women, in particular in normal weight and overweight 
individuals. If these results are confirmed in longitudinal studies, strategies to modify SUA 
should be tested to see whether they modify the long term risk of cardiovascular disease.   
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Abstract 
Rheumatoid arthritis (RA) is associated with cardiovascular morbidity and mortality. C-reactive 
protein (CRP) is an independent predictor of future vascular events in the general population. 
Studies have suggested that serum uric acid (SUA) may have a direct role in atherogenesis and 
epidemiologic studies have observed an independent association between SUA and CRP. 
However, it is unclear whether this association holds in the context of a “high-grade” chronic 
inflammatory disease, such as RA. The objective was to evaluate the association between 
concentrations of SUA and CRP in a cohort of patients with RA. 
Methods: We examined a cohort of 400 patients with RA recruited from routine outpatient 
clinics. We fitted fractional polynomial regression to evaluate the association between SUA and 
CRP, adjusting for potential confounders. 
Results: After excluding participants with concomitant gout, the study sample included 381 
participants with RA. Of those, 74% were female, 76% were seropositive, 70% were 
hypertensive and 10% had diabetes. Mean age was 61 years (SD±12) and mean disease duration 
was 12.5 years (SD±10.5). Men had higher SUA and CRP concentrations than women (6.0±1.3 
vs. 4.9 ±1.5 mg/dl and 17.3±20.8 vs. 16.8±23.5 mg/dl, respectively). There was a non-linear 
association between SUA and CRP concentrations (overall p-value 0.01) independent of age, 
gender, renal function, and other potential confounders.  
Conclusions: SUA concentrations are independently associated with inflammation in patients 
with RA. The physiologic basis of this association, as well as its significance in terms of the 
articular and vascular phenotype of RA require further exploration. 
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Association Between Bone Mineral Density and
C-Reactive Protein in a Large Population-Based Sample
Paola de Pablo, Mark S. Cooper, and Christopher D. Buckley
Objective. Several studies suggest that bone min-
eral density (BMD) is reduced in chronic inflammatory
diseases. Higher serum levels of C-reactive protein
(CRP) have been associated with lower BMD in women
and older adults. However, it is not clear whether this
association holds in a representative sample of the
general population. The purpose of this study was to
examine the relationship between BMD and CRP level
in a large representative US population-based sample
from the National Health and Nutrition Examination
Survey (NHANES).
Methods. We included participants age>20 years
with BMD (total and subregions) measured by dual
x-ray absorptiometry scans and complete information
on covariates from NHANES. The association between
CRP level and BMD was evaluated using multivariate
linear regression models, adjusting for potential con-
founders and further adjusting for comorbid diseases,
medications, and serum vitamin D levels.
Results. The study sample included 10,475 par-
ticipants (53% Caucasian, 22% Mexican American,
18% African American, and 7% other races). Men had
higher BMD and lower CRP concentrations than
women. BMD (total body BMD as well as subtotal BMD
and BMD of the extremities, ribs, and trunk subregions)
was inversely associated with quintiles of CRP concen-
tration both in men and in women in a dose-dependent
manner (for total BMD, P for trend < 0.0001 for men,
P for trend  0.0005 for women). The associations
were independent of medications, comorbidities, and
other potential confounders. The results remained
largely unchanged with further adjustment for serum
vitamin D levels.
Conclusion. Among men and women in a large
representative population-based sample, the CRP level
was inversely and independently associated with total
BMD in a dose-dependent manner.
Chronic inflammatory diseases are associated
with systemic bone loss (1), osteoporosis, and increased
risk of nontraumatic fracture. Such diseases include
rheumatoid arthritis (RA) (2,3), ankylosing spondylitis
(4), systemic lupus erythematosus (5), inflammatory
bowel disease (6,7), and chronic obstructive pulmonary
disease (COPD) (8). In this context, the pathogenic
damage to bone is mediated by the interaction of in-
flammatory cells, cytokines, and bone cells. For exam-
ple, in RA, generalized bone loss is related to increased
osteoclast activity mediated by inflammatory cytokines,
such as tumor necrosis factor (TNF), interleukin-1 (IL-1),
and IL-6, through the RANKL/RANK/osteoprotegerin
system (9,10). Bone loss reversal has been observed
with anti-TNF therapy, with some studies showing incre-
ments in spinal and femoral bone mineral density
(BMD) (6,11–17).
While the association between chronic inflamma-
tory diseases and bone loss, osteoporosis, and increased
fracture risk is well established, data are scarce regard-
ing whether low-grade inflammation has a similar effect
or whether there is a dose-response relationship be-
tween inflammation and bone loss in the general popu-
lation. Previous epidemiologic studies of the association
between biomarkers of inflammation and BMD or bone
loss have provided inconsistent or even contradictory
results, with 2 studies showing an inverse association
between C-reactive protein (CRP) level and BMD among
Korean women and Southern Tasmanian older adults
(18,19), and other studies showing no independent as-
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